NZ731504B2 - Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines - Google Patents

Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines Download PDF

Info

Publication number
NZ731504B2
NZ731504B2 NZ731504A NZ73150415A NZ731504B2 NZ 731504 B2 NZ731504 B2 NZ 731504B2 NZ 731504 A NZ731504 A NZ 731504A NZ 73150415 A NZ73150415 A NZ 73150415A NZ 731504 B2 NZ731504 B2 NZ 731504B2
Authority
NZ
New Zealand
Prior art keywords
difluoromethyl
triazinyl
pyridinamine
compound
dimethylmorpholinyl
Prior art date
Application number
NZ731504A
Other versions
NZ731504A (en
Inventor
Florent Beaufils
Thomas Bohnacker
Vladimir Cmiljanovic
Paul Hebeisen
Jean Baptiste LANGLOIS
Denise Rageot
Alexander Sele
Matthias Wymann
Original Assignee
Piqur Therapeutics Ag
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piqur Therapeutics Ag, Universität Basel filed Critical Piqur Therapeutics Ag
Priority claimed from PCT/EP2015/076192 external-priority patent/WO2016075130A1/en
Publication of NZ731504A publication Critical patent/NZ731504A/en
Publication of NZ731504B2 publication Critical patent/NZ731504B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

The invention relates to novel phosphoinositide 3-kinase (PI3K),mammalian target of rapamycin (mTOR)and PI3K-related kinase(PIKKs)inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases. , either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.

Description

WO 75130 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines Field of the Invention The invention relates to new difluoromethyI-aminopyridyl- and difluoromethyl- aminopyrimidinyI-substituted triazines and pyrimidines as therapeutic agents and diagnostic probes useful for modulating ar activities such as signal transduction, proliferation, differentiation, cell death, migration, and control, release and action of inflammatory mediators, chemokines and cytokines. The compounds of the invention modulate kinase activities, in particular those of phosphoinositide 3-kinase (PI3K), oinositide se (PI4K), mammalian target of rapamycin , Vps34 and PI3K-related s (PIKKs).
Background of the ion Protein kinases participate in the signaling events and control ar activation, growth, differentiation, survival and migration in response to extracellular mediators or stimuli including growth factors, nes or chemokines. In general, these kinases are classified in two , those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine and/or threonine residues. Tyrosine kinases include membrane-spanning growth factor receptors, for example the epidermal growth factor receptor (EGFR) and cytosolic non-receptor kinases including Src family kinases, the Syk family kinases and the Tec family s.
Increased protein kinase ties are involved in many diseases including cancer, metabolic diseases, immunological diseases and inflammatory disorders. These can be caused either directly or indirectly by the failure of control mechanisms due to mutation(s), overexpression or inappropriate control of enzyme activity.
Protein tyrosine kinases — both receptor tyrosine kinases and non-receptor kinases — are essential for the activation and proliferation of cells of the immune system. Among the earliest detectable events upon immunoreceptor tion in mast cells, T cells and B cells is the stimulation of non-receptor tyrosine kinases.
Phosphoinositide 3-kinases (PI3Ks) were early on identified as lipid kinases associated with viral nes an et al., Nature 315:239—242 (1985)], and for the last 20 years, the connection between cancer and PI3K has been further substantiated [Wymann WO 75130 etal., Curr. Opin. Cell Biol. 17:141-149 (2005)]. P|3Ks have since been recognized to modulate a wide range of cellular activities, and to be central to the growth and metabolic control. Genetically modified mice targeting the P|3K pathway, and the ation of human hereditary disease like Cowden's syndrome, tuberous sclerosis, ataxia telangiectasia, X-linked myotubular myopathy and t-Marie-Tooth neuropathy, have provided further insight into the cellular and systemic role of phosphoinositide ing.
Deregulation of phosphoinositide levels, and in particular the product of class I Pl3Ks, Ptdlns (3,4,5)P3, is involved in the pathogenesis of cancer, chronic inflammation, allergy, lic disease, diabetes and cardiovascular problems.
P|3Ks are a family of enzymes, which phosphorylate the 3'-OH position of the inositol ring of phosphoinositides. They have been divided into three classes on the basis of structural features and in vitro lipid substrate icity [Marone et al., Biochimica et Biophysica Acta 1784:159—185 (2008)]. Class | P|3Ks form heterodimers, which consist of one of the four closely related catalytic ts of approx. 110 kDa, and an ated regulatory subunit belonging to two ct families. In vitro they are capable to t Ptdlns to PtdlnsP, PtdlnsP to (3,4)P2, and Ptdlns(4,5)P2 to Ptdlns(3,4,5)P3, but the in vivo substrate is Ptdlns(4,5)P2 [Cantley eta/., Science 296:1655-1657 (2002)]. Class | P|3Ks are activated by a large variety of cell-surface receptors, comprising growth factor ors as well as G protein-coupled receptors.
Class II P|3Ks are capable to phosphorylate Ptdlns and PtdlnsP in vitro, but their relevant in vivo substrates are still under investigation. This class of large (170-200 kDa) enzymes has three members, all characterized by a C-terminal C2 homology domain. No adaptor molecules for class II P|3Ks have been identified so far. Class III P|3Ks are solely able to phosphorylate Ptdlns, and thus generate only PtdlnsP. The single member of this class is Vps34, of which the S. cerevisiae Vps34p (vacuolar protein sorting mutant 34 protein) is the prototype, and has been shown to play an essential role in trafficking of newly synthesized proteins from the Golgi to the yeast vacuole, an organelle equivalent to lysosomes in mammals [Schu etal., Science 260:88—91 (1993)].
Phosphoinositide 4-kinases (Pl4Ks) phosphorylate the 4'-OH on of the inositol ring of Ptdlns, and thereby generate PtdlnsP. This lipid can then be further phosphorylated by P ses to generate Ptdlns 2, which is the main source for phospholipase C and PI3K signaling at the plasma membrane. Four P|4Ks isoforms are known: P|4Kllcx and B and P|4Klllcx and B. The P|4Kllls are most closely related to Pl3Ks.
The class of Pl3K-related proteins, referred to as class IV Pl3Ks, consists of high molecular weight enzymes with a catalytic core similar to Pl3Ks and P|4Ks and include the mammalian target of rapamycin (mTOR, also known as FRAP), DNA-dependent protein kinase (DNA-PKcs), the ataxia telangiectasia mutated gene product (ATM), ataxia iectasia related (ATR), SMG-1 and transformation/transcription domain-associated protein (TRRAP). The first five members are active protein serine-threonine kinases that are involved in cell growth control and genome/transcriptome surveillance [Marone et al., Biochimica et Biophysica Acta 1784:159—185 (2008)]. DNA-PKcs, ATM, ATR and SMG-1 are involved in DNA damage responses. The only active kinase not involved in DNA damage is mTOR, which is regulated by growth factors and nutrient availability, and coordinates protein synthesis, cell growth and proliferation. Target of rapamycin (mTOR) complexes 1 and 2 integrate growth factor signaling (via KB and the Ras/MAPK cascade), energy status (LKB1 and AMPK) and nutrient detection. TOR is vely ted by PKB/Akt, which phosphorylates the negative regulator TSC2 in the tuberous sclerosis complex (TSC), resulting in activation of the GTPase Rheb and mTOR. In parallel, mTOR stimulates translation of ribosomal proteins and ore ribosome biogenesis via the activation [Wullschleger etal., Cell 124:471 (2006)]. Rapamycin and its derivatives, RAD001 and CCl-779, bind to FKBP12, and the complex blocks mTOR complex 1 (mTORC1) activity very selectively. Various clinical trials were ted using rapamycin and derivatives, mostly in patients with tumors displaying elevated P|3K signaling and hyperactive mTOR.
The P|3K pathway is a key signaling transduction cascade controlling the regulation of cell growth, proliferation, survival as well as cell migration. Pl3Ks are activated by a wide variety of ent stimuli including growth s, inflammatory ors, es, neurotransmitters, and immunoglobulins and antigens [Wymann et al., Trends Pharmacol.
Sci. -376 (2003)]. The class IA P|3K isoforms Pl3Ko, B and 6 are all bound to one of the p85/p55/p50 regulatory subunits, which all harbor two 8H2 s that bind with high ty to phosphorylated Tyr-X-X-Met motifs. These motifs are present in activated growth factor receptors, their substrates and numerous adaptor proteins. As described above, activation of the Pl3K/PKB signaling e has a positive effect on cell growth, survival and proliferation. Constitutive up-regulation of PI3K signaling can have a deleterious effect on cells leading to uncontrolled proliferation, ed migration and adhesion-independent growth. These events favor not only the formation of malignant , but also the development of inflammatory and autoimmune disease.
The patent applications WO2010/052569, WO2007/084786 and WO2008/098058 describe certain analogous triazines and pyrimidines derivatives having PI3K and mTOR inhibiting properties, and their use as pharmaceuticals.
Summary of the Invention In one aspect, there is ed a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (i) a linyl of a (II) R3 R4 (II) n the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form er a bivalent residue – R5R6– selected from -CH2-O-CH2-, -CH2-NH-CH2-, or C1-C3alkylene optionally substituted with 1 to 4 F, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 5- to 6-membered heterocyclic ring Z containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, 07_1 (GHMatters) P42872NZ00 C1-C3alkyl, CH2OH, CH2CH2OH, CH2F, CHF2, CF3, CH2CF3, lkoxy, C1- C2alkoxyC1-C3alkyl, ycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue –R10R11– selected from -CH2-OCH2- , -O-CH2CH2-O-, or C1-C3alkylene optionally substituted with 1 to 4 F; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and tautomers, es and pharmaceutically acceptable salts thereof.
In another aspect, there is provided a pharmaceutical composition comprising a compound of formula (I) as defined herein and a pharmaceutically acceptable carrier.
In another aspect, there is provided a use of a compound of formula (I) as defined herein in the preparation of a medicament for the treatment or prevention of a disease or condition ted by PI3Ks and/or mTOR and/or PIKKs in a human.
The invention relates in a first aspect to difluoromethyl-substituted heteroaromatic compounds of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are ndently of each other (i) a linyl of formula (II) R3 R4 (II) wherein the arrow denotes the bond in formula (I); and n R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue – 17511707_1 (GHMatters) P42872NZ00 4b followed by page 5 R5R6– selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures n the arrows denote the bonds in formula (II); (ii) phenyl optionally substituted with 1 to3 R7, wherein R7 is ndently at each occurrence halogen, -OH, C1-C3alkyl optionally substituted with one or two OH, 17511707_1 (GHMatters) P42872NZ00 C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (iii) a 5- to 6-membered heteroaryl ring W containing one to four heteroatoms ndently selected from N, O and S, optionally substituted by 1 to 3 R8, wherein R8 is ndently at each occurrence halogen, -OH, lkyl ally substituted with one or two OH, C1-szluoroalkyl, lkoxy, C1- CzalkoxyC1-Cgalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (W) a saturated 4- to 6-membered heterocyclic ring Z containing 1 to 3 atoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- xyC1-Cgalkyl, ycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1- Cgalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CHZCH2-O-; (V) OR”, wherein R12 is C1-Cgalkyl, C1-Cshaloalkyl, C1-Csalkoxy, ycloalkyl, C1-Czalkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle- P represents a saturated 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms ndently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Q represents 5- to ered heteroaryl ring ning one to four heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3); or (Vi) NR15R16; wherein R15 and R16 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or ; Cycle-Q or C1- CzalkyleneCycle-Q, wherein Q represents 5- to 6-membered heteroaryl 2015/076192 ring ning one to four heteroatoms independently selected from N, O and S, optionally tuted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or ; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof.
In further aspects, the invention relates to pharmaceutical compositions comprising a compound of formula (I) as defined hereinbefore, and to methods of preventing or treating a disease or er modulated by Pl3Ks, mTOR and PlKKs, in particular treating a hyperproliferative disorder, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula (I) as defined hereinbefore. An additional aspect of the ion is the use of a compound of formula (I) as defined hereinbefore for the treatment or prevention of a disease or ion modulated by Pl3Ks, mTOR and PlKKs in a mammal, and the use of a compound of formula (I) as defined hereinbefore in the preparation of a medicament for the treatment or prevention of a disease or condition ted by Pl3Ks, mTOR and PlKKs, in a mammal. ln again further aspects, the ion relates to the use of an effective amount of compounds of formula (I) as defined hereinbefore in combination with standard treatment, such as chemotherapy, herapy, targeted therapy or immunotherapy of a disease or disorder modulated by Pl3Ks, mTOR and PlKKs, in particular hyperproliferative disorders.
Further the invention relates to the synthesis of compounds of a (I) as defined hereinbefore including tautomers, solvates, intermediates, prodrugs and salts of said compounds.
Further aspects and embodiments of the present invention will be become apparent as this description continues.
Detailed Description of the Invention Reference will now be made in detail to the presented and further aspects and the presented and further ments of the ion, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, cations, and equivalents which may be ed within the scope of the present invention as defined by the aspects of the present invention and, in particular the . One skilled in the art will recognize many methods and materials similar or lent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials herein described.
Definitions The terms "treat" and "treatment" refer to both therapeutic treatment and prophylactic or preventative es, wherein the object is to prevent or slow down (lessen) an undesired pathological change or disorder, such as the development or spread of cancer.
For purpose of this ion, beneficial or d clinical results include, but are not limited to, alleviation of ms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or , r detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or er is to be prevented.
The phrase "effective amount" means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, rates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the ular disease, condition, or disorder described herein. In the case of cancer, the effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; t (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease ssion (TIP) and/or determining the response rate (RR).
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukaemia or lymphoid malignancies.
More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell ), lung cancer including small-cell lung cancer, non-small cell lung cancer ("NSCLC"), arcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or h cancer including intestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, trial or uterine carcinoma, salivary gland oma, kidney or renal cancer, prostate , vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, bile duct cancer, mantle cell lymphoma, CNS ma, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, as well as head and neck cancer.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer.
Examples of known chemotherapeutic agents include trastuzumab, pertuzumab, erlotinib (TARCEVA®, ech/Roche/OSI Pharm.), bortezomib (VELCADE®, Millennium Pharm.), fulvestrant (FASLODEX®, AstraZeneca), b (SUTENT®, Pfizer/Sugen), letrozole (FEMARA®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), finasunate (VATALAN|B®, Novartis), oxaliplatin (ELOXAT|N®, Sanofi), 5-FU (5-fluorouracil), leucovorin, rapamycin (Sirolimus, RAPAMUNE®, Wyeth), lapatinib (TYKERB®, GSK572016, Glaxo Smith Kline), lonafarnib (SCH 66336), sorafenib (NEXAVAR, Bayer Labs), and gefitinib (IRESSA®, AstraZeneca), AG1478, alkylating agents such as thiotepa and CYTOXAN® phosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, uone, meturedopa, and a; nimines and melamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins; a camptothecin (including the tic analog topotecan); bryostatin; tatin; 5 (including its adozelesin, carzelesin and bizelesin synthetic analogs); cryptophycins; dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, mustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, ine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., ca|icheamicin, especially ca|icheamicin gammal 1 and ca|icheamicin omegal 1; dynemicin, ing dynemicin A; phonates, such as c|odronate; an micin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, cin, carminomycin, carzinophillin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazoloxo-L-norleucine, ADRIAMYC|N® (doxorubicin), morpholino- doxorubicin, cyanomorpholino-doxorubicin, olino-doxorubicin and deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, onigrin, streptozocin, tubercidin, ubenimex, zinostatin, cin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, rexate; purine analogs such as abine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, bine, dideoxyuridine, doxifluridine, enocitabine, idine; androgens such as ca|usterone, tanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; yurea; lentinan; |onidainine; maytansinoids such as maytansine and ansamitocins; azone; mitoxantrone; mopidanmol; rine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex; ne; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; trichothecenes; urethane; indesine; dacarbazine; mannomustine; mitobronitol; mito|acto|; pipobroman; gacytosine; arabinoside; taxoids, e.g., TAXOL® (paclitaxel; Bristol-Myers Squibb), ABRAXANET'V' (Cremophor—free), albumin-engineered nanoparticle formulations of paclitaxel, and TAXOTERE® (docetaxel, doxetaxel; Sanofi-Aventis); mbucil; GEMZAR® (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisp|atin and carboplatin; vinblastine; etoposide; ifosfamide; mitoxantrone; vincristine; NAVELBI NE® (vinorelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA®); onate; CP-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts; acids and derivatives of any of the above.
Also included in the definition of "chemotherapeutic agent" are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), fene, droloxifene, and ON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)—imidazoles, MEGASE® trol acetate); AROMAS|N® stane; Pfizer), formestanie, fadrazole, RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and EX® (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide; (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) nse oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Rafl and H-Ras; (vii) mes such as VEGF expression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for e, ALLOVECT|N®, LEUVECT|N®, and ; PROLEUK|N® rll-2; a topoisomerase 1 inhibitor such as LURTOTECANE®; ABAREL|X® rmRH; (ix) ngiogenic agents such as bevacizumab (AVAST|N®, Genentech/Roche); and (x) pharmaceutically acceptable salts, acids and derivatives of any of the above.
The term "prodrug" as used in this application refers to a precursor or derivative form of a compound of the invention that may have improved properties such as better solubility, reduced cytotoxicity or increased bioavailability compared to the parent compound or drug and is capable of being activated or converted into the more active parent form. The gs of this ion include, but are not limited to, derivatives of the amino group connected to the pyridine or pyrimidine nucleus in which one or two hydrogens are replaced by a suitable substituent, or derivatives of the ring amino function if R2 is piperazinyl. Examples of such prodrugs are compounds acylated by an amino acid selected from the 20 most often occurring l L-alpha-amino acids, ed by a dipeptide such as L-Ala-L-Ala, by carbonic acid, ic acid or phosphoric acid, as well as pharmaceutically acceptable salts thereof.
A "metabolite" is a product produced through metabolism in the body of a ied compound or salt thereof. Metabolites of a compound may be identified using routine ques known in the art and their activities determined using tests such as those described . Such ts may result for example from the oxidation, reduction, ysis, amidation, deamidation, esterification, deesterification, enzymatic ge, and the like, of the administered nd. In particular, compounds of formula (I) as defined hereinbefore, which are oxygenated or hydroxylated at any one position in the morpholine, piperazine or thiomorpholine ring R1 and/or R2 are considered metabolites.
Further metabolites considered are thiomorpholine S—oxides and thiomorpholine 8,8- dioxides. Accordingly, the invention is also directed to metabolites of compounds of the ion, including compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactants, which is useful for ry of a drug (such as the P|3K and mTOR kinase inhibitors disclosed herein and, optionally, a chemotherapeutic agent) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
The term "chiral" refers to molecules, which have the property of perimposability of the mirror image partner, while the term al" refers to molecules, which are superimposable on their mirror image partner.
The term "stereoisomers" refers to compounds, which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
"Diastereomer" refers to a isomer with two or more centers of chirality in which the compounds are not mirror images of one another. Diastereomers have different physical properties, e.g. g points, boiling points, spectral properties, and chemical and biological vities. Mixtures of diastereomers may be separated under high resolution analytical procedures such as electrophoresis and chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
Stereochemical definitions and conventions used herein generally follow S.P. Parker, Ed., McRaw—Hiff Dictionary of Chemical Terms (1984), McGraw—Hill Book Company, New York; and Eliel, E. and Wilen, 8., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc, New York, 1994. The nds of the ion may contain asymmetric or chiral centers, and therefore exist in ent stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, reomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention. Many c compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light.
In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and | or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (—) or | meaning that the nd is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric or a scalemic mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate. The term "tautomer" or meric form" refers to structural isomers of different energies, which are onvertible via a low energy barrier. For example, proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations.
The phrase aceutically acceptable salt" as used herein, refers to pharmaceutically acceptable c or nic salts of a compound of the ion, in particular acid addition salts. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, , tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, ate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate (mesylate), ethane- sulfonate, benzenesulfonate, enesulfonate, and pamoate salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent nd. Furthermore, a pharmaceutically acceptable salt may have more than one d atom in its structure. lnstances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
If the nd of the invention is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, c acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as c acid or cinnamic acid, a sulfonic acid, such as p- toluenesulfonic acid or ethanesulfonic acid, or the like.
The phrase "pharmaceutically acceptable" indicates that the substance or ition must be compatible ally and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
A "solvate" refers to an association or x of one or more solvent molecules and a compound of the invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl ide (DMSO), ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to the complex where the solvent molecule is water.
The term cting group" refers to a substituent that is ly employed to block or protect a particular functionality during the reaction of other functional groups on the compound. For example, an "amino-protecting group" is a substituent ed to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, tert—butoxycarbonyl (BOC), benzyloxycarbonyl and 9-fluorenylmethylenoxycarbonyl (Fmoc). For a general description of protecting groups and their use, see T. W. , Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
The terms "compound of this invention" and "compounds of the present invention" and "compounds of formula (l)” include stereoisomers, geometric isomers, tautomers, solvates, ceutically acceptable salts, and solvates of the salts thereof.
The term "mammal" includes, but is not limited to, humans, mice, rats, guinea pigs, s, dogs, cats, horses, cows, pigs, and sheep. The term "mammal", as used herein, ably refers to humans.
The t invention provides new difluoromethyl—aminopyridyl- and difluoromethyl- aminopyrimidinyl-substituted triazines and dines, and pharmaceutical formulations thereof, which are useful as therapeutic agents and novel diagnostic probes. Moreover, these compounds are potentially useful in the treatment of diseases, conditions and/or disorders modulated by protein kinases and lipid kinases.
More specifically, in a first aspect, the present invention provides a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the o that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are ndently of each other (i) a linyl of formula (ll) Rsi 1R4 f (H) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue— R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in a (II); (ii) phenyl optionally substituted with 1 to 3 R7, wherein R7 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (iii) a 5- to 6-membered heteroaryl ring W containing one to four heteroatoms independently ed from N, O and S, optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, ycloalkyl, -NH2, NHCH3 or N(CH3)2; (W) a saturated 4- to 6-membered heterocyclic ring Z ning 1 to 3 heteroatoms ndently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, Cs-Cscycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 tuents form together a bivalent residue —R10R11— selected from C1- Cgalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CHZCH2-O-; (V) OR”, wherein R12 is C1-Cgalkyl, C1-Cshaloalkyl, C1-Csalkoxy, Cs-Cscycloalkyl, C1-CzaIkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle- P represents a saturated 4- to ered cyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- l optionally substituted with one or two OH, uoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Q or C1- leneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing one to four heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3); or (Vi) NR15R16; wherein R15 and R16 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl; Cycle-P or lkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6-membered cyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- C3alkyl ally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered aryl ring containing one to four heteroatoms independently ed from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-C3alkyl ally tuted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3); with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically able salts thereof.
In another , the present invention provides for a compound of formula (I), xfégfijxg Fm“ WF 95 ’§/~ L R x3 “rf,» w i? Y "M, at‘N N" am wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 f (H) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, CN, or C1-C2alkyl; or R3 and R4 form together a bivalent residue— R5R6— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures n the arrows denote the bonds in formula (II); (ii) phenyl optionally substituted with 1 to 3 R7, wherein R7 is independently at each occurrence halogen, -OH, lkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (iii) a 5- to 6-membered heteroaryl ring W ning one to four atoms independently ed from N, O and S, optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, lkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (iv) a saturated 4- to 6-membered heterocyclic ring Z containing 1 to 3 heteroatoms independently selected from N, O and S, optionally tuted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, Cs-Cscycloalkyl, =O, -NH2, NHCH3 or 2; or two R9 substituents form together a bivalent residue 1— selected from C1- Cgalkylene ally substituted with 1 to 4 F, -CH2- or CH2-O-; (v) OR”, wherein R12 is C1-Cgalkyl, C1-Cshaloalkyl, C1-Csalkoxy, Cs-Cscycloalkyl, C1-Czalkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle- P represents a saturated 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing one to four heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, lkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3); or (vi) NR15R16; wherein R15 and R16 are ndently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-C3alkyl; Cycle-P or C1-C2alkyleneCycle-P, wherein Cycle-P represents a saturated 4- to ered heterocyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- C3alkyl optionally substituted with one or two OH, luoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- C2alkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing one to four heteroatoms ndently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence n, -OH, C1-C3alkyl ally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3); with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and gs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, and further with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, ylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 3-azaoxabicyclo[3.2.1]octy|, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 3-aza oxabicyclo[3.2.1]octyl, razinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- holinyl, octadeuterio—4-morpholinyl, 3-oxabicyclo[3.2.1]octyl or 3-azaoxabicyclo[3.2.1]octy|.
In another aspect, the present invention provides for a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (vii)a morpholinyl of formula (ll) R3: 2 R4 i (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, uoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1- Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form er a nt residue — R5R6— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, H-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); (viii)phenyl optionally substituted with 1 to 3 R7, wherein R7 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (ix) a 5- to 6-membered heteroaryl ring W containing one to four heteroatoms independently selected from N, O and S, optionally tuted by 1 to 3 R8, wherein R8 is ndently at each occurrence n, -OH, C1-Cgalkyl optionally tuted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; (x) a saturated 4- to 6-membered heterocyclic ring Z containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, lkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl, ycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1- Cgalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CHZCH2-O-; (xi) OR”, wherein R12 is C1-Cgalkyl, C1-Cshaloalkyl, C1-Csalkoxy, Cs-Cscycloalkyl, C1-Czalkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle- P represents a saturated 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or ; Cycle-Q or C1- CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing one to four heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is ndently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3); or (xii) NR15R16; wherein R15 and R16 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Cgalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6-membered cyclic ring containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R13, wherein R13 is independently at each occurrence halogen, -OH, C1- Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cg-Cecycloalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Q represents 5- to 6-membered heteroaryl ring containing one to four atoms independently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally tuted with one or two OH, C1-szluoroalkyl, lkoxy, lkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3); with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, lites, tautomers, solvates and pharmaceutically able salts thereof, and further with the proviso that R1 is not holinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 3-oxabicyclo[3.2.1]octyl or 3- azaoxabicyclo[3.2.1]octyl; and R2 is not 4-morpholinyl, 2-methyl morpholinyl, ylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 3-azaoxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl.
In another aspect, the invention provides for a nd of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 is 4-morpholinyl, 2-methylmorpholinyl, ylmorpholinyl, octadeuterio—4- morpholinyl, 8-azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4- morpholinyl, 8-azaoxabicyclo[3.2.1]octyl, 3-aza-8—oxabicyclo[3.2.1]octyl, zinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl. ln again another aspect, the present invention provides for a compound of formula (I) as defined herein for use in a method of preventing or treating a disease or disorder modulated by any one of Pl3Ks, mTOR and PlKKs either individually or in any combination, n said method ses administering to a mammal in need of such prevention or treatment an effective amount of said a compound of formula (I). Preferably, said e or disorder is a hyperproliferative disorder.
In again a r aspect, the present invention provides for a use of a nd of formula (I) as defined herein in the preparation of a medicament for the ent or prevention of a disease or condition modulated by any one of Pl3Ks, mTOR and PlKKs either individually or in any combination, in a mammal, preferably in a human. Preferably, said disease or disorder is a hyperproliferative disorder.
In again a further aspect, the present invention provides for a use of a compound of a (I) as defined herein in the manufacture of a medicament for the treatment or prevention of a disease or condition modulated any one of Pl3Ks, mTOR and PlKKs either individually or in any combination, in a mammal, preferably in a human. Preferably, said disease or disorder is a hyperproliferative disorder.
WO 75130 In again another aspect, the present invention provides for a method of preventing or treating a disease or disorder modulated any one of Pl3Ks, mTOR and PlKKs either individually or in any combination, wherein said method comprises administering to a mammal in need of such prevention or ent an effective amount of a compound of formula (I) as defined .
Each alkyl moiety either alone or as part of a larger group such as alkoxy is a straight or ed chain and is preferably C1-Cgalkyl, more preferably C1-Czalkyl. Examples include in particular methyl, ethyl, n-propyl and propyl ropyl). Examples of an alkoxy include in particular methoxy, ethoxy, n-propoxy and iso-propoxy. As described herein, alkoxy may include further substitutents such as halogen atoms leading to haloalkoxy moieties.
The term “alkoxyalkyl” refers to a R-O-R’ moiety in which the R and R’ groups are alkyl groups as defined herein. Examples include methoxymethyl, methoxyethyl, ethoxyethyl and methoxypropyl.
Each alkylene moiety is a straight or branched chain and is, particularly for example, - CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(CH3)-CH2-, or -CH(CHZCH3)-, preferably -CH2-, -CH2-CH2- or -CH(CH3)-.
Each haloalkyl moiety either alone or as part of a larger group such as haloalkoxy is an alkyl group substituted by one or more of the same or different halogen atoms. Haloalkyl es include for example 1 to 5 halo tuents, or 1 to 3 halo substituents.
Examples include in particular fluoromethyl, romethyl, trifluoromethyl, chlorodifluoromethyl and 2,2,2-trifluoro-ethyl.
Each haloalkenyl moiety either alone or as part of a larger group such as haloalkenyloxy is an alkenyl group substituted by one or more of the same or different halogen atoms.
Examples include,2-difluoro-vinyl and 1,2-dichlorofluoro-vinyl. kenyl moieties include for example 1 to 5 halo substituents, or 1 to 3 halo substituents.
Each cycloalkyl moiety can be in mono- or bi-cyclic form, typically and preferably in mono- cyclic form, and preferably contains 3 to 6 carbon atoms. red es of monocyclic cycloalkyl groups include in particular cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Halogen is fluorine, ne, bromine, or iodine, preferably fluorine.
The term "heteroaryl" refers to an aromatic ring system containing at least one heteroatom, and preferably up to four heteroatoms selected from nitrogen, oxygen and sulfur as ring members. aryl rings do not contain adjacent oxygen atoms, adjacent sulfur atoms, or adjacent oxygen and sulfur atoms within the ring. Preferred examples include in particular pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, yl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, furanyl, and thiophenyl The term "heterocyclic ring" refers to a ted or partially unsaturated carbocyclic ring containing one to three heteroatoms selected from nitrogen, oxygen and sulfur as ring members. Such rings do not contain adjacent oxygen atoms, adjacent sulfur atoms, or adjacent oxygen and sulfur atoms within the ring. Preferred examples include in particular tetrahydrofuranyl, pyrrolidinyl, pyrazolidinyl, olidinyl, piperidinyl, piperazinyl, dioxanyl, morpholinyl, oxazolidinyl and isooxazolidinyl.
Where a group is said to be ally tuted, preferably there are ally 1-3 substituents, more preferably optionally 1-2 substituents. n compounds of formula (I) may contain one or two or more centers of chirality and such compounds may be provided as pure enantiomers or pure diastereoisomers as well as mixtures thereof in any ratio. The compounds of the invention also include all tautomeric forms of the compounds of formula (I).
In a red embodiment, the present invention provides for the compound of formula (I) as defined herein and tautomers, solvates and pharmaceutically acceptable salts thereof.
In r preferred embodiment, the present invention provides for the compound of formula (I), wherein X1, X2 and X3 are N.
In another preferred embodiment, (i) said x1 and said x2 are N, and said x3 is CH; (ii) said x1 and said x3 are N, and said x2 is CH; or (iii) said x2 and said x3 are N, and said x1 is CH, and ably tautomers, solvates and pharmaceutically acceptable salts thereof. In another embodiment, (i) said X1 and said X2 are N, and said X3 is CH; or (ii) said X2 and said X3 are N, and said X1 is CH, and ably tautomers, solvates and pharmaceutically acceptable salts thereof. In another preferred embodiment, said X1 and said X3 are N, and said X2 is CH; and preferably tautomers, solvates and pharmaceutically acceptable salts In another preferred embodiment, said Y is N, and preferably tautomers, solvates and pharmaceutically acceptable salts thereof. In another preferred embodiment, said Y is CH, and preferably tautomers, solvates and pharmaceutically acceptable salts thereof.
In another preferred embodiment, said R1 and said R2 are independently of each other (i) a morpholinyl of formula (II); (ii) said 5- to 6-membered aryl ring W; (iii) said saturated 4- to 6-membered heterocyclic ring 2; (iv) said OR”; or (v) said NR15R16.
In another preferred embodiment, said R1 and said R2 are independently of each other ed from [E1 [EL [EL [EL ,EEL ,erlr “15.th ESL, EELE [Ef- TE‘J’ TEL lr l l i ii lg [ELL [ELLEEJ’[ET[EEJQ m m [EL Cl {E}: EED [E1: [3" Ci E? Q [j El “Q E13 $53963?wa i i i i + i i ”i" ‘i‘ Pi i" F L9 Lmé L w 1* ii ilr lr i ii WO 75130 m f—‘a. /_/< [:>—N fierH—HMa" Q N —1-~ 3—? 3—.” 3—." 3—,! ., N N “I‘M__ H H In another preferred ment, said R1 and said R2 are independently of each other selected from Q {[21 x: $313 EELKEEf'YEfTEL ["tj‘H CRQ$ 88w $3: E:3: [5:3: $3 $3 $31Ir :3» F’ F N N + + + 5? 2015/076192 ' 5f 5“ E [EL/F [$ij (Elf: D E [:>—N N+ xix: Ha- 1:3 ran.
F F F F “‘ "““ '3‘“ ‘~ | “H ":3 N—h— I f f I " ‘~_f HEN N HEN N N ff; Hi H “a EMa [NJ-"’7" Q N; NJ I 0 r r' A '3 L N N DH H D H F-d" i _| N ll | .H IHH L: M l m' ”*N H H N‘N NEE", F H F H F . F l . | F>'\/r~41 F, Mi Mi mama '7' F F D F D‘s-t In another preferred embodiment, R1 and R2 are independently of each other selected from N [Elm 61(3)” if g; l E l l +‘ $ 3 Na. HN isle-r —M Ma- i._f i._.i 3—3“ In another preferred embodiment, R1 and R2 are ndently of each other selected from £23 ESL [fl E53 [01¢ ijk i l l l l l ,rjj..,,,, Erik *w W 1Ir 1 In another preferred ment, said nd of formula (I) is selected from 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazinyl)pyrimidinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)(3-oxa-8—azabicyclo[3.2.1]octan-8—y|)—1 ,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)—6-morpholino—1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)—6-morpholino—1,3,5-triazin-2—yl)—4- (difluoromethyl)pyrimidinamine; -(4,6-bis((S)—3-methy|morpholino)—1,3,5-triaziny|)(difluoromethyl)pyridinamine; -(4,6-bis((S)—3-methy|morpholino)—1,3,5-triaziny|)(difluoromethyl)pyrimidinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-morpholino—1,3,5-triaziny|)pyridin amine; (difluoromethyl)(4-(3-methy|morpho|ino)—6-morpholino—1,3,5-triaziny|)pyrimidin- 2-amine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)((S)—3-methy|morpho|ino)—1,3,5-triazinyl)—4- (difluoromethyl)pyridinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)((S)—3-methy|morpho|ino)—1,3,5-triazinyl)—4- (difluoromethyl)pyrimidinamine; 4-(difluoromethyl)(4-morpho|ino—6-(piperaziny|)-1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)(4-morpho|ino—6-(piperaziny|)-1,3,5-triazinyl)pyrimidinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-(piperaziny|)-1,3,5-triazin y|)pyridinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-(piperaziny|)-1,3,5-triazin y|)pyrimidinamine; 4-(difluoromethyl)—5-(2,6-dimorpholinopyrimidiny|)pyridinamine; 4'-(difluoromethyl)—2,6-dimorpholino—[4,5'-bipyrimidin]—2'-amine; 4-(difluoromethyl)—5-(4,6-dimorpholinopyrimidiny|)pyridinamine; 4'-(difluoromethyl)—4,6-dimorpholino—[2,5'-bipyrimidin]—2'-amine; 4-(difluoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triaziny|)pyridinamine; 4-(difluoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triaziny|)pyrimidinamine; -(6-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octan-8— y|)pyrimidiny|)(difluoromethyl)pyridinamine; 3-oxaazabicyclo[3.2.1]octany|)morpho|inopyrimidiny|) (difluoromethyl)pyridinamine; 2-(3-oxaazabicyclo[3.2.1]octan-8—y|)—4’-(difluoromethyl)—6-morpholino—[4,5’-bipyrimidin]— 2’-amine; -(2,6-bis((S)—3-methy|morpholino)pyrimidiny|)(difluoromethyl)pyridinamine; 4'-(difluoromethyl)-2,6-bis((S)—3-methy|morpholino)—[4,5'-bipyrimidin]—2'-amine; (difluoromethyl)(6-(3-methy|morpho|ino)—2-morpholinopyrimidinyl)pyridin amine; (S)—4'-(difluoromethyl)(3-methy|morpholino)—2-morpholino—[4,5'-bipyrimidin]—2'-amine; -(4-(8—Oxaazabicyclo[3.2.1]octany|)(8—oxaazabicyclo[3.2.1]octany|)—1 ,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; 5-[4,6-bis(2,2-dimethylmorpholinyl)—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; (S)—4-(difluoromethyl)(2-(3-methy|morpholino)—6-morpholinopyrimidinyl)pyridin amine; -(difluoromethyl)(3-methy|morpholino)—6-morpholino—[4,5'-bipyrimidin]—2'-amine; 4-(difluoromethyl)—5-[4-[(28,6R)—2,6-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; -[4,6-bis[(2R,6S)—2,6-dimethylmorpholiny|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin- 2-amine; 4-[4-[6-amino—4-(difluoromethyl)pyridy|]—6-morpho|ino—1,3,5-triazinyl]morpholin one; 4-[4-[2-amino—4-(difluoromethyl)pyrimidinyl]—6-morpholino—1,3,5-triazinyl]morpholin one; -[4,6-bi3(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—6-(3-oxa-8— azabicyclo[3.2.1]octan-8—y|)—1,3,5-triazinyl]pyridinamine; -[4,6-bis(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; -[4,6-bis[(3R,58)—3,5-dimethylmorpholiny|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin- 2-amine; -[4,6-bis[(3R)—3-methy|morpholinyl]—1,3,5-triazinyl]—4-(difluoromethyl)pyridin amlne; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-morpholino—1,3,5-triaziny|]pyridin- 2-amine; -[4-[6-amino—4-(difluoromethyl)pyridy|]—6-[(3R)—3-methy|morpholinyl]—1,3,5-triazin y|](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]pyridinamine; luoromethyl)[4-[(3R)—3-(methoxymethyl)morpholinyl]—6-[(3R)—3- methylmorpholinyl]—1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—6-[(3R)—3- methylmorpholinyl]—1,3,5-triaziny|]pyridinamine; (4S,5R)—3-[4-[2-amino—4-(difluoromethyl)pyrimidinyl]—6-morpholino—1,3,5-triazinyl]—4- (hydroxymethyl)—5-methy|—oxazolidinone; (4S,5R)—3-[6-[2-amino—4-(difluoromethyl)pyrimidinyl]—2-morpholino—pyrimidiny|] (hydroxymethyl)—5-methy|—oxazolidinone; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](3-oxaazabicyclo[3.1.1]heptan- 6-y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](6-oxaazabicyclo[3.1.1]heptan- 3-y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1R,4R)—2-oxa azabicyc|o[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1S,4S)—2-oxa azabicyc|o[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine; -[4,6-bis[(3R)—3-ethy|morpholinyl]—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; 5-[4,6-bis(8—oxaazaspiro[3.5]nonanyI)-1,3,5-triazinyl]—4-(difluoromethyl)pyridin-2— amine; -[4,6-bis[(3R)—3-isopropy|morpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridin amine; 4-[6-amino—4-(difIuoromethyl)pyridy|]-N-methy|—6-[(3R)—3-methy|morpholinyl]—Ntrifluoroethyl)—1,3,5-triazinamine; 4-[6-amino—4-(difIuoromethyl)pyridy|][(3R)—3-methy|morpholinyl]—N-(2,2,2- oroethyl)—1,3,5-triazinamine; 4-[6-amino—4-(difIuoromethyl)pyridy|]-N-(cyc|opropy|methyl)[(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2,2,2-trifluoroethoxy)—1,3,5-triazin- 2-yl]pyridinamine; -[4-(2,2-difluoroethoxy)—6-[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine; -[4-[(3aR,6aS)—1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrro|y|][(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; -[4-[(4aS,7aR)—2,3,4a,5,7,7a-hexahydro—[1,4]dioxino[2,3-0]pyrrolyl]—6-[(3R)—3- methylmorpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridinamine; 4-(difluoromethyl)—5-[4-(4,4-difluoro—1-piperidyl)[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2-oxaazaspiro[3.5]nonany|)— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R,58)—3,5-dimethylmorpholin y|]-1,3,5-triaziny|]pyridinamine; luoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-(methoxymethyl)morpholin- 4-y|]-1,3,5-triazinyl]pyridinamine; [(3R)—4-[4-[6-amino—4-(difluoromethyl)pyridy|]—6-(3,3-dimethylmorpholinyl)—1 ,3,5- triazinyl]morpholinyl]methanol; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(3,7-dioxa-9— yclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine; 4-cyclopropylpiperaziny|)(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[4-(2-methoxyethyl)piperaziny|]- triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)(oxetany|oxy)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3S)—tetrahyd rofurany|]oxy-1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3R)—tetrahyd rofurany|]oxy-1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-tetrahydropyranyloxy-1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(1,1-dioxo—1,4-thiazinany|)-1,3,5- triazinyl]pyridinamine; [(3R)—4-[4-[6-amino—4-(difluoromethyl)pyridyl]—6-[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]morpholinyl]methanol; 4-(difluoromethyl)[4-[(3R,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-[(3S,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)—5-[4-morpholino—6-(3-oxa-9—azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazin y|]pyridinamine; -[4,6-bis(3-oxa-9—azabicyc|o[3.3.1]nonan-9—yI)-1,3,5-triazin-2—yl]—4-(difluoromethyl)pyridin- 2-amine; -[4-[6-amino—4-(difluoromethyl)pyridy|]—6-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)— 1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; luoromethyl)[4-[(3R)—3-methy|morpholiny|](4-morpho|ino—1-piperidy|)—1 ,3,5- triazinyl]pyridinamine; -[4-(4-cyclopropylpiperaziny|)[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine; -[4-(4-Cyclopropylpiperaziny|)[(3S,5R)—3,5-dimethylmorpholinyl]—1,3,5-triazin y|](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[4-(2-methoxyethyl)piperaziny|][(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[4-(2- methoxyethyl)piperaziny|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-(4-morpho|ino—1-piperidy|)— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(1,1-dioxo—1,4-thiazinanyl)[(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-(1,1-dioxo—1,4-thiazinan y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]tetrahydropyranyloxy-1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-tetrahyd ropyranyloxy- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(3S)—tetrahydrofurany|]oxy- triazinyl]pyridinamine; luoromethyl)[4-[(3R)—3-methy|morpholinyl][(3R)—tetrahyd rofurany|]oxy- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholiny|][(3S)—tetrahydrofuran -1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—tetrahyd rofuran y|]oxy-1,3,5-triazinyl]pyridinamine; 2015/076192 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](oxetanyloxy)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholiny|](oxetanyloxy)—1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-(3,7-dioxa-9— azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine; 3-[4-[6-amino—4-(difluoromethyl)pyridyl]—6-[(3R,58)—3,5-dimethylmorpholinyl]—1 ,3,5- ny|]oxazo|idinone; -(4-((1R,2R,48,5S)—7-oxa-9—azatricyclo[3.3.1.02‘4]nonan-9—yl)((2R,4S)—7-oxa-9— cyclo[3.3.1.02‘4]nonanyI)-1,3,5-triazinyl)—4-(difluoromethyl)pyridinamine; -[4,6-bis(6,6-difluoro—3-oxa-8—azabicyclo[3.2.1]octan-8—yI)-1,3,5-triazinyI] (difluoromethyl)pyridinamine; -[4,6-bis(6,7-difluoro—3-oxa-8—azabicyclo[3.2.1]octan-8—yI)-1,3,5-triazinyI] (difluoromethyl)pyridinamine; 5-[4-(6-amino—3-pyridyl)[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine; 4-(difluoromethyl)—5-[4-[4-(difluoromethyl)pyridy|]—6-[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morph0|iny|](3-pyridy|)-1,3,5-triazinyl]pyridin- 2-amine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]pyraziny|-1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1,2,4-triazoly|)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-1,2,4-triazoly|)—1,3,5-triazin- 2-yl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2H-tetrazolyl)—1,3,5-triazin y|]pyridinamine.
In another red embodiment, said compound of formula (I) is selected from 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazinyl)pyrimidinamine; -(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octan-8—y|)—1 ,3,5- nyl)—4-(difluoromethyl)pyridinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)—6-morpholino—1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine; -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)—6-morpholino—1,3,5-triazin-2—yl)—4- (difluoromethyl)pyrimidinamine; -(4,6-bis((S)—3-methy|morpholino)—1,3,5-triazinyl)—4-(difluoromethyl)pyridinamine; -(4,6-bis((S)—3-methy|morpholino)—1,3,5-triazinyl)—4-(difluoromethyl)pyrimidinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-morpholino—1,3,5-triaziny|)pyridin amine; (difluoromethyl)(4-(3-methy|morpho|ino)—6-morpholino—1,3,5-triaziny|)pyrimidin- 2-amine; -(4-(3-oxaazabicyc|o[3.2.1]octan-8—y|)((S)—3-methy|morpho|ino)—1,3,5-triazinyl)—4- (difluoromethyl)pyridinamine; 5-(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)((S)—3-methy|morpho|ino)—1,3,5-triazinyl)—4- (difluoromethyl)pyrimidinamine; 4-(difluoromethyl)(4-morpholino—6-(piperaziny|)-1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)(4-morpho|ino—6-(piperaziny|)-1,3,5-triazinyl)pyrimidinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-(piperaziny|)-1,3,5-triazin y|)pyridinamine; (S)—4-(difluoromethyl)(4-(3-methy|morpho|ino)—6-(piperaziny|)-1,3,5-triazin y|)pyrimidinamine; 4-(difluoromethyl)—5-(2,6-dimorpholinopyrimidiny|)pyridinamine; 4'-(difluoromethyl)—2,6-dimorpholino—[4,5'-bipyrimidin]—2'-amine; 4-(difluoromethyl)—5-(4,6-dimorpholinopyrimidiny|)pyridinamine; 4'-(difluoromethyl)—4,6-dimorpholino—[2,5'-bipyrimidin]—2'-amine; 4-(difluoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triaziny|)pyridinamine; 4-(difluoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triaziny|)pyrimidinamine; -(6-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octan-8— y|)pyrimidiny|)(difluoromethyl)pyridinamine; -(2—(3-oxaazabicyclo[3.2.1]octany|)morpho|inopyrimidiny|) oromethyl)pyridinamine; 2-(3-oxaazabicyclo[3.2.1]octan-8—y|)—4’-(difluoromethyl)—6-morpholino—[4,5’-bipyrimidin]— 2’-amine; 5-(2,6-bis((S)—3-methy|morpholino)pyrimidiny|)(difluoromethyl)pyridinamine; 4'-(difluoromethyl)-2,6-bis((S)—3-methy|morpholino)—[4,5'-bipyrimidin]—2'-amine; WO 75130 (S)—4-(difluoromethyl)(6-(3-methy|morpho|ino)morpho|inopyrimidiny|)pyridin amine; (S)—4'-(difluoromethyl)(3-methy|morpho|ino)—2-morpho|ino-[4,5'-bipyrimidin]-2'-amine; -(4-(8—Oxaazabicyclo[3.2.1]octanyl)(8—oxaazabicyclo[3.2.1]octany|)—1 ,3,5- triaziny|)(difluoromethyl)pyridinamine; -[4,6-bis(2,2-dimethylmorpholinyl)—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; (S)—4-(difluoromethyl)(2-(3-methy|morpho|ino)morpho|inopyrimidiny|)pyridin amine; (S)—4'-(difluoromethyl)(3-methy|morpholino)—6-morpho|ino-[4,5'-bipyrimidin]-2'-amine; 4-(difluoromethyl)—5-[4-[(28,6R)—2,6-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; -[4,6-bis[(2R,6S)—2,6-dimethylmorpholiny|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin- 2-amine.
In another preferred ment, said compound of formula (I) is ed from 4-[4-[6-amino(difluoromethyl)pyridy|]—6-morpho|ino-1,3,5-triaziny|]morpho|in one; 4-[4-[2-amino(difluoromethyl)pyrimidinyl]—6-morpholino-1,3,5-triaziny|]morpho|in one; 5-[4,6-bi3(3,7-dioxa-9—azabicyc|o[3.3.1]nonany|)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyc|o[3.3.1]nonan-9—y|)—6-(3-oxa-8— azabicyclo[3.2.1]octan-8—y|)—1,3,5-triazinyl]pyridinamine; -[4,6-bis(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; 5-[4,6-bis[(3R,58)—3,5-dimethylmorpholiny|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin- 2-amine; -[4,6-bis[(3R)—3-methy|morpholiny|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin amine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-morpholino-1,3,5-triaziny|]pyridin- 2-amine; -[4-[6-amino(difluoromethyl)pyridy|]—6-[(3R)—3-methy|morpholiny|]-1,3,5-triazin y|](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-methy|morpholiny|]-1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-(methoxymethyl)morpholinyl]—6-[(3R)—3- methylmorpholinyl]—1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—6-[(3R)—3- morpholinyl]—1,3,5-triaziny|]pyridinamine; (4S,5R)—3-[4-[2-amino—4-(difluoromethyl)pyrimidinyl]—6-morpholino—1,3,5-triazinyl]—4- (hydroxymethyl)—5-methy|—oxazolidinone; (4S,5R)—3-[6-[2-amino—4-(difluoromethyl)pyrimidinyl]—2-morpholino—pyrimidiny|] (hydroxymethyl)—5-methy|—oxazolidinone; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](3-oxaazabicyclo[3.1.1]heptan- 6-y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](6-oxaazabicyclo[3.1.1]heptan- 3-y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1R,4R)—2-oxa azabicyc|o[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1S,4S)—2-oxa azabicyc|o[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine; -[4,6-bis[(3R)—3-ethy|morpholinyl]—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; -[4,6-bis(8—oxaazaspiro[3.5]nonanyI)-1,3,5-triazinyl]—4-(difluoromethyl)pyridin-2— amine; 5-[4,6-bis[(3R)—3-isopropy|morpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridin amine; 4-[6-amino—4-(difIuoromethyl)pyridy|]-N-methy|—6-[(3R)—3-methy|morpholinyl]—N- (2,2,2-trifluoroethyl)—1,3,5-triazinamine; 4-[6-amino—4-(difIuoromethyl)pyridy|][(3R)—3-methy|morpholinyl]—N-(2,2,2- trifluoroethyl)—1,3,5-triazinamine; 4-[6-amino—4-(difIuoromethyl)pyridy|]-N-(cyc|opropy|methyl)[(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2,2,2-trifluoroethoxy)—1,3,5-triazin- 2-yl]pyridinamine; 5-[4-(2,2-difluoroethoxy)—6-[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine; -[4-[(3aR,6aS)—1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrro|y|][(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; -[4-[(4aS,7aR)—2,3,4a,5,7,7a-hexahydro—[1,4]dioxino[2,3-0]pyrrolyl]—6-[(3R)—3- morpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridinamine; 4-(difluoromethyl)—5-[4-(4,4-difluoro—1-piperidyl)[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2-oxaazaspiro[3.5]nonany|)— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R,58)—3,5-dimethylmorpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-(methoxymethy|)morpholin- 1,3,5-triazinyl]pyridinamine; [(3R)—4-[4-[6-amino—4-(difluoromethyl)pyridy|]—6-(3,3-dimethylmorpholinyl)—1 ,3,5- triazinyl]morpholinyl]methanol; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(3,7-dioxa-9— azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine; -[4-(4-cyclopropylpiperaziny|)(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[4-(2-methoxyethy|)piperaziny|]- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)(oxetany|oxy)—1,3,5-triazin idinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3S)—tetrahyd rofurany|]oxy-1 ,3,5- nyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3R)—tetrahyd rofurany|]oxy-1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-tetrahydropyranyloxy-1,3,5- triazinyl]pyridinamine; luoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(1,1-dioxo—1,4-thiazinany|)-1,3,5- triazinyl]pyridinamine; [(3R)—4-[4-[6-amino—4-(difluoromethyl)pyridyl]—6-[(3R)—3-methy|morpholinyl]—1 ,3,5- triazinyl]morpholinyl]methanol; 4-(difluoromethyl)[4-[(3R,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-[(3S,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-morpho|ino—6-(3-oxa-9—azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazin y|]pyridinamine; -[4,6-bis(3-oxa-9—azabicyc|o[3.3.1]nonan-9—yI)-1,3,5-triazin-2—yl]—4-(difluoromethyl)pyridin- 2-amine; -[4-[6-amino—4-(difluoromethyl)pyridy|]—6-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)— 1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](4-morpho|ino—1-piperidy|)—1 ,3,5- triazinyl]pyridinamine; -[4-(4-cyclopropylpiperaziny|)[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine; -[4-(4-Cyclopropylpiperaziny|)[(3S,5R)—3,5-dimethylmorpholinyl]—1,3,5-triazin y|](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[4-(2-methoxyethyl)piperaziny|][(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[4-(2- methoxyethyl)piperaziny|]-1,3,5-triaziny|]pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-(4-morpho|ino—1-piperidy|)— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(1,1-dioxo—1,4-thiazinanyl)[(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-(1,1-dioxo—1,4-thiazinan y|)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]tetrahydropyranyloxy-1,3,5- triazinyl]pyridinamine; luoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-tetrahyd nyloxy- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(3S)—tetrahydrofurany|]oxy- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholinyl][(3R)—tetrahyd rofurany|]oxy- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholiny|][(3S)—tetrahydrofuran y|]oxy-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—tetrahyd rofuran y|]oxy-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](oxetanyloxy)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-(oxetanyloxy)—1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-(3,7-dioxa-9— yclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine; 3-[4-[6-amino—4-(difluoromethyl)pyridyl]—6-[(3R,58)—3,5-dimethylmorpholinyl]—1 ,3,5- nyl]oxazolidinone; -(4-((1R,2R,4S,5S)—7-oxa-9—azatricyc|o[3.3.1.02*4]nonany|)((2R,4S)—7-oxa-9— azatricyclo[3.3.1.02‘4]nonany|)-1,3,5-triazinyl)—4-(difluoromethyl)pyridinamine; -[4,6-bis(6,6-difluorooxa-8—azabicyclo[3.2.1]octany|)—1,3,5-triazinyI] (difluoromethyl)pyridinamine; -[4,6-bis(6,7-difluorooxa-8—azabicyc|o[3.2.1]octany|)—1,3,5-triazinyI] (difluoromethyl)pyridinamine; -[4-(6-aminopyridyl)[(3R)—3-methy|morpholiny|]-1,3,5-triaziny|] (difluoromethyl)pyridinamine; 4-(difluoromethy|)[4-[4-(difluoromethyl)pyridyl]—6-[(3R)—3-methy|morpholiny|]-1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](3-pyridy|)-1,3,5-triaziny|]pyridin 2-amine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]pyraziny|—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1,2,4-triazo|—1-y|)—1,3,5-triazin y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-1,2,4-triazo|—3-y|)—1,3,5-triazin- 2-y|]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2H-tetrazoIy|)-1,3,5-triazin y|]pyridinamine.
In another preferred embodiment, said compound of formula (I) is ed from the group ting of - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triaziny|)pyrimidinamine; - 3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octan-8—y|)—1 ,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)—6-morpho|ino-1,3,5-triazin-2—y|) (difluoromethyl)pyridinamine; - 5-(4,6-bis((S)methy|morpho|ino)—1,3,5-triaziny|)(difluoromethyl)pyrimidin amine; - (S)(difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin- 2-amine; - 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyrimidinamine; - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyridinamine; and - (S)(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazin y|)pyrimidinamine; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In another preferred embodiment, said nd of formula (I) is selected from - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; - (S)(difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin- 2-amine; and tautomers, solvates and pharmaceutically acceptable salts f.
In another very preferred ment, said compound of formula (I) is 4-(difluoromethyl)- -(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine.
In another very red embodiment, said compound of formula (I) is 4-(difluoromethyl)- -(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; and tautomers, solvates and ceutically acceptable salts thereof.
In another very preferred ment, said nd of formula (I) is 5-(4-(3-oxa azabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octanyl)-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine.
In another very preferred embodiment, said compound of formula (I) is 5-(4-(3-oxa azabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octanyl)-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In another very preferred embodiment, said compound of formula (I) is (S) (difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin amine.
In another very red embodiment, said compound of formula (I) is (S) (difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin amine; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In another preferred embodiment, said compound of formula (I) is selected from 4-[4-[6-amino(difluoromethyl)pyridyl]—6-morpholino-1,3,5-triazinyl]morpholin one; 4-[4-[2-amino(difluoromethyl)pyrimidinyl]—6-morpholino-1,3,5-triazinyl]morpholin one; 5-[4,6-bis(3,7-dioxa-9—azabicyclo[3.3.1]nonanyl)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—yl)—6-(3-oxa-8— azabicyclo[3.2.1]octanyl)-1,3,5-triazinyl]pyridinamine; -[4,6-bis(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine; 5-[4,6-bis[(3R,58)—3,5-dimethylmorpholinyl]-1,3,5-triazinyl]—4-(difluoromethyl)pyridin- 2-amine; -[4,6-bis[(3R)—3-methylmorpholinyl]—1,3,5-triazinyl]—4-(difluoromethyl)pyridin amine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-morpholino-1,3,5-triazinyl]pyridin- 2-amine; -[4-[6-amino(difluoromethyl)pyridyl]—6-[(3R)—3-methylmorpholinyl]—1,3,5-triazin yl]—4-(difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methylmorpholin yl]—1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-methylmorpholinyl]—1 ,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)—3-(methoxymethyl)morpholinyl]—6-[(3R)—3- morpholinyl]—1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—yl)—6-[(3R)—3- methylmorpholinyl]—1,3,5-triazinyl]pyridinamine; (4S,5R)—3-[4-[2-amino(difluoromethyl)pyrimidinyl]—6-morpholino-1,3,5-triazinyl]—4- (hydroxymethyl)methyI-oxazolidinone; and tautomers, es and pharmaceutically able salts thereof.
In another preferred embodiment, said compound of formula (I) is (4S,5R)—3-[4-[2-amino- 4-(difluoromethyl)pyrimidinyl]—6-morpholino-1,3,5-triazinyl]—4-(hydroxymethyl)—5- -oxazolidinone.
In another red embodiment, said compound of formula (I) is (4S,5R)—3-[4-[2-amino- 4-(difluoromethyl)pyrimidinyl]—6-morpholino-1,3,5-triazinyl]—4-(hydroxymethyl)—5- methyl-oxazolidinone; and tautomers, es and pharmaceutically acceptable salts thereof.
In another preferred ment, said R1 and R2 are independently of each other a morpholinyl of formula (II). In one preferred embodiment, said R1 is equal to R2. In another preferred embodiment, said R1 is not equal to R2.
In another preferred embodiment, said R1 and R2 are independently of each other a morpholinyl of formula (II) and said 5- to 6-membered heteroaryl ring W.
In another preferred embodiment, said R1 and R2 are independently of each other a morpholinyl of a (II) and said saturated 4- to 6-membered heterocyclic ring Z.
In r preferred embodiment, said R1 and R2 are independently of each other a morpholinyl of formula (II) and said OR12.
In another preferred embodiment, said R1 and R2 are independently of each other a morpholinyl of formula (II) and said NR15R16.
In another preferred embodiment, within said morpholinyl of formula (ll) Rsfi 1R4 I (II) R3 and R4 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, uoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, H-CH2-, or any of the structures / \ I \ ; wherein the arrows denote the bonds in formula (II).
In the instance that R3 and R4 together form a nt residue and are bound to vicinal carbon atoms annulated morpholinyl substituents are formed. In the instance that R3 and R4 together form a bivalent residue and are spanning across the morpholine ring bridged morpholinyl substituents are . In the ce that R3 and R4 together form a bivalent residue and are bound to the same carbon atom of the morpholine, spiro morpholinyl substituents are formed.
In a preferred embodiment, R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene optionally substituted with 1 to 4 F, -CH2-, -CH2-NH-CH2-, or any of the structures f O and forming a bridged morpholinyl substituent.
In another preferred embodiment, said R1 and R2 are independently of each other a morpholinyl of formula (II), wherein R3 and R4 form together a bivalent residue leading to a bridged morpholinyl, wherein R3 and R4 form together a bivalent residue —R5R6— selected from lkylene, preferably C1-Czalkylene, -CHZCF2-, -CHFCHF-, -CHZCFZCH2-, -CH2- O-CH2-, -CH2-NH-CH2-, or any of the structures / \ I \ ; wherein the arrows denote the bonds in formula (II).
In a further preferred embodiment, said morpholinyl of formula (ll) Rsi 1R4 i (II) is independently of each other a morpholinyl of said formula (II), wherein R3 and R4 are ndently of each other H, C1-Csalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene, preferably C1-Czalkylene, -CH2CF2-, F-, 2CH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the stru ctu res i \ I \ ; wherein the arrows denote the bonds in formula (II).
In a further preferred embodiment, said linyl of formula (II) is independently of each other a morpholinyl of said formula (II), wherein R3 and R4 are independently of each other H or CH3.
In a further preferred embodiment, said morpholinyl of formula (II) is independently of each other a morpholinyl of said formula (II), wherein R3 and R4 are ndently of each other CZ-Csalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1- xyC1-Cgalkyl, ON, or C(O)O-C1-Cza|kyl; or R3 and R4 form together a bivalent residue —R5R6— selected from —CH2— or Cgalkylene, preferably —CH2—, -CHZCF2-, - CHFCHF-, -CHZCFZCH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures / \ I \ ; wherein the arrows denote the bonds in formula (II).
In a further preferred embodiment, said morpholinyl of formula (II) is independently of each other ed from [E1 [EL [EL [EL ,EEL ,erl o [a or r3 1:} a L MW1% [ELL [ELLEEJ’[ET[EEJQ Q Q [EL IZEI {E}: EE13 [EE0]: o :3» @ewee%%, a 3 E} 21:} * i l l l l i M L? {$35 M El F VF wI3 '3" [G ‘3‘ r F‘ F E F N N NL N jfi/ Njfi< F i if l if F + F ['3' I Ci 1:» a E E E l a. a + N i + In a further preferred embodiment, said morpholinyl of formula (II) is independently of each other selected from [Ct] [01 [I33 [It [[3, [1 lil E -.--.-__I_ L E E :k '3 :1 E All: j\ _ [It In D i | ,r J. E L a w M N A ll 1i 1i DH 1* In a further preferred ment, R1 or R2 is said 5- to 6-membered heteroaryl ring W.
WO 75130 In a further preferred embodiment, said one to four atoms of said 5- to 6-membered heteroaryl ring W are solely N, and n said 6-membered heteroaryl ring W is optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1- Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically able salts f. Preferably, said 5- to 6-membered heteroaryl ring W containing one to four N is optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, lkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, , C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs- Cscycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further preferred embodiment, said heteroaryl ring W is a 6-membered heteroaryl ring containing one to four heteroatoms, wherein said atoms are solely N, and wherein said 6-membered heteroaryl ring W is optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, preferably fluorine, -OH, C1-Csalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs- Cscycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a r preferred embodiment, said 5- to 6-membered heteroaryl ring W is selected from F F F F 6’ 6” 6’ 6’ 6’ HEN N” HEN N” N” N’ N’ In a further very preferred embodiment, said aryl ring W is a 6-membered aryl ring selected from F F F F %’ I?” 6’ m” [If HEN N” HEN N” N” N” N” In a further preferred embodiment, R1 or R2 is said 4- to 6-membered heterocyclic ring Z.
In a further preferred ment, said heterocyclic ring Z is a ted 5- to 6- membered heterocyclic ring Z ning 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1- Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs-Cecycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1-Cgalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CHZCH2-O-; In a further preferred embodiment, said heterocyclic ring Z is a saturated 5- to 6- membered heterocyclic ring Z selected from III-F .13 N+ 06. N III—h HN Na...
F t I a s 2015/076192 “0*” it Cl" H -I r In an again further preferred embodiment, said heterocyclic ring Z is a saturated 5- to 6- membered heterocyclic ring Z selected from F r “a a“ H F ‘a_.-" t it J or {—4 :1 ;’—‘~, ‘3'” ll 1m.-’ L-. :3,5 Ma- 0 I‘ll—h tale-F Hon In a preferred embodiment, said heterocyclic ring Z is an oxazolidinyl optionally tuted with halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHchs, C1-Czalkoxy, C1-CzalkoxyC1-Cgalkyl, =O, -NH2, NHCH3 or N(CH3)2.
In a further preferred embodiment, said heterocyclic ring Z is if} kill; In a further preferred embodiment, R1 or R2 is said OR”.
In a further preferred ment, said R12 is C1-Cgalkyl, CH2F, CHF2, CF3, CHZCHZF, CHZCHFZ, CHZCFs, C1-Cgalkoxy, Cg-Cecycloalkyl, C1-Czalkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to ered heterocyclic ring containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 2 R13, wherein R13 is independently at each occurrence halogen, -OH, lkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1-Czalkoxy, C1- CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1-CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing 1 to 2 heteroatoms ndently selected from N, O and S, optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1- szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Cgalkyl, -NH2, NHCH3 or N(CH3).
In a further preferred ment, said R12 is C1-Cgalkyl, CH2F, CHF2, CF3, CHZCHZF, CHZCHFZ, , C1-Cgalkoxy, Cg-Cecycloalkyl, C1-Czalkylenecg-Cscycloalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6-membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from O and 8, preferably from O, ally substituted by 1 to 2 R13, wherein R13 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1- Czalkoxy, C1-CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to 6-membered heteroaryl ring containing 1 to 2 heteroatoms, wherein said heteroatoms are N, and wherein said heteroaryl ring is optionally tuted by 1 to 3 R14, n R14 is ndently at each occurrence n, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3).
In an again further preferred embodiment, said OR12 is selected from In a further preferred embodiment, R1 or R2 is said NR15R16.
In a further preferred embodiment, said R15 and R16 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6- membered heterocyclic ring containing 1 to 2 heteroatoms independently selected from O and 8, preferably from O, optionally substituted by 1 to 2 R13, wherein R13 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1- Czalkoxy, C1-CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Cycle-Q represents 5- to ered aryl ring containing 1 to 2 heteroatoms, wherein said heteroatoms are N, and wherein said heteroaryl ring is optionally substituted by 1 to 3 R14, wherein R14 is ndently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3).
In a further red embodiment, said R15 and R16 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, uoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl; Cycle-P or C1-CzalkyleneCycle-P, wherein Cycle-P represents a saturated 4- to 6- ed cyclic ring containing 1 to 2 atoms independently selected from O and 8, preferably from O, optionally substituted by 1 to 2 R13, wherein R13 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, OH, C1-szluoroalkyl, C1- Czalkoxy, C1-CzalkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3); Cycle-Q or C1- CzalkyleneCycle-Q, wherein Q represents 5- to 6-membered heteroaryl ring ning 1 to 2 heteroatoms, wherein said heteroatoms are N, and wherein said heteroaryl ring is optionally substituted by 1 to 3 R14, wherein R14 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, C1-szluoroalkyl, C1-Czalkoxy, lkoxyC1-Csalkyl, -NH2, NHCH3 or N(CH3).
In an again further preferred embodiment, said NR15R16 is selected from , l: H l: H F . F l 4k].
Fix/m1 kai Ni 3.3%“: 3me1_ In another preferred embodiment of the t invention, said R1 and said R2 are independently of each other a morpholinyl of formula (II) WO 75130 l (H) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1- Cgalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue — R5R6— ed from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II).
In another preferred embodiment of the present invention, said R1 and said R2 are independently of each other a morpholinyl of formula (ll) Rafi 1R4 l (H) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1- Csalkyl, ON, or C1-Czalkyl; or R3 and R4 form together a bivalent residue — R5R6— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-, -CH2-NH-CH2-, or any of the structures A A- wherein the arrows denote the bonds in formula (II); with the provisos that (a) when R1 is holinyl, ylmorpholinyl, ylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 3-azaoxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8-azaoxabicyclo[3.2.1]octyl, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8-azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyclo[3.2.1]octyl.
In a further red embodiment, said R1 is equal to said R2, and said R1 and said R2 are independently of each other a morpholinyl of formula (ll) Rsi 1R4 i (ll) n the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl ally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, lkoxyC1- Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue — R5R6— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-, -CH2-NH-CH2-, or any of the ures wherein the arrows denote the bonds in formula (II).
In a further preferred embodiment, said R1 is equal to said R2, and said R1 and said R2 are independently of each other a morpholinyl of formula (II) R3E j—R‘i i (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl optionally substituted with one or two OH, C1-szluoroalkyl, C1-Czalkoxy, C1-CzalkoxyC1- Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue — WO 75130 R5R6— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 3-aza-8—oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octy| or 3-aza-8—oxabicyclo[3.2.1]octyl.
In a further preferred ment of the t invention, said R1 and said R2 are independently of each other a morpholinyl of formula (II) R3— _R4 f (H) n the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl, CHZOH, OH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene, preferably C1-Czalkylene, -CHZCF2-, F-, -CHZCFZCH2-, -CH2-O-CH2-, H-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II).
WO 75130 In a further preferred embodiment of the present invention, said R1 and said R2 are independently of each other a morpholinyl of formula (ll) Rsi 1R4 I (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, lkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— ed from C1-Cgalkylene, preferably C1-Czalkylene, -CHZCF2-, -CHFCHF-, -CHZCFZCH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures A A- n the arrows denote the bonds in formula (II); with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 3-oxabicyclo[3.2.1]octy| or 3-aza-8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]oct—8-y|, 3-aza-8—oxabicyclo[3.2.1]octy|, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, ylmorpholinyl, octadeuteriomorpholinyl, 3-oxabicyclo[3.2.1]octy|, 8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyc|o[3.2.1]octy|.
In a further preferred embodiment of the present invention, R1 is equal to R2, and said R1 and said R2 are a morpholinyl of formula (II) I (ll) wherein the arrow denotes the bond in formula (I); and 2015/076192 wherein R3 and R4 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— ed from C1-Cgalkylene, preferably C1-Czalkylene, -CHZCF2-, -CHFCHF-, -CHZCFZCH2-, -CH2-O-CH2-, H-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II).
In a further preferred embodiment of the present invention, R1 is equal to R2, and said R1 and said R2 are a morpholinyl of a (II) R3— _R4 i (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene, preferably lkylene, -CHZCF2-, -CHFCHF-, -CHZCFZCH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octy| or 8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, ylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octy|, 3-aza-8—oxabicyc|o[3.2.1]octy|, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octy|, 3-aza-8— yclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 3-oxabicyclo[3.2.1]oct—8—yl or 3-aza-8—oxabicyclo[3.2.1]octyl.
In another aspect and preferred embodiment, the present invention provides for a compound of (I) X’l/‘Nx2 {3% ,F it a, at “x3 “fits! ”a. ”flak N“ “Ni-i2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other a morpholinyl of formula (ll) R3E —R4 l (H) wherein the arrow denotes the bond in formula (I); and R1 is not equal to R2, and at least one of said R1 and said R2 are a morpholinyl of formula (II), R3— —R4 l ("l n R3 and R4 are independently of each other C2-C3alkyl, CHZOH, CH2CH20H, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, lkoxyC1-C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from —CH2— or C3alkylene, preferably —CH2—, -CH2CF2-, -CHFCHF-, -CH2CF2CH2-, -CH2-O-CH2-, H-CH2-, or any of the structures / \ I \ ; wherein the arrows denote the bonds in formula (II).
Preferably, said R3 and R4 form er a nt residue —R5R6— selected from — CH2— or C3alkylene, preferably —CH2—, -CH2CF2-, -CHFCHF-, -CH2CF2CH2-, -CH2- O-CH2-, -CH2-NH-CH2-, or any of the structures f \ I \ In a further aspect and preferred embodiment, the t invention provides for a compound of formula (I), wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said 5- to 6-membered heteroaryl ring W, and ers, solvates and pharmaceutically acceptable salts thereof.
In a further aspect and preferred embodiment, the present invention provides for a compound of (l) x'f/étl‘xz F“ /F if L 3‘ N“ x3?“ “NE,, W, Y ”m iijx N NH2 (I) wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a linyl of formula (ll) Rsi 1R4 i (ll) wherein the arrow denotes the bond in formula (I); and n R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, lkoxyC1- C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue— R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a 5- to 6-membered heteroaryl ring W containing one to four heteroatoms independently selected from N, O and S, optionally tuted by 1 to 3 R8, wherein WO 75130 R8 is independently at each occurrence halogen, -OH, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3)2; and prodrugs, metabolites, ers, solvates and pharmaceutically acceptable salts f, preferably and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the present invention provides for a compound of(|) 33,},W21“ ,3:.1 I R 1,3 “m x, N NH2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (II) R3E j—R‘i 1 (ll) wherein the arrow denotes the bond in formula (I); and n R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form er a bivalent residue— R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a 5- to 6-membered heteroaryl ring W containing one to four atoms, wherein said heteroatoms are solely N, and wherein said ered heteroaryl ring W is optionally tuted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, C1-C3alkyl optionally substituted with one or two OH, C1- C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically acceptable salts thereof.
Preferably, said 5- to 6-membered heteroaryl ring W containing one to four N is optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, C1-C3alkyl, CHZOH, CH2CH20H, CH2F, CHF2, CF3, , C1- C2a|koxy, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further preferred embodiment, the t invention provides for a compound of(|) X1’jkfx2 fix, w i: Rum,l I “it 3; ”NH; wherein X1, X2 and X3 are, independently of each other, N or CH; with the o that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 f (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene, preferably C1-C2alkylene, -CH2CF2-, -CHFCHF-, -CH2CF2CH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in a (II); and (ii) a 5- to ered heteroaryl ring W containing one to four heteroatoms, wherein said heteroatoms are solely N, and n said 5- to ered aryl ring W is optionally substituted by 1 to 3 R8, wherein R8 is independently at each occurrence halogen, -OH, C1-C3alkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, ycloalkyl, -NH2, NHCH3 or N(CH3)2, and tautomers, solvates and pharmaceutically able salts thereof.
In a further preferred embodiment, the present invention provides for a compound of(l) x1 N x2 a, ,9 Rf ”3:3? RD“ “its! ““Nifikmi-iz wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 i (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are ndently of each other H, C1-C3alkyl, CHZOH, 0H, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene, preferably C1-C2alkylene, -CH2CF2-, -CHFCHF-, -CH2CF2CH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a 5- to 6-membered heteroaryl ring W containing one to four atoms, wherein said heteroatoms are solely N, and wherein said 5- to 6-membered heteroaryl ring W is optionally substituted by 1 to 3 R8, wherein R8 is independently at each ence n, -OH, C1-C3alkyl, CHZOH, CH2CH20H, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl, -NH2, NHCH3 or N(CH3)2; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further preferred embodiment, the present invention es for a nd of(l) wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said 5- to 6-membered heteroaryl ring W, wherein said R1 and said R2 are independently of each other selected from 1 0 [:1 1;); ESL [Eli JEL 2:1;l 1:», E1 1:2} 1:} IIIIII I [a T3113)” [:1 E? E3} [ELGH rrrriir {j} [:33 [:13 [:0]: (:3? [:36 + i i i i [TL/F [it]? [i114 [tilting Kills“ F F’ F F [if if?” a “a ,.-' I I HEN N H2“ M if [”3” N” H” N4Pf i‘ K N" IN“ | "R hf hr [5} HHH i M “an Ira} [.N N Haw” H r H “rm M' and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further preferred ment, the present invention provides for a compound of (I) it; at 1/ R? (X3 Mix“ Mutt "“N "est—i2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said 5- to 6-membered aryl ring W, wherein said R1 and said R2 are independently of each other selected from D II} a i} Eli [il‘ jfik ,ENJ; WINL r Li + [i iii 5 0 '3" t [f-Ti’tletle”i 0‘“ i i i i i ®$#$%$$ TLVWWWW 99%???thl i it Erik? [$15]; [flick (irks, [it]? [Eh [31> 1:}: [3:0 (:33, l l + and tautomers, es and ceutically acceptable salts thereof.
In a further aspect and red embodiment, the present invention provides for a compound of formula (I), wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said saturated 4- to 6-membered heterocyclic ring Z, and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further aspect and preferred embodiment, the present invention provides for a compound of (l) WO 75130 gwx g: XI; “1-4:? X2 if L l/ R? NXS‘ \{W “31“}; “‘N'fi’i‘wi—i2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are ndently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 i (ll) wherein the arrow denotes the bond in formula (I); and n R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- l, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue — R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 4- to 6-membered heterocyclic ring Z containing 1 to 3 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, C3-C6cycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; and prodrugs, metabolites, tautomers, solvates and pharmaceutically able salts thereof, preferably and tautomers, es and pharmaceutically acceptable salts thereof.
In a further aspect and preferred embodiment, the present ion provides for a compound of (I) WO 75130 gwx g: XI; “1-4:? X2 if at l/ R? NXS‘ \{W “31“}; i‘wi—i2 X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 i (ll) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, ON, or C1-C2alkyl; or R3 and R4 form together a bivalent residue— R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 4- to ered heterocyclic ring Z containing 1 to 3 heteroatoms independently ed from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, C3-C6cycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a nt residue —R10R11— selected from C1-C3alkylene ally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, preferably and tautomers, solvates and pharmaceutically acceptable salts thereof; with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8-azaoxabicyc|o[3.2.1]oct—8-y| or 3-aza-8— WO 75130 oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8—aza yclo[3.2.1]oct—8-y|, 3-aza-8—oxabicyclo[3.2.1]octy|, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8—azaoxabicyclo[3.2.1]oct—8-y|, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, uteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 8—oxabicyclo[3.2.1]octy|.
In a preferred embodiment, the present invention provides for a compound of(|) L 1% x? x2 fr: kl 1 R1 ”X3 KEV/"wry N Mir—l2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (II) R3E j—R‘i i (ll) wherein the arrow denotes the bond in a (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally tuted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue — R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 5- to ered heterocyclic ring Z containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is ndently at each occurrence halogen, -OH, C1-C3alkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CH2CF3, lkoxy, lkoxyC1-C3alkyl, C3- Cecycloalkyl, =O, -NH2, NHCH3 or 2; or two R9 substituents form together a bivalent residue 1— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or CH2-O-; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the present invention provides for a compound of(|) xfijgxz F», “or: .13, ,XL :l RT x3 E NYa , filli‘x N NH2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 f (H) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue— R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 5- to 6-membered heterocyclic ring Z containing 1 to 2 atoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein WO 75130 R9 is independently at each occurrence halogen, -OH, C1-C3alkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, , C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3- Cecycloalkyl, =O, -NH2, NHCH3 or 2; or two R9 substituents form er a bivalent residue —R10R11— selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; and tautomers, solvates and pharmaceutically acceptable salts thereof; with the provisos that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 3-aza-8—oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- piperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyclo[3.2.1]octyl.
In a further preferred ment, the present invention provides for a compound of(l) wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) KN7R4 ¢ (ll) n the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, lkyl, CHZOH, CH2CH20H, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, ON, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene, preferably C1-C2alkylene, -CH2CF2-, -CHFCHF-, -CH2CF2CH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 5- to 6-membered heterocyclic ring Z containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-C3alkyl, CHZOH, CH2CH20H, CH2F, CHF2, CF3, , C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, C3- Cecycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1-C3alkylene ally substituted with 1 to 4 F, -CH2- or -O-CH2CH2-O-;. and tautomers, solvates and pharmaceutically acceptable salts f.
In a further preferred embodiment, the present invention provides for a compound of(l) wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and R1 and R2 are independently of each other (i) a morpholinyl of formula (ll) Rsi 1R4 l (H) n the arrow s the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, CHZCFs, C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, ON, or C(O)O-C1-Czalkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-Cgalkylene, preferably C1-Czalkylene, 2-, -CHFCHF-, -CHZCFZCH2-, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); and (ii) a saturated 5- to 6-membered heterocyclic ring Z containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-Cgalkyl, CHZOH, CHZCHZOH, CH2F, CHF2, CF3, , C1-Czalkoxy, C1-CzalkoxyC1-Csalkyl, Cs- Cecycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form together a bivalent residue —R10R11— selected from C1-Csalkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CHZCH2-O-;. and ers, solvates and pharmaceutically acceptable salts thereof; with the os that (a) when R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octy| or 3-aza-8— oxabicyclo[3.2.1]octyl; then R2 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 3- yclo[3.2.1]octy|, 3-aza-8—oxabicyc|o[3.2.1]octy|, 4-piperazinyl, 4- piperazinyl, or 4-thiomorpholinyl; (b) when R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octy|, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- rpholinyl; then R1 is not holinyl, ylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyc|o[3.2.1]octy|.
In a further preferred embodiment, the present invention provides for a compound of (l) I at I R? (X3 Mix“ Matt "“N "hit—i2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said saturated 4- to 6-membered cyclic ring 2, wherein said R1 and said R2 are independently of each other selected from «:3» fit [It 1:} Ct Us I][lIJ\[1{/[j\,[j 'i 'i i 'i 'i i izi D :3 C; a; “”[il‘ t 1V t t f ‘t J’ i 'i i i \th tgi’ gr“ 5;; E? tgiw tileW 6% w M a 633 “:5 tint WP “i? is i" i it i l t rrrriir [3- Ci 0 1:} Q Q {E} (p: [21:0 [@1130 [i]? [@103 o o a U D E’4?ij E jfi/F I: kl: E JW’U‘“ l: F i FF i a ilk?“ : Cit-1"" Ci><:H* USN N—h HMS“; —r~4 N-h N N+ I22} iii—h w._.r -_x n_x -._r ff; H, r—t EL I M '3 NJ 18 N" H m S New '3 a r o DH H L“0"” it 3:- D NJ In a further preferred ment, the present invention provides for a compound of (I) I at I R? (X3 Mix“ Matt "“N "hit—i2 wherein X1, X2 and X3 are, independently of each other, N or CH; with the o that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said saturated 4- to 6-membered heterocyclic ring 2, wherein said R1 and said R2 are independently of each other selected from «:3» fit [It 1:} Ct Us I][lIJ\[1{/[j\,[j 'i 'i i 'i 'i i izi D :3 C; a; “”[il‘ t 1V t t f ‘t J’ i 'i i i \th tgi’ gr“ 5;; E? tgiw tileW 6% w M a 633 “:5 tint WP “i? is i" i it i l t wvthtv [3- G 0 1:} Q Q {E} [21]: [21:0 [@1130 £th [$10.3 a D E} U D E’4?ij E jfi/F I: kl: E JW’U‘“ l: F t FF t [3 wk?“ : Chi-l" Ct>6???- DSH N—h HMS“; —r~4 N—a- N N+ I22} Nan w._r -_.a* -_x -._r ff; H, x—t EL I M '3 NJ a r 0 DH H L“0’" it 3:- D NJ with the provisos that (a) when R1 is 4-morpholinyl, 2-methyImorpholinyl, 3-methyImorpholinyl, octadeuterio—4-morpholinyl, 8—aza0xabicyclo[3.2.1]oct-8—y| or 3-aza-8— yclo[3.2.1]octy|; then R2 is not 4-morpholinyl, 2-methyImorpholinyl, 3-methyImorpholinyl, octadeuterio—4-morpholinyl, 8—aza yclo[3.2.1]oct—8-y|, 3-aza-8—oxabicyclo[3.2.1]octy|, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; (b) when R2 is holinyl, 2-methylmorpholinyl, 3-methylmorpholinyl, octadeuterio—4-morpholinyl, 8-azaoxabicyclo[3.2.1]oct—8-y|, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4- thiomorpholinyl; then R1 is not 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8-azaoxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyclo[3.2.1]octy|.
In a further red embodiment, the present invention es for a compound of(l) Lza F 1‘: UM” “QTY X31 Mi wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; and wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said saturated 4- to 6-membered heterocyclic ring Z, wherein said R1 and said R2 are independently of each other selected from [TL 12L 1T1; “(TL (TL, ”ETA“ET3”- YTTr [Tim £31» Tib$$$TiTElflEfi {3} {in €13“ {I} Ella 3%YfffpEll, 0‘ FF W» i , i l $74? l El)“ [l]? [ljri Elli“ [le [le [:19 [31> [311:0 [:33 + l i i + F Chi—r- r “a to>Cl-«l-h U N Na- F ‘~_f M Ma- :3 Pal—h “1* ~._.r -_.r a_»* DJ} U fl r1 1' '3' NH N’i‘" '3 CI NJ A ‘3" L DAM” OH H '3 H t l In a further aspect and preferred embodiment, the present invention provides for a compound of a (I), wherein R1 and R2 are independently of each other said morpholinyl of formula (II) and said OR12.
In a further aspect and preferred embodiment, the present invention provides for a compound of formula (I), wherein R1 and R2 are ndently of each other said morpholinyl of formula (II) and said NR15R16.
In another preferred embodiment, R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl.
In another red embodiment, R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl linyl, octadeuteriomorpholinyl, 3-oxabicyclo[3.2.1]octyl, 3-aza-8— oxabicyclo[3.2.1]octyl, razinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl, and X1, X2 and X3 are N; and ers, solvates and ceutically acceptable salts thereof. Preferably Y is N or CH; R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 3-aza-8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a further red embodiment, R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl- 4-morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl or 8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, yl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]octyl, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl, and X1 and X3 are N, and X2 is CH; and tautomers, solvates and pharmaceutically acceptable salts thereof. Preferably Y is N or CH; R1 is 4-morpholinyl, 2-methyl linyl, 3-methylmorpholinyl, octadeuteriomorpholiny|, 8—aza oxabicyclo[3.2.1]octyl or 3-aza-8—oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2- methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]octyl, 8—oxabicyclo[3.2.1]octyl, 4-piperaziny, 4- methylpiperazinyl, or 4-thiomorpholinyl; and tautomers, solvates and pharmaceutically able salts thereof.
In a preferred embodiment, R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]oct—8—yl or 3-aza-8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]oct—8—yl, 3-aza-8— yclo[3.2.1]octyl, 4-piperazinyl, ylpiperazinyl, or 4-thiomorpholinyl, and X1 and X2 are N, and X3 is CH; and tautomers, solvates and pharmaceutically acceptable salts thereof. Preferably, Y is N or CH; R1 is 4-morpholinyl, 2-methyl morpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]oct—8—yl or 3-aza-8—oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2- morpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 3- oxabicyclo[3.2.1]oct—8—yl, 3-azaoxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, R1 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl morpholinyl, octadeuteriomorpholinyl, 8—azaoxabicyclo[3.2.1]oct—8—yl or 3-aza-8— oxabicyclo[3.2.1]octyl; and R2 is 4-morpholinyl, 2-methylmorpholinyl, 3-methyl linyl, uteriomorpholinyl, 3-oxabicyclo[3.2.1]oct—8—yl, 3-aza-8— oxabicyclo[3.2.1]octyl, 4-piperazinyl, 4-methylpiperazinyl, or 4-thiomorpholinyl, and X2 and X3 are N, and X1 is CH; and tautomers, solvates and pharmaceutically acceptable salts thereof. Preferably, Y is N or CH; R1 is 4-morpholinyl, 2-methyl morpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza oxabicyclo[3.2.1]oct—8—yl or 3-aza-8—oxabicyclo[3.2.1]octyl; and R2 is holinyl, 2- methylmorpholinyl, 3-methylmorpholinyl, octadeuteriomorpholinyl, 8—aza yclo[3.2.1]oct—8—yl, 3-azaoxabicyclo[3.2.1]octyl, 4-piperazinyl, 4- methylpiperazinyl, or 4-thiomorpholinyl; and tautomers, solvates and pharmaceutically able salts thereof.
In a red embodiment, the compound of formula (I) is selected from the group consisting of - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyridinamine; - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyrimidinamine; - 5-(4,6-bis((S)—3-methylmorpholino)-1,3,5-triazinyl)(difluoromethyl)pyridinamine; - -bis((S)—3-methylmorpholino)—1,3,5-triazinyl)—4-(difluoromethyl)pyrimidin amine; - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin- 2-amine; - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazin y|)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)—3-methylmorpholino)—1,3,5-triazinyl)— 4-(difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)—3-methylmorpholino)—1,3,5-triazinyl)— 4-(difluoromethyl)pyrimidinamine; - 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyridinamine; - 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyrimidin amine; - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)—6-(piperazinyl)-1,3,5-triazin y|)pyridinamine; and - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)—6-(piperazinyl)-1,3,5-triazin y|)pyrimidinamine; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the compound of formula (I) is selected from the group ting of - 4-(difluoromethyl)—5-(2,6-dimorpholinopyrimidinyl)pyridinamine; - fluoromethyl)—2,6-dimorpholino-[4,5'-bipyrimidin]-2'-amine; - 5-(6-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octan imidinyl)—4-(difluoromethyl)pyridinamine; - 5-(6-(3-oxaazabicyclo[3.2.1]octanyl)morpholinopyrimidinyl)—4- (difluoromethyl)pyridinamine; - 6-(3-oxaazabicyclo[3.2.1]octanyl)-4'-(difluoromethyl)—2—morpholino-[4,5'- bipyrimidin]—2'-amine; - 5-(2,6-bis((S)—3-methylmorpholino)pyrimidinyl)—4-(difluoromethyl)pyridinamine; - 4'-(difluoromethyl)-2,6-bis((S)—3-methylmorpholino)-[4,5'-bipyrimidin]-2'-amine; - (S)—4-(difluoromethyl)(6-(3-methylmorpholino)morpholinopyrimidinyl)pyridin amine; - (S)—4'-(difluoromethyl)(3-methylmorpholino)—2-morpholino-[4,5'-bipyrimidin]-2'-amine; - 5-(2—(3-oxaazabicyclo[3.2.1]octanyl)morpholinopyrimidinyl)—4- (difluoromethyl)pyridinamine; - 2-(3-oxaazabicyclo[3.2.1]octanyl)-4'-(difluoromethyl)—6-morpholino-[4,5'- bipyrimidin]—2'-amine; - (S)—4-(difluoromethyl)(2-(3-methylmorpholino)morpholinopyrimidinyl)pyridin amine; and - -(difluoromethyl)(3-methylmorpholino)morpholino-[4,5'-bipyrimidin]-2'-amine; and ers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the compound of formula (I) is selected from the group consisting of luoromethyl)(6-morpholino(piperazinyl)pyrimidinyl)pyridin amine and 4'-(difluoromethyl)—6-morpholino(piperaziny|)-[4,5'-bipyrimidin]—2'-amine; and tautomers, solvates and ceutically acceptable salts thereof.
In a preferred embodiment, the compound of formula (I) is selected from the group consisting of 4-(difluoromethyl)—5-(4,6-dimorpholinopyrimidinyl)pyridinamine and 4'- (difluoromethyl)—4,6-dimorpholino-[2,5'-bipyrimidin]-2'-amine; and tautomers, solvates and pharmaceutically acceptable salts thereof.
In a preferred embodiment, the compound of formula (I) is selected from the group ting of - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxa-8—azabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)—4-(difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine; - 5-(4,6-bis((S)—3-methylmorpholino)—1,3,5-triazinyl)—4-(difluoromethyl)pyrimidin amine; - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)—6-morpholino-1,3,5-triazinyl)pyridin- 2-amine; - 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyrimidinamine; - 4-(difluoromethyl)—5-(4,6-dimorpholino-1,3,5-triazinyl)pyridinamine; and - (S)—4-(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazin y|)pyrimidinamine; and tautomers, solvates and pharmaceutically acceptable salts thereof. red are compounds wherein R1 and R2 are 4-morpholinyl.
Likewise preferred are compounds wherein R1 and R2 are 3-aza-8—oxabicyclo[3.2.1]oct Likewise red are compounds wherein R1 and R2 are (S)—3-methylmorpholinyl.
Likewise preferred are compounds wherein R1 is 4-morpholinyl and R2 is (S)—3-methyl morpholinyl.
Likewise preferred are compounds wherein R1 is 4-morpholinyl and R2 is 3-aza-8— oxabicyclo[3.2.1]octyl.
Likewise red are compounds n R1 is 4-morpholinyl and R2 is 4-piperazinyl.
Likewise preferred are compounds wherein R1 is 4-morpholinyl and R2 is 4-thio- morpholinyl.
More preferred are compounds of formula (I) n R1 and R2 are 4-morpholinyl, and Y is CH.
Equally preferred are compounds of formula (I) wherein R1 and R2 are holinyl, and Y is N.
More preferred are compounds of formula (I) wherein R1 and R2 are 3-aza-8— oxabicyclo[3.2.1]octyl, and Y is CH.
More preferred are compounds of formula (I) wherein R1 and R2 are (S)—3-methyl linyl, and Y is N.
More preferred are compounds of formula (I) wherein R1 is 4-morpholinyl and R2 is 4- piperazinyl, and Y is N.
More preferred are compounds of formula (I) wherein R1 is 4-morpholinyl and R2 is (S) methylmorpholinyl, and Y is CH.
More preferred are compounds of formula (I) wherein R1 is 4-morpholinyl and R2 is 3-aza- 8-oxabicyclo[3.2.1]octyl, and Y is N.
More preferred are compounds of formula (I) wherein R1 is methylmorpholinyl and R2 is 8—oxabicyclo[3.2.1]octyl, and Y is CH.
More preferred are compounds of formula (I) wherein R1 is (S)—3-methylmorpholinyl and R2 is 4-piperazinyl, and Y is CH.
Likewise preferred are compounds of formula (I) n R1 is (S)—3-methylmorpholinyl and R2 is 4-piperazinyl, and Y is N.
More preferred are compounds of formula (I) wherein R1 is 4-morpholinyl and R2 is 4- thiomorpholinyl, and Y is CH.
Likewise preferred are compounds of formula (I) wherein R1 is 4-morpholinyl and R2 is 4- rpholinyl, and Y is N.
Even more preferred are compounds of formula (I), wherein X1, X2 and X3 are N.
Likewise preferred are compounds of formula (I), wherein X1 and X3 are N, and X2 is CH.
Most preferred are the ing compounds shown by formula: (The names of the corresponding structures were produced using ChemDraw Ultra, version 13.0.1 as well as lower and upper software ns thereof, CambridgeSoft Corp., Cambridge MA). 2015/076192 Compound 1: 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazin-2—y|)pyridinamine Compound 2: 4-(difluoromethyl)—5-(4,6-dimorpholino—1,3,5-triazin-2—y|)pyrimidin-2—amine Compound 3: gt: F N N 0@*flN/ -(4-(3-oxaazabicyclo[3.2.1]octan-8—y|)(3-oxa-8—azabicyclo[3.2.1]octan-8—y|)—1 ,3,5- triazin-2—y|)(difluoromethyl)pyridin-2—amine Compound 4: N N |\ CK) N/ NH2 -(4-(3-oxaazabicyclo[3.2.1]octany|)morpho|ino-1,3,5-triazin-2—yl)—4- (difluoromethyl)pyridinamine WO 75130 Compound 5: 4F}: N1 N 0QNxNéng| AN -(4-(3-oxaazabicyclo[3.2.1]octany|)morpho|ino-1,3,5-triazin-2—y|)—4- (difluoromethyl)pyrimidin-2—amine Compound 6: -(4,6-bis((S)—3-methylmorpholino)—1,3,5-triazin-2—yI)(difluoromethyl)pyridinamine Compound 7: 5-(4,6-bis((S)—3-methylmorpholino)—1,3,5-triazin-2—yI)(difluoromethyl)pyrimidin-2—amine Compound 8: (S)—4-(difluoromethyl)(4-(3-methy|morpholino)—6-morpho|ino-1,3,5-triazin-2—y|)pyridin amine Compound 9: (S)—4-(difluoromethyl)(4-(3-methy|morpholino)—6-morpho|ino-1,3,5-triazin-2— y|)pyrimidin-2—amine Compound 10: |\ N O(ZN N/ NH2 -(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)—3-methy|morpholino)—1,3,5-triazin-2—yl)— 4-(difluoromethyl)pyridinamine Compound 11: F F N \N (g ;N/kN/ \N O 42 -(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)—3-methy|morpholino)—1,3,5-triazin-2—yl)— 4-(difluoromethyl)pyrimidin-2—amine Compound 12: 4-(difluoromethyl)(4-morpho|ino(piperaziny|)-1,3,5-triazin-2—y|)pyridinamine Compound 13: jig“! F F N N \N 0d l N/)\NH2 4-(difluoromethyl)(4-morpho|ino—6-(piperaziny|)-1,3,5-triazin-2—y|)pyrimidin-2—amine Compound 14: (S)—4-(difluoromethyl)(4-(3-methy|morpholino)—6-(piperaziny|)-1,3,5-triazin-2— yl)pyridin-Z-amine Compound 15: (S)—4-(difluoromethyl)(4-(3-methy|morpholino)—6-(piperaziny|)-1,3,5-triazin-2— yl)pyrimidin-Z-amine nd 16: N\F F N N |\ N/NH2 4-(difluoromethyl)—5-(2,6-dimorpholinopyrimidinyl)pyridin-2—amine Compound 17: 4'-(difluoromethyl)—2,6-dimorpholino—[4,5'-bipyrimidin]—2'-amine Compound 18: N N |\ 0d N/ NH2 4-(difluoromethyl)—5-(4,6-dimorpholinopyrimidin-2—yl)pyridin-2—amine Compound 19: I“ F N ‘N/ 0d N/)\NH2 4'-(difluoromethyl)—4,6-dimorpholino—[2,5'-bipyrimidin]-2'-amine Compound20: luoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triazin-2—y|)pyridinamine Compound21: 4-(difluoromethyl)(4-morpho|ino—6-thiomorpholino—1,3,5-triazin-2—y|)pyrimidin-2—amine Further preferred are the following compounds Compound 22: -(6-(3-oxaazabicyclo[3.2.1]octan-8—y|)(3-oxa-8—azabicyclo[3.2.1]octan-8— yl)pyrimidinyl)—4-(difluoromethyl)pyridinamine Compound 23: / \ ~ / tttt difluoromethl ridinamine Compound 24: 2- 3-oxaazabic Clo 3.2.1 octan-8— | -4'- rometh | mor holino— 4 5'—bi rimidin - 2'—amine Compound 25: (:1.,,, : N \ r AN/| N \ 0d 3 N/ NH2 -(2,6-bis((S)—3-methylmorpholino)pyrimidinyl)—4-(difluoromethyl)pyridinamine Compound 26: 4'-(difluoromethyl)-2,6-bis((S)—3-methylmorpholino)—[4,5'-bipyrimidin]—2'-amine 2015/076192 Compound 27: [31.1,] AN/1 N \ 0d § N/ NH2 (S)—4-(difluoromethyl)(6-(3-methy|morpholino)—2—morpholinopyrimidinyl)pyridin amine Compound 28: (S)—4'-(difluoromethyl)—6-(3-methylmorpholino)—2—morpho|ino-[4,5'-bipyrimidin]—2'-amine Compound 29: 5-(4-(8—Oxaazabicyclo[3.2.1]octanyl)(8—oxaazabicyclo[3.2.1]octanyl)—1 ,3,5- triazin-2—y|)(difluoromethyl)pyridin-2—amine Compound 30: -[4,6-bis(2,2—dimethylmorpholinyl)—1,3,5-triazin-2—yI](difluoromethyl)pyridinamine Compound 31: (S)—4-(difluoromethyl)(2—(3-methy|morpholino)—6-morpholinopyrimidinyl)pyridin amine nd 32: /////////////// (S)—4'-(difluoromethyl)—2—(3-methylmorpholino)—6-morpho|ino-[4,5'-bipyrimidin]-2'-amine Compound 33: 4-(difluoromethyl)—5-[4-[(28,6R)—2,6-dimethylmorpholinyl]—6-[(3R)—3-methylmorpholin y|]-1,3,5-triazin-2—yl]pyridinamine Compound 34: W,»O\r N? f F mg” N FL; ix 7LMMMMMMMm‘: -[4,6-bis[(2R,6S)—2,6-dimethylmorpholiny|]-1,3,5-triazin-2—yI](difluoromethyl)pyridin- 2—amine Compound 35: 6-amino(difluoromethyl)pyridy|]—6-morpho|ino-1,3,5-triaziny|]morpho|in Compound 36: 4-[4-[2—amino(difluoromethyl)pyrimidinyl]—6-morpholino—1,3,5-triaziny|]morpho|in- 3-one Compound 37: 0 o \ I r“ if -[4,6-bis(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazin-2—yl]—4- (difluoromethyl)pyridinamine Compound 38: 4-(difluoromethyl)—5-[4-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)—6-(3-oxa-8— azabicyclo[3.2.1]octan-8—y|)—1,3,5-triazin-2—yl]pyridinamine WO 75130 Compound 39: -[4,6-bis(3,3-dimethylmorpholinyl)—1,3,5-triazin-2—y|]—4-(difluoromethyl)pyridinamine Compound 40: -[4,6-bis[(3R,58)—3,5-dimethylmorpholiny|]-1,3,5-triazin-2—y|]—4-(difluoromethyl)pyridin- 2—amine Compound 41: -[4,6-bis[(3R)—3-methylmorpholinyl]—1,3,5-triazin-2—yI](difluoromethyl)pyridin amine Compound 42 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyI)—6-morpho|ino-1,3,5-triazin-2— yI]pyridin-Z-amine Compound 43: 6-amino(difluoromethyl)pyridy|]—6-[(3R)—3-methylmorpholinyl]—1,3,5-triazin-2— y|](difluoromethyl)pyridinamine Compound 44: 4-(difluoromethyl)—5-[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methylmorpholin y|]-1,3,5-triazin-2—y|]pyridinamine Compound 45: N“ “NHZ 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3R)—3-methylmorpholinyl]— 1,3,5-triazin-2—y|]pyridinamine Compound 46: (”O\ 3 {Wk 0m x» a /,F 1 *2 T?‘ T ,/ m ,.»”‘~x Ng/x \\ x»! 433‘? gx N /) g {A}.
N, x “x N NH; 4-(difluoromethyl)[4-[(3R)—3-(methoxymethyl)morpholinyl]—6-[(3R)—3- methylmorpholinyl]—1,3,5-triazin-2—y|]pyridinamine Compound 47: 4-(difluoromethyl)—5-[4-(3,7-dioxa-Q-azabicyclo[3.3.1]nonan-9—y|)—6-[(3R)—3- methylmorpholinyl]—1,3,5-triazin-2—y|]pyridinamine nd 48: NAN F 03%EN A NJKNH (4S,5R)—3-[4-[2—amino(difluoromethyl)pyrimidinyl]—6-morpho|ino-1,3,5-triazin-2—yI] (hydroxymethyl)—5-methyI-oxazo|idinone Compound 49: HO“; NAN F F .......fiN 0&0 | N N H2 (4S,5R)—3-[6-[2—amino(difluoromethyl)pyrimidinyl]—2—morpho|ino-pyrimidiny|] (hyd roxymethyl)methy|—oxazo|idinone Compound 50: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholinyl](3-oxaazabicyclo[3.1.1]heptan- 6-y|)-1,3,5-triazin-2—yl]pyridinamine Compound 51: F F J5 ' O N” NH 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](6-oxaazabicyclo[3.1.1]heptan- 3-y|)-1,3,5-triazinyl]pyridinamine Compound 52: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1R,4R)—2-oxa azabicyclo[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine Compound 53: [1*ti 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(1S,4S)—2-oxa azabicyclo[2.2.1]heptany|]—1,3,5-triazinyl]pyridinamine Compound 54: [:1v 1it?“ DVD 5 IN/ NH2 5-[4,6-bis[(3R)—3-ethy|morpholinyl]—1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine Compound 55: [N19 N’I’L‘NF F ad I N NH2 -[4,6-bis(8—oxaazaspiro[3.5]nonany|)—1,3,5-triazinyl]—4-(difluoromethyl)pyridin-2— amine Compound 56: [wk/F N23: F 0QN’lfiwkfg,.N -bis[(3R)—3-isopropy|morpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridin amine Compound 57: NAP F F F a.
F rlJ N K F M” NH 2 4-[6-amino(difIuoromethyl)pyridy|]-N-methy|—6-[(3R)—3-methy|morpholinyl]—N- (2,2,2-trifluoroethyl)—1,3,5-triazinamine Compound 58: [0ML [1%]in F N RN “x F H I F f 4-[6-amino(difIuoromethyl)pyridy|][(3R)—3-methy|morpholinyl]—N-(2,2,2- trifluoroethyl)—1,3,5-triazinamine Compound 59: 4-[6-amino(difIuoromethyl)pyridy|]-N-(cyc|opropy|methyl)[(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinamine Compound 60: A F F 3:” T”a N NHR 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2,2,2-trifluoroethoxy)—1,3,5- triazinyl]pyridinamine nd 61: A F F N’ N FjflOJxN | a F N/ NH2 -[4-(2,2-difluoroethoxy)—6-[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine Compound 62: [0ML N'FL‘P F F « [*4er 0 NI NH2 -[4-[(3aR,6aS)—1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrro|y|][(3R)—3-methy|morpholin- 4-y|]-1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine CompoundO63: -[4-[(4aS,7aR)—2,3,4a,5,7,7a-hexahydro-[1,4]dioxino[2,3-0]pyrrolyl]—6-[(3R)—3- methylmorpholinyl]—1,3,5-triaziny|](difluoromethyl)pyridinamine Compound 64: {WEE 4-(difluoromethyl)—5-[4-(4,4-difluoropiperidyl)[(3R)—3-methy|morpholinyl]—1 ,3,5- nyl]pyridinamine Compound 65: Er:L N H- 31;?1 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](2-oxaazaspiro[3.5]nonany|)— 1,3,5-triazinyl]pyridinamine Compound 66: NAN F F (LN’JQL‘N I N N H»: 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R,58)—3,5-dimethylmorpholin y|]-1,3,5-triaziny|]pyridinamine Compound 67: 0 N’L‘M F F £11”le, & I I I 0 x “V” N NH2 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[(3R)—3-(methoxymethyl)morpho|in- 4-y|]-1,3,5-triazinyl]pyridinamine Compound 68: Ho NAN F F (I A I N N “a 0V1 | N NH2 [(3R)—4-[4-[6-amino(difluoromethyl)pyridy|]—6-(3,3-dimethylmorpholinyl)—1 ,3,5- triazinyl]morpholinyl]methanol Compound 69: Ni‘L‘N F F ,JQ. ' G?N N a o M” N Hz 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(3,7-dioxa-9— azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine nd 70: V/ “V” N NH2 5-[4-(4-cyclopropylpiperaziny|)(3,3-dimethylmorpholinyl)—1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine Compound 71: [HIV 51-me F ”NANfiN | “QWNH/l I N NH», 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)[4-(2-methoxyethyl)piperaziny|]- 1,3,5-triazinyl]pyridinamine Compound 72: [33¢ A F F NilNANAEEN’N N N Ha: 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)(oxetany|oxy)—1,3,5-triazin y|]pyridinamine Compound 73: [a[‘ij <3: ”NV N N NH2 luoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3S)—tetrahydrofuranyl]oxy- 1,3,5-triazinyl]pyridinamine Compound 74: 0:: N‘AN F F VANO/AAN I Na 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-[(3R)—tetrahydrofuranyl]oxy- 1,3,5-triazinyl]pyridinamine Compound75: [aMJV 01 Ng‘rlq F F K “”51 N NH; 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-tetrahyd ropyranyloxy—1 ,3,5- triazin-2—y|]pyridinamine nd 76: L if” I? x w F F mg) E J 4-(difluoromethyl)—5-[4-(3,3-dimethylmorpholinyl)—6-(1,1-dioxo-1,4-thiazinanyI)-1,3,5- triazin-2—y|]pyridinamine Compound 77: HO, TM ,/ F» /F J '? u r N “N” ”I x Ox/J [\ Nari“ 1 0 NH2 [(3R)—4-[4-[6-amino(difluoromethyl)pyridyl]—6-[(3R)—3-methylmorpholinyl]—1 ,3,5- triazinyl]morpholinyl]methanol Further preferred compounds are Compound [0ML A F F (lN’JflmfiN r If] Od'hr’ , N NH2 4-(difluoromethyl)[4-[(3R,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methylmorpholin y|]-1,3,5-triazin-2—yl]pyridinamine Compound: 4-(difluoromethyl)[4-[(3S,58)—3,5-dimethylmorpholinyl]—6-[(3R)—3-methy|morpholin y|]-1,3,5-triaziny|]pyridinamine Compound: N” NF @111km0 4-(difluoromethyl)[4-morpho|ino(3-oxa-9—azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazin- 2-yl]pyridinamine Compound: ‘: F :2“*fii -[4,6-bis(3-oxa-9—azabicyclo[3.3.1]nonan-9—yI)-1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine Compound: F NAN]: F I“ I“ HN N” M” NH 5-[4-[6-amino(difluoromethyl)pyridy|]—6-(3,7-dioxa-9—azabicyclo[3.3.1]nonan-9—y|)— 1,3,5-triazinyl]—4-(difluoromethyl)pyridinamine Compound: (NIKE;N “N “x INX NHZ 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](4-morpho|inopiperidy|)—1,3,5- triazinyl]pyridinamine Compound: -[4-(4-cyclopropylpiperaziny|)[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine Compound: V/ V’ NH2 -[4-(4-Cyclopropylpiperaziny|)[(3S,5R)—3,5-dimethylmorpholinyl]—1,3,5-triazin y|](difluoromethyl)pyridinamine Compound: [0ML [4ng F F “r N I“: N N H2 luoromethyl)[4-[4-(2-methoxyethyl)piperaziny|][(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine 2015/076192 Compound: F F N” N (W? N I“ ‘QAx/Nx/ NI) m H2 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[4-(2- methoxyethyl)piperaziny|]-1,3,5-triaziny|]pyridinamine Compound ’ENL NAN F F N M “a rxll N [“ng 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholiny|](4-morpho|inopiperidy|)— 1,3,5-triazinyl]pyridinamine Compound: 4-(difluoromethyl)—5-[4-(1,1-dioxo-1,4-thiazinanyl)[(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine Compound: (ENL N‘LL‘N F F ,qu | 0f“? N p(" LII‘M/ N o MH2 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-(1,1-dioxo-1,4-thiazinan y|)-1,3,5-triazinyl]pyridinamine Compound: 01 N‘L‘rlal F F k 0% M! NH? 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]tetrahydropyranyloxy-1,3,5- triazinyl]pyridinamine Compound: 0’1 I‘J F F K OANKEELHf 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-tetrahyd ropyranyloxy- 1,3,5-triazinyl]pyridinamine Compound: [0ML DAN “x M NH: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|][(3S)—tetrahydrofuranyl]oxy- 1,3,5-triazinyl]pyridinamine Compound: [0ML 0‘1. Am F F K/fo-_ I KN “a M NH“ 4-(difluoromethyl)[4-[(3R)—3-methy|morpholinyl][(3R)—tetrahydrofuranyl]oxy- 1,3,5-triazinyl]pyridinamine Compound: N’l‘ OAN a N/ NH... 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholiny|][(3S)—tetrahydrofuran -1,3,5-triazinyl]pyridinamine Compound: 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholinyl]—6-[(3R)—tetrahyd rofuran y|]oxy-1,3,5-triazinyl]pyridinamine Compound: N”N[HEP 51le N NH2 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](oxetanyloxy)—1,3,5-triazin y|]pyridinamine Compound: we:|/ N N Ha. 4-(difluoromethyl)[4-[(3S,5R)—3,5-dimethylmorpholiny|](oxetanyloxy)—1,3,5- triazinyl]pyridinamine Compound: /EN]\ HAN F F Ax ' 0.2744 n “a 0" M MHZ 4-(difluoromethyl)[4-[(3R,58)—3,5-dimethylmorpholinyl]—6-(3,7-dioxa-9— azabicyclo[3.3.1]nonan-9—y|)—1,3,5-triazinyl]pyridinamine Compound: 3-[4-[6-amino(difluoromethyl)pyridyl]—6-[(3R,58)—3,5-dimethylmorpholinyl]—1 ,3,5- nyl]oxazolidinone Compound: A: F F N N N N a 0 Hf NH 2 -(4-((1R,2R,48,5S)—7-oxa-9—azatricyclo[3.3.1.02:4]nonan-9—yl)((2R,4S)—7-oxa-9— azatricyclo[3.3.1.02*4]nonanyI)-1,3,5-triazinyl)—4-(difluoromethyl)pyridinamine Compound: ‘7‘ F F F F N I, N F | N N “H U N NH2 5-[4,6-bis(6,6-difluorooxa-8—azabicyclo[3.2.1]octan-8—y|)—1,3,5-triazinyI] (difluoromethyl)pyridinamine 1 10 Compound: «33;: F F F N Am N N “a F I or N NHE -[4,6-bis(6,7-difluorooxa-8—azabicyclo[3.2.1]octan-8—y|)—1,3,5-triazinyI] oromethyl)pyridinamine Compound: [0ML NfiLN F F E? | a K N a HEM N N NH2 -[4-(6-aminopyridyl)[(3R)—3-methy|morpholinyl]—1,3,5-triaziny|] (difluoromethyl)pyridinamine Compound: EDMl F F A F F N , IN N am “x. | | , f N N NHz 4-(difluoromethyl)—5-[4-[4-(difluoromethyl)pyridy|]—6-[(3R)—3-methy|morpholinyl]— 1,3,5-triazinyl]pyridinamine Compound: NA? F F x “N “a: | | , I, N N ran-12 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](3-pyridy|)-1,3,5-triazin y|]pyridinamine WO 75130 Compound: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|]pyraziny|-1,3,5-triazin y|]pyridinamine Compound: [1:L 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine Compound: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1H-pyrazolyl)—1,3,5-triazin y|]pyridinamine Compound: 4-(difluoromethyl)[4-[(3R)—3-methy|morpholiny|](1,2,4-triazoly|)—1,3,5-triazin y|]pyridinamine Compound: wfil4*\lel 4-(difluoromethyl)[4-[(3R)—3-methylmorpholinyl]—6-(1H-1,2,4-triazolyl)—1,3,5- triazinyl]pyridinamine Compound: I/01L M :l‘l 4-(difluoromethyl)[4-[(3R)—3-methylmorpholinyl]—6-(2H-tetrazolyl)—1,3,5-triazin y|]pyridinamine Preparation of compounds of the invention The compounds of the invention may be synthesized by synthetic routes that include processes analogous to those well known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources or are readily prepared using methods well known to those skilled in the art.
In preparing compounds of the invention, protection of remote functionality (e.g., y or secondary amine) of intermediates may be ary. The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. le amino-protecting groups include tert—butyloxycarbonyl (BOC), bis-tert—butyloxycarbonyl or dimethylaminomethylenyl. The need for such protection is readily ined by one skilled in the art. For a l description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
Methods of tion In the methods of preparing the compounds of this invention, it may be advantageous to separate reaction products from one another and/or from ng materials. The desired products of each step or series of steps are separated and/or purified to the desired degree of homogeneity by the ques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; high, medium and low re liquid chromatography s and apparatus; small scale analytical; and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
Selection of appropriate methods of separation depends on the nature of the materials involved, for example, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction, and the like. One skilled in the art will apply techniques most likely to e the d separation.
Examples The Examples are intended to illustrate the present invention without restricting it.
The chemical reactions described in the es may be readily adapted to prepare a number of other lipid kinase tors of the invention, and ative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.
As a rule, 1” NMR and mass spectra have been obtained for the compounds prepared. In the Examples described below, unless ise indicated, all temperatures are set forth in degrees Celsius (°C). Reagents were purchased from commercial suppliers such as Sigma Aldrich, chem, Acros, Lancaster, TCl or Maybridge, and were used without r purification unless otherwise indicated. The reactions setforth below were done generally under a positive pressure of nitrogen or with a drying tube (unless otherwise stated) in anhydrous solvents, and the on flasks were typicallyfitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried. Column chromatography was performed using Merck silica gel. 1” NMR spectra 1” NMR spectra were recorded on a Bruker instrument operating at400 MHz. were obtained for solutions in various ated solvents such as CDCI3, (CD3)ZSO, CD30D or (CD3)2CO. The chemical shift 6 values were ed in ppm and corrected to the signal of the deuterated solvents (7.26 ppm for CDCI3) or TMS (0 ppm). 19F NMR spectra were calibrated relative to CFCI3 (6 = 0 ppm) as external standard. 19F NMR a were recorded 1H-decoupled. When peak multiplicities are reported, the ing abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), quint (quintet), br (broadened).
Coupling constants, when given, are reported in Hertz (Hz). MALDI-ToF Mass a (MS) have been obtained on a Voyager-DeTM Pro measured in m/z.
The following iations are used hereinafter: BSA (bovine serum albumin), DMSO (dimethyl sulfoxide), ESI (electronspray ionization), HCI (hydrochloric acid), M (molar), MALDI (Matrix-assisted Laser Desorption/Ionization), MS (mass spectrometry), PBS hate buffered saline), TLC (thin layer chromatography).
Preparation of Intermediate Compounds The following methods were used to prepare the intermediates compounds used to produce nds of a (I).
Method 1: 8- 4- 3-oxa-8—azabic clo 3.2.1 octan l chloro-1 3 5-triazin l oxa azabicyclo|3.2.1|octane (i1 ) Cl N NJ§N —> N/KN A ‘ / / Cl N Cl «3%N N Cl 3-Oxa-8—azabicyclo[3.2.1]octane-HC| (Advanced ChemBlocks lnc, product number A—861, 2.00 g, 13.4 mmol, 2.0 eq.) and N,N-diisopropylethylamine (4.80 mL, 27.6 mmol, 4.1 eq.) are charged into a flask and dissolved in dichloromethane (20 mL). The flask is placed in an ice bath and the solution subsequently cooled down to 0 °C. This solution is then added dropwise to a solution of cyanuric chloride in dichloromethane (20 mL) at 0 °C. The resulting reaction mixture is stirred overnight, while it is allowed to warm up to room temperature. Additional dichloromethane (100 mL) is added and the organic layer is washed with a saturated aqueous solution of sodium bisulfate. The organic layer is then dried over ous sodium sulfate, filtered and the solvent is evaporated under reduced pressure. Purification by flash chromatography hexane/ ethyl e 4:1) gives the desired intermediate i1 as a colorless solid (79% yield). 1H NMR (400 MHz, CDCI3): 8 4.70-4.54 (m, 4 H), 3.80-3.58 (m, 8 H), 2.14-1.89 (m, 8 H); MS (MALDI): m/z = 338.4 ([M+H]+).
Method 1 is also used for the ation of the following ediate compounds i2 to HO, and intermediates i79 to i81.
Reagent Structure NMR MS (:1 1H NMR (400 MHz, CDCI3): MS (MALDI): 8 3.78 (m, 8 H), 3.70 (m, m/z = 287.6 8 H). ([M+Hl+)- 1H NMR (400 MHz, CDCI3): 8 4.75-4.56 (m, 2 H), 4.34-4.30 (m, 2 H), 3.94 (dd, 2.0)., = 12.0 Hz, 3.0,), = 4.0 Hz, 2 H), 3.74 (d, 2.0,), =12.0 Hz, 2 H), MS (MALDI): E 1, 3.63 (dd, 2.0,), = 12.0 Hz, m/z = 314.4 I2 3.0,), = 4.0 Hz, 2 H), 3.49 (dt, ([M+Hl+)- 2JH), = 12.0 Hz, 3./.,,.,= 4.0 Hz, 2 H), 3.25 (dt, 2JH), = 12.0 Hz, 3.0,), = 4.0 Hz, 2 H), 1.31 (d, 3.0)., = 8.0 Hz, 6 H).
KAN. Lax/K 1H NMR (400 MHz, : MS (MALDI): i4 L )8- 6 3.81-3.72 (m, 8 H), 3.43 (s, m/z = 342.5 “N”!1‘” l E]: $4 H 4 H ), 1.43 (br s, 12 H). ([M+H]+ ). (“f N,- 8w 6.0% 1H NMR (400 MHz, CDCI3): 6 4.75-4.56 (m, 2 H), 4.34- 4.30 (m, 2 H), 3.94 (dd, 2.1),), = 12.0 Hz, (”OAK 3.1),), = 4.0 Hz, 2 H), 3.74 (d, .208. ml“ 2.1),), = 12.0 Hz, 2 H), 3.63 MS (MALDI): i5 L f}\ Nag-N (dd, 2.1),), = 12.0 Hz, m/z = 314.3 g (LN, *"N”1i”‘"c: 3JH,H= 4.0 Hz, 2 H), 3.49 (dt, ([M+H]+). j 2.1),), = 12.0 Hz, 06-... 3.1),), = 4.0 Hz, 2 H), 3.25 (dt, 2.1),), = 12.0 Hz, 3.1),), = 4.0 Hz, 2 H), 1.31 (d, 3.1),), = 8.0 Hz, 6 H). 1H NMR (400 MHz, : ,0...
M0“ )Nk :4.40-4.37 (m, 4 H), 3.74 (d, MS (MAI—DI): J”’” = 11'6 HZ’ 4 H)’ i6 J 5%. m/z = 342.8 WNW“k .1. Z ff“ 3.53 (dd, 3JH,H= 11.6 Hz, H ([M+H]+) ( W N’ W? ' 2.1),), = 4.0 Hz, 4 H), 1.26 (d, O‘w/K 3.1),), = 6.9 Hz, 12 H). (0‘50 (01 ;::5? M, %{8// :,N - ( r S’ )’ - ( rs, i7 m/z = 370.3 2 H), 4.12-4.06 (m,8 H), N ,NAN‘C’LWC: ([M]+)_ H 6:”???.2 3.92-3.83 (m, 8 H). 1H NMR (400 MHz, ,0. .... 4 H), 3.85-3.75 (m, 4 H), .8 [, k m/z = 342 3 I I (”#3, x x /' g f‘f 3.48-3.45 (m, 2 H), .34 ([W) (m, 2 H), 3.14-3.09 (m, 2 H), 1.72 (m, 4 H), 0.82 (m, 6 H). ,« 1H NMR (400 MHz, L» i ‘ “'3 (MALD'): .434. (003)280): 6 , 8 H), i9 ka» NAN ”7/2 = 366-7 3.351-3.48 (m, 4 H), 2.46- H .N-N/Lx‘N» 8Q 2.38 (m, 4 H), 2.20-2.16 (m, ([M] )- 09. 4 H), 1.73-1.66 (m, 4 H). 1H NMR (400 MHz, ~ (CD3)280): 6 4.40-4.25 (m, MS (MALD'): o «- k 2 H), 4.20-4.05 (m, 2 H), 4.08 “0 [NR N}. ”7/2 = 370-4 (m, 2 H), 3.95 (m, 2 H), 3.83 H J (m, 4 H), 3.08 (m, 2 H), 2.30 (WIT)- (m, 2 H), 0.98 (m, 6 H), 0.48 (m, 6 H).
\[,O 1/ 1H NMR (400 MHz, CDCI3): a MS (MALDI): \f f 6 4.59-4.31 (m, 4 H), 3.66- i79 m/z= 342.4 ii ii 1. \wa/ . 3.46 (m, 4 H), 2.70 (m, 4 H), ([M+H]+). 1.14 (m, 12 H). 0x " [Sf/1H NMR (400 MHz, CDCI3): 6 MS (MALDI)_' ‘ ” 3.73-3.64 (m, 8 H), 3.57 (s, I80_ m/z=342.3 $1M) 2H) 35”, . s, 2H) 114(, . s, ([M+H1+ ). 12 H). 206 1H NMR (400 MHz, CDCI3): .08, 6 4.41 (br s, 4 H), 4.32- MS (MALDI): i81 4.16 (m, 4 H), .10 (m, m/z = 338.4 4 f fi 4 H), 1.99-1.84 (m, 4 H), ([M+H]+) 1.84-1.67 (m, 4 H). 1 18 Method 2: 2,4-dichloromorpholino—1,3,5-triazine (H1) 0 D i: EN] [if] N f 'f' MAN _,. 21 KNACl _C,|/J\H‘NN‘fII\E| To a solution of cyanuric chloride (18.1 g, 0.100 mol, 1.0 eq.) in dichloromethane (200 mL) is dropwise added a cold solution of morpholine (17.4 g, 0.200 mol, 2.0 eq.) at — 78 °C over 2 hours. The resulting mixture is allowed to warm to 0 °C with stirring and mixed with an ice cold saturated solution of sodium ate in water. The phases are separated and the organic phase is washed with half concentrated brine dried over sodium sulfate and evaporated to yield the title compound i11 as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 3.90-3.86 (m, 4 H), 3.77-3.72 (m, 4 H).
Method 3: 8- 4-chloromor holino—1 3 5-triazin l oxaazabic clo 3.2.1 octane f” f“ (\N N/ C! (\N N/ CI CV 0d H1 "2 3-Oxaazabicyclo[3.2.1]octane-HC| (Advanced ChemBlocks lnc, product number A—861, 200 mg, 1.34 mmol, 1.1 eq.) and N,N-diisopropylethylamine (470 uL, 2.69 mmol, 2.1 eq.) are charged in a flask and dissolved in ethanol (3 mL). The flask is placed in an ice bath.
A solution of nd H1 (300 mg, 1.28 mmol, 1.0 eq.) in ethanol (2 mL) is added to the above on at 0 °C. The ing mixture is stirred overnight, while allowing it to warm up to room temperature. Deionized water (20 mL) is added and the aqueous layer is extracted with ethyl acetate (3 x 30 mL). The combined organic layer is dried over anhydrous sodium sulfate, filtered and the solvent is evaporated under reduced pressure.
Purification by flash chromatography hexane / ethyl e 9:1 —> 8:2) gives the desired intermediate i12 as a ess solid (78% yield). 1H NMR (400 MHz, CDCI3): 1 19 6 4.69-4.56 (m, 2 H), 3.86-3.59 (m, 12 H), 2.12-1.91 (m, 4 H); MS (MALDI): m/z = 312.7 ([M+H]+).
Method 3 is also used for the preparation of the following intermediate compounds i13 to i16.
Reagent Structure NMR 0 1H NMR (400 MHz, CDCI3): 6 .61 (m, o LN)», 1 H), 4.34—4.31 (m,1 H), 3.96—3.92 (m,1 H), i13 [N] MAW 3.79—3.70 (m, 9 H), 3.65-3.61 (m,1 H), 3.51— " l H kN/1'1L661 3.45 (m,1 H), 3.29—3.21 (m, 1 H), 1.36— ’’’’’’’ 1.30 (d, , = 6.9 Hz, 3 H). 0:: ,ON ,,/" 1 l :l,WOWL, W 1H NMR (400 MHz, CDCI3): 6 3.79—3.71 (m, _14 {.N/ .
I ,, L. 3 NAN 12 H), 3.46 (m, 4 H), 1.48 (s, 9 H).
S A, ,4 ,1... 1“ ” “‘N’ “c: ohm/l fax N] 1H NMR (400 MHz, CDCI3): 6 4.12-3.98 (m, i15 lW/l MEN 4 H), 3.84-3.70 (m, 4 H), 3.70-3.62 (m, 4 H), H ”a. MEL. fig» 2.66 2.56 (m,4H)._ {,6 N N, C: A)... L611 1H NMR (400 MHz, CDCI3): 6 3.77 (m, 4 H), i16 L k Nag,“ 3.68-3.63 (m, 8 H), 3.44 (s, 2 H), 1.44 (s, it A A Mi 6 H). {1 N” N (:1 Method 4: S 4 6-dichloro-1 3 5-triazin l meth lmor holine i17 To a solution of cyanuric de (450 mg, 2.44 mol, 1.0 eq.) in dichloromethane (4 mL) is slowly added a solution of (S)—3-methylmorpholine (Activate Scientific, product number AS3424, 0.28 mL, 2.44 mol, 1.0 eq.) and triethylamine (0.35 mL, 2.51 mol, 1.02 eq.) in dichloromethane (2 mL) at — 50 °C. The resulting mixture is stirred for 2 hours at — 50 °C, then allowed to warm to 0 °C with stirring and mixed with an ice cold saturated solution of sodium bisulfate in water. The phases are separated and the organic phase is washed with brine dried over sodium e and evaporated to yield the title compound H? as a colorless solid (95% yield). 1H NMR (400 MHz, CDCI3): 8 4.78-4.69 (m, 1 H), 4.43-4.39 (m, 1 H), 3.98-3.96 (m, 1 H), .76 (m, 1 H), 3.67-3.65 (m, 1 H), 3.51-3.47 (m, 1 H), 3.40- 3.37 (m, 1 H), 1.36 (m, 3 H).
Method 5: 8— 4-chloro S meth lmor holino 1 3 5-triazin loxa azabicyclo|3.2.1|octane (i18) 3-Oxa-8—azabicyclo[3.2.1]octane-HC| (Advanced ChemBlocks lnc, product number A—861, 383 mg, 2.55 mmol, 1.1 eq.) and N,N-diisopropylethylamine (1.0 mL, 5.60 mmol, 2.4 eq.) are charged in a flask and dissolved in ethanol (4 mL). The flask is placed in an ice bath.
A solution of nd i1? (580 mg, 2.33 mmol, 1.0 eq.) in ethanol (2 mL) is added to the above solution at 0 °C. The resulting mixture is d for 4 hours, while allowing it to warm up to room temperature. Deionized water(20 mL) is added and the aqueous layer is extracted with ethyl acetate (3 x 30 mL). The combined c layer is dried over anhydrous sodium sulfate, filtered and the solvent is evaporated under reduced pressure.
Purification by flash chromatography (cyclohexane/ ethyl acetate 9:1 —> 8:2) gives the 2015/076192 desired ediate i18 as a colorless solid (88% yield). 1H NMR (400 MHz, CDCI3): 8 4.75-4.52 (m, 3 H), 4.37-4.24 (m, 1 H), 3.95-3.92 (m, 1 H), 3.73-3.70 (m, 3 H), 3.64-3.61 (m, 3 H), 3.52-3.42 (m, 1 H), 3.29-3.17 (m, 1 H), 2.11-1.89 (m, 4 H), 1.31 (m, 3 H).
Method 6: tert—but l4- 4 6-dichloro-1 3 5-triazin l i erazinecarbox late i19 To a cooled (- 50 oC) solution of cyanuric chloride (1.0 g, 5.42 mmol, 1.0 eq.) in dichloromethane (4 mL) is added dropwise a solution of tert—butyl piperazine carboxylate (Sigma, product number 343536, 1.02 g, 5.48 mmol, 1.01 eq.) and triethylamine (0.767 mL, 5.53 mmol, 1.02 eq.) in dichloromethane (2 mL). The resulting reaction mixture is stirred at - 50 °C for 4 hours. A saturated aqueous solution of sodium ate (10 mL) and dichloromethane (20 mL) are added. The mixture is transferred to a separating funnel. The organic layer is separated, washed with a saturated aqueous solution of sodium bisulfate (20 mL), dried over anhydrous sodium sulfate, filtered and then the t is evaporated under reduced pressure to give pure intermediate HQ (80% yield). 1H NMR (400 MHz, CDCI3): 8 3.88-3.85 (m, 4 H), 3.53-3.51 (m, 4 H), 1.49 (m, 9 H).
Method 7: tert—but l 4- 4- 8-azabic clo 3.2.1 8- l chloro-1 3 5-triazin yl)piperazinecarboxylate (i20) Ow, ,/O\“ x” 03.1% «OX :3, i a; l/ l J f j N N‘ i —. A Di; ”if Ni l CI mN" Cl [’fN RN"? or 0:31 I19 i20 3-Oxa-8—azabicyclo[3.2.1]octane-HC| (Advanced ChemBlocks lnc, product number A—861, 235 mg, 1.57 mmol, 1.0 eq.) and N,N-diisopropylethylamine (592 uL, 3.14 mmol, 2.1 eq.) are charged in a flask and dissolved in ethanol (6 mL). The flask is placed in an ice bath.
A solution of compound HQ (500 mg, 1.5 mmol, 1.0 eq.) in ethanol (2 mL) is added to the above solution at 0 °C. The resulting e is d overnight, while allowed to warm up to room temperature. Deionized water (10 mL) is added and the aqueous layer is extracted with ethyl acetate (3 x 30 mL). The combined organic layer is dried over anhydrous sodium sulfate, filtered and the solvent is ated under reduced pressure.
Purification by flash chromatography (cyclohexane/ ethyl acetate 8:2) gave the d intermediate i20 as a colorless solid (77% yield). 1H NMR (400 MHz, CDCI3): 8 4.68- 4.60 (m, 2 H), 3.76-3.70 (m, 6 H), 3.64-3.62 (m, 2 H), 3.47-3.45 (m, 4 H), 2.08-1.95 (m, 4 H), 1.48 (br s, 9 H); MS (MALDI): m/z = 411.8 ([M+H]+).
Method 7 is also used for the preparation of the following ediate compound i21.
Reagent Structure NMR MS 1H NMR (400 MHz, 00013): 84.76-4.61 (m,1 H), 4.35-4.30 09... x04. , (m, 1 H), 3.94 (dd, 2./.,,.,= 12 Hz, AR, 3JH,H= 4.0 Hz, 1 H), 3.76-3.72 o ) ] MS (MALDI): (m, 5 H), 3.65 (dd, 2 / _ JHH: 12 Hz, .21 m/z= 399.1 N I" if <5 3,;H,H= 4 0 H 1H) 351344 - N) 3’ - Z, , . . 2 ([M+H] )- {f/mN MN?” NC: (m, 5 H), 3.25 (dt, JH,H= 12 HZ, o...,/~j 3JH,H= 4.0 Hz, 1 H), 1.48 (s, 9 H), 1.30 (d, 3JH,H= 8.0 Hz, 3 H). {.49.
Cl Cl KN) ,1%? ,,,,,, ”O A... ,1)? 12:14—th ,1) +111- 01” ” ‘N N” \01 g (N “N! “NW“? Cl N" 1 O\,,,,,, Lu“ 0 L /O 122 .23 Trichloropyrimidine (Manchester Organics, product number Y17832, 11.2 g, 61 mmol, 1.0 eq.), N,N-diisopropylethylamine (23.3 mL, 134.2 mmol, 2.2 eq.) and morpholine (11.7 mL, 134.2 mmol, 2.2 eq.) are charged in a flask and ved in ethanol (120 mL). The flask is equipped with a refluxed condenser and placed in an oil bath preheated at 100 °C. The reaction mixture is stirred at this temperature for 18 hours. After this time, the reaction mixture is cooled down to room temperature and volatiles are removed under reduced pressure. The resulting mixture is dissolved in dichloromethane (100 mL) and washed twice with an aqueous solution of sodium bisulfate (2 x 80 mL). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure using a rotary ator. Products i22 and i23 are isolated by flash chromatography on silica gel (cyclohexane / ethyl acetate 3:1 9 1:1). The product fractions are pooled and evaporated to yield i22 as a colorless powder (13.8 g, 80%) and i23 as a colorless powder (2.2 g, 13% yield). 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine (i22): 1H NMR (400 MHz, CDCI3): 8 5.85 (s, 1 H), 3.71-3.75 (m, 12 H), 3.52-3.55 (m, 4 H); MS ): m/z: 285.4 ([M+H]+). 4,4'-(2-chloropyrimidine-4,6-diyl)dimorpholine (i23): 1H NMR (400 MHz, CDCI3): 8 5.38 (s, 1 H), .76 (m, 8 H), 3.52-3.54 (m, 8 H); MS (MALDI): m/z: 285.2 ([M+H]+).
Method 9: 8- 4- 3-oxaazabic clo 3.2.1 octan | chloro rimidin | oxa azabicyclo|3.2.1|octane (i24) c; KNEE} /»*"j??b «”01 L ll .3 + EU —* 1” 1 or N c: g Wm,“ ”N , ‘0; 0.1/ A solution of2,4,6-trichloropyrimidine (0.676 mL, 5.88 mmol, 1.0 eq.), 8- azabicyclo[3.2.1]octane hloride (1.76 g, 11.8 mmol, 2.0 eq.), and MN- diisopropylethylamine (4.10 mL, 23.5 mmol, 4.0 eq.) in ethyl acetate (18 volumes) is heated for 16 hours (100 °C). Then, the solvent is removed under reduced pressure and the residue is ved in dichloromethane (60 s) and washed with a saturated s sodium ate (3 x 60 volumes). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane / ethyl acetate 3:1 9 1:1) affords the desired intermediate i24 as a colorless solid (1.23 g, 62%).1H NMR (400 MHz, CDCI3): 8 5.80 (s, 1 H), 4.59 (s, 2 H), 4.35 (m, 2 H), 3.76 (13.11,), = 10.8 Hz, 4 H), 3.59 (d, 2.11,), = 10.8 Hz, 4 H), 2.03 (m, 8 H); MS (MALDI): m/z = 337.7 ([M+H]+).
Method 9 is also used for the preparation of the following ediate compound i25.
Reagent Structure NMR MS 1H NMR (400 MHz, CDCI3): MS (MALDI): m/z 8 5.83 (s, 1 H), 4.64-4.57 (m, = 313.6 ([M+H]+). [/1011 1 H), 4.27 (dd, 3.1),), = 2.4 Hz, 0 2‘11”” 2JH.H = 13.5 Hz, 1 H), 4.20-4.11 ”5 [N] 3 51/114. (m, 1 H), .87 (m, 3 H), H (£2311 “Néf'x‘cs 3.77-3.63 (m, 4 H), 3.56-3.46 (m, ‘1"! 2 H), 3.26-3.15 (m, 2 H), 1.28 (d, 3.1.1,.4 = 3.2 Hz, 3 H), 1.27 (d, 3.1.1,.4 = 3.2 Hz, 3 H).
Method 10: 4- 4 6-dichloro rimidin l mor holine i26 and 4- 2 loro rimidin yl)morpholine (i2?) ,/O\., iii 33‘ L J 1”}? + E ,l ————-—-——-» 11 + t or" "“N‘Acs {:13 (”N ‘1 N? “C: N; 19.] 0.1/3 Cl/ N”; “‘0; i26 i27 To a solution of trichloropyrimidine (14.0 mL, 122 mmol, 1.0 eq.) in EtOH (150 mL) is added a solution of morpholine (11.2 mL, 256 mmol, 2.1 eq.) and MN- diisopropylethylamine (44.6 mL, 256 mmol, 2.1 eq.) in EtOH (150 mL) dropwise at 0 °C.
The reaction e is stirred overnight at room temperature and the solvent is removed under reduced pressure. The crude product is extracted with dichloromethane (3 x 100 mL) and the organic phase is successively washed with saturated aqueous sodium bisulfate (3 x 400 mL). The ed organic layers are dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The crude mixture is purified by flash column chromatography (SiOz, cyclohexane / ethyl acetate 9:1 9 3:1) to yield i26 (5.02 g, 18%) and i2? (16.7 g, 59%), both as ess solids. 4-(4,6-dichloropyrimidinyl)morpholine (i26): 1H NMR (400 MHz, CDCI3): 8 6.56 (s, 1 H), 3.78 (m, 4 H) 3.74 (m, 4 H). 4-(2,6-dichloropyrimidinyl)morpholine (i27): 1H NMR (400 MHz, CDCI3): 8 6.41 (s, 1 H), 3.78 (m, 4 H), 3.65 (m, 4 H).
Method 11: S romor holino rimidin lmeth lmor holine i28 1’0”) 1”“ /§. + [0) ”b k?) ab /‘ .. XN‘ £1 g); Ci / N Cl )/ N N Ci i27 I28 A solution of i27 (694 mg, 2.97 mmol, 1.0 eq.), (S)—3-methylmorpholine (0.500 mL, 4.46 mmol, 1.5 eq.) and N,N-diisopropylethylamine (1.29 mL, 7.43 mmol, 2.5 eq.) in EtOH (5.0 mL) is heated to reflux for 3 days. Then, the solvent is removed under reduced pressure. The residue is dissolved in dichloromethane (60 volumes) and washed with saturated aqueous sodium bisulfate (3 x 60 volumes). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture is ed by flash chromatography (SiOz, cyclohexane / ethyl acetate 3:1 9 1:1) to afford the title compound (2-chloromorpholinopyrimidinyl)—3- methylmorpholine (i28) as a colorless solid (425 mg, 48%). 1H NMR (400 MHz, CDCI3): 8 5.85 (s, 1 H), 4.62 (dd, 2.0,), = 13.6 Hz, 3.0,), = 2.9 Hz, 1 H), 4.25 (dd, 2.0,), = 13.6 Hz, 3.0,), = 2.9 Hz, 1 H), 3.93 (dd, 2.0,), = 11.4 Hz, 3.0,), = 3.8 Hz, 1 H), 3.75, (t, 3.0,), = 5.0 Hz, 4 H), 3.71 (s,1 H), 3.66 (dd, 2JH,H = 11.3 Hz, 3JH,H = 3.2 Hz,1 H), 3.53 (m, 5 H), 3.23 (m, 1 H), 1.26 (d, 2JH,H = 11.3 Hz, 3 H); MS (MALDI): m/z = 299.4 ([M+H]+).
Method 11 is also used for the preparation of the following intermediate compound i29.
Reagent Structure NMR M8 (O) 1H NMR (400 MHz, : MS WALD”: W2 93:. MN/ 85.86 (s, 1 H), 4.60 (brs, 2 H), =309-6([M+H1+)- i29 {UN} 9/133] 3.80-3.72 (m,6H), 3.62-3.56 (m, H (51’1“‘1011‘3N’E‘MC; 2H), 3.56-3.50 (m, 4H), 2.08- 0571 1.90 (m, 4 H).
Method 12: S romor holino rimidin lmeth lmor holine i30) A solution of (S)—3-methylmorpholine (194 mg, 1.32 mmol, 1.5 eq.), i26 (300 mg, 1.28 mmol, 1.0 eq.) and N,N-diisopropylethylamine (3.0 eq.) in DMF (17 s) is heated for 16 hours (130 °C). Then, the solvent is removed under reduced pressure. The residue is ved in dichloromethane (100 volumes) and washed with saturated aqueous sodium bisulfate (3 x 100 volumes). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture is purified by flash chromatography (SiOz, cyclohexane/ethyl acetate 5:1) to afford the title compound i30 as a colorless solid (257 mg, H NMR (400 MHz, CDCI3): 8 5.84 (s, 1 H), 4.18 (m, 1 H), 3.94 (m, 2 H), 3.71 (m, 10 H), 3.53, (dt, 2JHH = 12.0 Hz, 3JH,H = 3.1 Hz, 1 H), 3.20 (dt, 2.1.”, = 12.8 Hz, 3.1.”, = 3.8 Hz, 1 H), 1.27 (d, 3.1.”, = 6.8 Hz, 3 H); MS (MALDI): m/z = 298.4 ([M]+).
Method 13: 4- 4-chloromor holino-1 3 5-triazin l mor holinone i31 E0] E21 NlN + [Cl ————» "lg” i11 i31 A round bottom flask was charged with compound i11 (5.37 g, 22.9 mmol, 1.5 eq), morpholine—3-one (1.54 g, 15.3 mmol, 1.0 eq), 4,5-bis(diphenylphosphino)—9,9- dimethylxanthene (530 mg, 0.915 mmol, 0.06 eq.), cesium carbonate (9.95 g, 30.5 mmol, 2.0 eq) and palladium(ll) e (383 mg, 0.170 mmol, 0.04 eq.). The reaction mixture was flushed with nitrogen and 1,4-dioxane (100 mL) was added. The reaction e was stirred at reflux (100 °C) for 4 hours. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with romethane (2x 30 mL). ts were removed under reduced pressure and the crude product was purified using silica gel chromatography (cyclohexane/ethyl acetate 1:0 9 1:3) to yield the title compound i31 as a colorless solid (390 mg, 31%).1H NMR (400 MHz, CDCI3): 8 4.32 (s, 2 H), 4.03-3.97 (m, 4 H), 3.93-3.86 (m, 4 H), 3.75-3.73 (m, 4 H); MS (MALDI): m/z = 299.6 ([M+Hl+)- Method 14: 8— 4 loro-1 3 5-triazin l oxaazabic clo 3.2.1 octane i32 A solution of ic chloride (1.97 g, 10.7 mmol, 1.0 eq.) in dichloromethane (10 mL) is cooled to — 50 °C. A solution of 3-oxaazabicyclo[3.2.1]octane hloride (1.60 g, .7 mmol, 1.0 eq.) and N,N-diisopropylethylamine (3.73 mL, 21.4 mmol, 2.0 eq.) in dichloromethane (40 mL) is slowly added over a period of 5 hours. The mixture is stirred for another 5 hours at this temperature. Then, dichloromethane (20 mL) and saturated aqueous sodium bisulfate (50 mL) are added and the mixture is allowed to warm to room temperature. The layers are separated and the organic layer is washed with saturated aqueous sodium bisulfate (2 x 50 mL). The organic layer is dried over anhydrous sodium e and the solvent is removed under d pressure. The crude mixture is recrystallized from n-heptane / dichloromethane (20 mL/ 13 mL) to afford the title compound 8—(4,6-dichloro-1,3,5-triazinyl)oxaazabicyclo[3.2.1]octane (i32) as a colorless solid (2.47 g, 47%). 1H NMR (400 MHz, CDCI3): 8 4.74 (m, 2 H), 3.72 (d,3JH,H = 1.5 Hz, 4 H), 2.08 (m, 4 H).
Method 14 is also used for the preparation of the following intermediate compounds i33 and i34.
Reagent Structure NMR 1H NMR (400 MHz, CDCI3): 5454-450 (m, 01 H), 4.20 (dd, 3J1”, = 2.9 Hz, 2J1”, = 14 Hz, 01. E k 1 H), 3.92 (dd, 3J1”, = 3.4 Hz, 2J1”, = 12 Hz, i33 [hi/k ML 1 H), 3.71 (d, 2J1”, = 12 Hz, 1 H), 3.57 (dd, H 3‘1 fi‘: 3J1”, = 3.2 Hz, 2J1”, = 12 Hz, 1 H), 3.42 (m, 0‘“ “N! Cl 1 H), 3.32 (m, 1 H), 1.27 (d, 3J1”, = 6.9 Hz, 3 H).
Lek ” 1H NMR (400 MHz, (CD3)ZSO): 5 3.88- g" 111111 3.81 (m, 4 H), 3.51 (s, 2 H), 1.46 (s, 6 H).
J1 J1.
Cl N Ci 0 131. 1N” 4’01 19 f: g? A f». + 11——> N 11 N‘ “N 1| ,1 ”fl 11 :1 N MN ‘91 CE,«/ 1N." NC. f offi? 1;) i32 i35 To a solution of 3,7-dioxaazabicyclo[3.3.1]nonane (184 mg, 0.700 mmol, 1.0 eq.) and N,N-diisopropylethylamine (0.170 mL, 0.970 mmol, 1.4 eq.) in 1,4-dioxane (1.0 mL) a solution of i32 (100 mg, 0.770 mmol, 1.1 eq.) in 1,4-dioxane (2.0 mL) is added. The resulting mixture is heated for1 hour at 70 °C. Then, dichloromethane (50 mL) and water (50 mL) are added. The aqueous layer is extracted with dichloromethane (3 x 50 mL), the combined organic layers are dried over anhydrous sodium sulfate and the solvent is evaporated. The crude mixture is purified by automated flash tography on silica gel (cyclohexane / ethyl acetate 2:1 9 0:1 ) to afford the title compound 9-(4-(3-oxa-8— azabicyclo[3.2.1]octanyl)chloro-1 ,3,5-triazinyl)-3,7-dioxa yclo[3.3.1]nonane (i35) as a colorless solid (192 mg, 77%).1H NMR (400 MHz, SO): 8 4.70 (m, 1 H), 4.55 (m, 2 H), 4.44 (m, 1 H), 4.12 (m, 4 H), 3.90 (m, 4 H), 3.72 (m, 2 H), 3.64 (m, 2 H), 2.08 (m, 2 H), 1.97 (m, 2 H); MS (MALDI): m/z = 354.3 ([M]+).
Method 16: 9- 4-chloro R meth lmor holino -1 3 5-triazin l -3 7-dioxa-9— azabicyclo|3.3.1|nonane (i36) [ k L,CLL.
N"L 0 o N M J‘; J L + mgr/1,2 —> N” 1 N NXQ‘LN \ / {fl /! ,1} 2.6L :1 N” “N “'01 ‘‘‘‘‘‘ Cl“ ”‘N/ “Cl Off/:5?f i33 i36 To a solution of 3,7-dioxa-9—azabicyclo[3.3.1]nonane (173 mg, 1.27 mmol, 1.05 eq.) and N,N-diisopropylethylamine (0.50 mL, 2.52 mmol, 2.1 eq.) in tetrahydrofuran (5 mL) a on of i33 (300 mg, 2.52 mmol, 2.1 eq.) in 1,4—dioxane (2.0 mL) is added. The resulting mixture is heated for2 hours (70 °C). Then, ethyl acetate (20 mL) and saturated aqueous sodium bisulfate (20 mL) are added. The phases are separated and the c layer is washed with saturated aqueous sodium ate (2 x 20 mL). The organic layer is dried over anhydrous sodium sulfate and the solvent is removed under reduced pressure.
The crude mixture is purified by automated flash chromatography (Si02, cyclohexane / ethyl e 2:1 9 0:1) to afford the title compound i36 as a colorless solid (316 mg, H NMR (400 MHz, (CD3)ZSO): 8 4.55-4.53 (m, 1 H), 4.42 (m, 1 H), 4.32 (m, 1 H), 4.25-4.16 (m, 1 H), 4.01-3.97 (m, 4 H), 3.87 (dd, 3JH,H = 3.8 Hz, 2J1”, = 11.2 Hz, 1 H), 3.73-3.65 (m, 5 H), 3.53 (dd, 3.0,), = 3.0 Hz, 2.0,), = 11.6 Hz, 1 H), 3.38 (m, 1 H), 3.15 (m, 1 H), 1.20 (d, 3.0,), = 6.9 Hz, 3 H).
Method 16 is also used for the preparation of the following intermediate compounds i37 to i53, and intermediate i82. t Structure NMR MS ,,..o... 1H NMR (400 MHz, .10... [KN/k (003)280): 6458-450 (m, MS (MALDI): 137 JWK Til/1%” 1H), 4.44—4.35 (m, 2H), m/z=328.2 H {wwaN/ACEl 4.25-4.12 (m, 1 H), 3.90- ([M+H]+). ovk 3.86 (m, 1 H), 3.75— 3.65 (m, 3 H), 3.56- 3.49 (m, 3 H), 3.38 (m, 1 H), 3.16 (m, 1 H), 1.25 (d, 3.4,), = 6.9 Hz, 6 H), 1.19 (d, 3.4,), = 6.9 Hz, 3 H). 1H NMR (400 MHz, 80): 6 4.54-4.46 (m, {XOXL 1 H), 4.18-4.13(m, 1 H), .404, N 3.88 (m, 1 H), 3.80- i38 {Wk {xi/EN 3.65 (m, 5 H), 3.54 (m, H fixN/‘xmzixa 1H), 3.44-3.36 (m, 3H), ow} 3.18 (m, 1 H), 1.44 (s, 6 H), 1.21 (d, 3.1%,), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 64.65-451 (m, XOR 2H), 4.31-4.20 (m, 2H), ,ok {NK 3.66 (m, 3 H), 3.69- MS (MALDI): 139 L “kyom 0». NAQN 3.56 (m, 2 H), 3.54- m/z= 344.2 fit {/]«.ij'\»N>:¢/i~~0; 3.48 (m, 3 H), 3.42— ([M+H]+). 06,} 3.35 (m, 2 H), 3.31 (s, 3 H), 3.21-3.13 (m, 2 H), 1.21 (d, 3.4,), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 451 (m, 1H), 4.42-4.35 (m, 2H), 4.12-4.25 (m, 2 H), 4.04- .29» E k 4.07 (m, 1 H), 3.86- 3.88 (m, 1 3.78- m pg :f H), W ‘f if 3.75 (m, 2 H), 3.69-3.65 H 1”qu \N “‘3“ (m, 1 H), 3.55-3.51 (m, 1H), 3.38 (m, 1H), 3.20- 3.13 (m, 1H), 2.68 (m, 1 H), 1.81 (m, 1 H), 1.20 (d, 3.4,), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 8 4.69-4.53 (m, ”,0- 3H), 4.31-4.15(m, 1H), #0 L k 3.93-3.78 (m, 3H), 3.71- W“ ii 3.53 (m, 4 H), 3.42- l41. N35;- 8N H {:27”“1§””N’” “a: 3.16(m, 1H), 3.12-3.08 03% (m, 1H), 1.81 (m, 1H), 1.21 (d, 3.1),), = 6.9 Hz, 3 H). 1H NMR (400 MHz, 80): 8 4.95-4.88 (m, 1H), 4.64 (m, 1H), .0. 4.54 (m, 1 H), 4.31- ,,GN [ML 4.09 (m, 1H,) 3.89- MS ): 3.85 (m, 1 3.75- _ .i H), .42 m/z = 312.2 , ”fix-N ”N” 3.73 (m, 2 H), 3.66-3.63 ,1 4, ([M+H]+) H ((3)? 38’ “Ci ' (m, 2H), 3.52 (m, 1H), O“ 1‘ 3.45-3.32 (m, 3H), 3.18- 3.12(m, 1H), 1.90- 1.83 (m, 2 H), 1.21 (d, 3.1),), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 8 4.94-4.88 (m, 1H), 4.64 (m, 1H), ,0. 4.54 (m, 1 H), 4.29- { 3.89- . 4.12(m, 1H), .»08 MS (MALDI): 4“..- 3.85 (m, 3.75- I43_ m L 1H), prN m/z=312.2 “1». ,9 N1 3.73 (m, A 2H), 3.66-3.63 H /. , :- 1L _, ([M+H] ). (m, 2H), 3.52 (m, 1H), 3.45-3.32 (m, 2H), 3.18- 3.12 (m, 1 H), 1.90- 1.83 (m, 2 H), 1.21 (d, 3JH,H = 6.9 Hz, 3 H). 1H NMR (400 MHz, ,,o.,\ (003)280): 84.82-4.17(m, {LN/L 4 H), 3.88 (m, 1 H), MS (MALDI): 1': . i44 12:7“ "3‘“ NAN 3.68 (m, 1 H), 3.54- m/z=326.8 F ::;T/rr-»,§¢»-3\~::«NLi901, 3 + 3.51 (m, 1 H), 3.41 (m, ([M+H] ).
F 1H), 3.25-3.15(m, 4H), 1.21 (m, 3 H). 1H NMR (400 MHz, (003)280): 88.55-40 (m, [f L 1 H), 4.65-4.77 (m, 1 H), “N” MS (MALDI): FL.../~ 4.36-4.01 (m, 3.83 _145 F“? NH2 A 3H), m/z=312.1 f3 L L{V (m, 1 H), 3.62 (m, 1 H), 1:, ).+ M g N c; 3.52 (m, 1 H), 3.35 (m, 1 H), 3.10 (m, 1 H), 1.18 (d, , = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 8 8.12-7.89 (m, 1 H), 4.52 (m, 1 H), 4.16(m, 1 H), 3.88 (m, MS (MALDI): A N 1 H ) , 368 NHz A - (m, 1 H ) i46 WW , m/z=284.9 N” N 3.52 (m, 1 H), 3.35 (m, + A, ,L. ji, ([M+H] )- *T/ ii “N“ 0% 2H), 3.10(m,2H),1.18(d, 3.1),), = 6.9 Hz, 3 H), 1.04 (m, 1 H), 0.42 (m, 2 H), 0.20 (m, 2 H). 1H NMR (400 MHz, (003)280): 85.10-497 (m, f ]\ 2 H), 4.70-4.54 (m, 1 H), F LN/ MS (MALDI): L H 4.25 (m, 1 3.91 _147 92L L H), (m, 4;. m/z=313.6 g: :31 1 H), 3.71 (m, 1 H), + 8. m A» A L ([M+H1).
F4 0 N 0* 3.57 (m, 1 H), 3.41 (m, 1 H), 3.29 (m, 1 H), 1.25 (d, 3.1),), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 66.37 (m, 1 H), ,0», 1 4.68-4.53 (m, 3 H), MS (MALDI): P W N1\ 7 4 25 (m 1 H) 3 90 (m ‘3” ,«L ' ’ ’ ' ’ M8 m/z= 295.7 1:: ;f 1 H), 3.70 (m, 1 H), 6:, A x, / ([M+H], )- 2; 0 N C' 3.55 (m, 1 H), 3.41 (m, 1 H), 3.25 (m, 1 H), 1.24 (d, 3JH,H = 6.9 Hz, 3 H). 1H NMR (400 MHz, 3.0,, (003)280): 64.55 (m, 1 H), l, L 4.21 (m, 1H), 3.89 (m, 1:} N MS (MALDI): WW»). 3.79-3.66 (m, _ 3L, 1H), 5H), :49 or I NH N“ N m/z= 326.2 waw H 3.54-3.51 (m, , l, fl 3H), 3.45- g 35”” N N (33 ([M+H] ). a; :,.,l 3.32 (m, 3 H), 3.11 (m, .1, ”H 1 H), 2.97 (m, 2 H), 1.20 (d, 3JH,H = 6.9 Hz, 3 H). 1H NMR (400 MHz, .0, (003)280): 64.56 (m, 1 H), E L 4.24 (m, 3 H), 3.88 (m, H N MS (MALDI): ‘1’ ‘1 "3 l 1H), 3.77 (m, 2H), 3.67- 150_ [ I NH N“ N m/z= 342.8 6 H 4. ,l, fl 3.51 (m, 8 H), 3.40-3.37 g Q,1, N‘ N c: ([M+H], ). 1W; (m, 1 H), 3.16 (m, 1 H), 1 A, ‘1—0’ “H 1.21 (d, 3JH,H = 6.9 Hz, 3 H). 1H NMR (400 MHz, ,0, (003)280): 64.56 (m, 1 H), H LNL 4.24 (m, 1 H), 3.87 (m, H), 3.68 (m, 1 _ H), 151 N“ N a, 1 A, 1,, 1,1, 3.53 (m, H), 3.35 (m, /‘- 1” “‘N/ “N“ “C: F F F if 1 H), 3.18 (m, 1 H), :3 2.01 (m, 4 H), 1.21 (d, 3JH,H = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 6 4.53 (m, 1 H), {/01 4.35 (m, 5 H), 4.20 (m, 1 H), 3.87 (m, 1 H), MS (MALDI): i52 L, J NVEN 3.65 (m, 4 H), 3.52 (m, m/z=340.2 ;; ”1:: [1“‘“*N~“”L“N“"cs 1 H), 3.37 (m, 1 H), ([M+H]+). gm""" 3.16 (m, 1 H), 1.79 (m, 4 H), 1.20 (d, 3.1),), = 6.9 Hz, 3 H). 1H NMR (400 MHz, (003)280): 64.65 (m, 1 H), 4.55 (m, 1 H), 4.32 (m, LN/L 1H), 4.22(m, 2H), H MSWALDD: ,9 N 3.98 (m 1 H , ) , 3.86 (m, i53 HO \{ ”1g HO“, 5k m/z = 330.1 ,5, ,5 1 1. 2 H), 3.63 (m, 2 H), 6 , (3f 3N”/ "C‘ ([M+H] )- 3.55 (m, 1 H), 3.49- 3.34 (m, 4 H), 3.17(m, 1 H), 3.12 (m, 1 H), 1.21 (d, 3.1),), = 6.9 Hz, 3 H). 1H NMR (400 MHz, 80): 6 4.67-4.53 (m, 1H), .34 (m, 2H), 112:3:(,0.3 4.31-4.09 , (1m, 1H, MSWALDD: 3.88 (m, H), 3.68 (m), i82 WOT N m/z = 328.3 . A H fi/“N’W‘N‘f c; 1 H), 3.55 (m, 3 H), o. ,3 ([IVI+H] + )- 3.38 (m, 1 H), 3.13 (m, 1 H), 2.55 (m, 2 H), 1.20 (d, 3.1),), = 6.9 Hz, 3 H), 1.19 (d, 3.1),), = 6.9 Hz, 6 H).
WO 75130 Method 17: 9- 4-chloro 3 3-dimeth lmor holino -1 3 5-triazin l -3 7-dioxa-9— azabicyclo|3.3.1|nonane (i54) “NM M z? 1%,? 4 m H m i34 i54 To a solution of 3,7-dioxa-9—azabicyclo[3.3.1]nonane (155 mg, 1.20 mmol, 1.05 eq.) and N,N-diisopropylethylamine (0.42 mL, 2.40 mmol, 2.1 eq.) in 1,4-dioxane (5 mL) a solution of i34 (300 mg, 1.14 mmol, 1 eq.) in 1,4-dioxane (1 mL) is added. The resulting mixture is heated for 2 hours (70 °C). Then, ethyl acetate (20 mL) and saturated aqueous sodium bisulfate (20 mL) are added. The phases are separated and the organic layer is washed with saturated aqueous sodium bisulfate (2 x 20 mL). The organic layer is dried over anhydrous sodium sulfate and the solvent is removed under reduced pressure. The crude e is purified by automated flash chromatography (8102, cyclohexane / ethyl acetate 2:1 9 0:1) to afford the title nd i54 as a colorless solid (178 mg, 44%). 1H NMR (400 MHz, (CD3)ZSO): 8 4.32 (m, 2 H), .98 (m, 4 H), 3.77 (m, 4 H), 3.71 (m, 4 H), 3.44 (m, 2 H), 1.41 (s, 6 H). MS (MALDI): m/z = 356.3 ([M+H]+).
Method 17 is also used for the preparation of the following intermediate compounds i55 to i64. t Structure NMR MS 1H NMR (400 MHz, (003)280): 5 4.36 (m, 3.77—3.74 (m, MS (MALDI): . ,o.
” LN? 2H), I55 JaNk NAN 6H), 3.55 (m, 2H), m/z=343.0 H (AN/isN/Lml % 3.44 (m, 2 H), 1.44 (s, ([M+H] ). 0wk 6 H), 1.26 (d, 3.1),), = 6.9 Hz, 6 H). 1H NMR (400 MHz, (003)280): 8452 (m, 1 H), 4.20 (m, 1 H), 3.90 (m, 2 H), 3.77 (m, i56 [ -]\/0-. 4 H), 3.65 (m, 1 H), 3.51-3.41 (m, 5 H), 3.28 (s, 3 H), 3.12 (m, 1 H), 1.44 (s, 3 H), 1.43 (s, 3 H). 1H NMR (400 MHz, (CD3)280): 84.98 (m, 1 H), 4.35 (m, 1 H), 4.18 (m, 1 H), 4.00 (m, MS (MALDI): 1 3.87 (m, 1 i57 W'fi’: H), H), J m/z = 344.2 3.81-3.65 (m, 5 H), ([M+H]+)- 3.51-3.35 (m, 5 H), 3.21-3.04 (m, 1 H), 1.44 (s, 3 H), 1.45 (s, 3 H). 1H NMR (400 MHz, (CD3)280): 8 3.77 (m, 4 H), 3.65 (m, 4 H), MS (MALDI): i58 {4. j 3.44 (m, 2 H), 2.56 (m, m/z = 351.2 4 H), 1.64 (m, 1 H), ([M+H]+)- 1.44 (s, 6 H), 0.44 (m, 2 H), 0.35 (m, 2 H). 1H NMR (400 MHz, (CD3)280): 8 3.76 (m, 4 H), 3.68 (m, 4 H), MS (MALDI): 159 ”N .44 (m, 4 H), m/z = 369.0 3.24 (m, 3 H), 2.52- ([M+H]+)- 2.45 (m, 6 H), 1.44 (s, 6 H).
W0 2016/075130 2015/076192 1H NMR (400 MHz, ((303)280): 65.56 (m, 0 [01:5 MS (MALDI): . 1 4.87 (m, 2 H), mo Q\ T H), m/z=3o1.1 09: 4.60 (m, 2 H), 3.81 (m, Q If? ([M+H]+). 6” «CNN/1 4 H), 3.48 (m, 2 H), 3.13 (s, 6 H). 1H NMR (400 MHz, ,0 (CD3)2SO): 65.46 (m, 0.: I: M 1 H), 3.84-3.73 (m, MS (MALDI): "51 J: 3: 8H), 3.49 (m, 2H), m/z=315.0 4: l i]: E]: 2.21 (m, 1 H), 2.05 (m, ([M+H]+). 0" MN: 0* 1 H), 1.46 (s, 3 H). 1.45 (s, 3 H). 1H NMR (400 MHz, (003)280): 65.46 (m, 0.,“ L if 1 H), 3.84-3.73 (m, MS (MALDI): {W5 :E : "52 8H), 3.49 (m, 2H), m/z=315.0 0“ f: I]: E] 2.21 (m, 1 H), 2.05 (m, ([M+H]+).
O: N: C‘ 1 H), 1.46 (s, 3 H). 1.45 (s, 3 H). 1H NMR (400 MHz, LOL (003)280): 85.11 (m, MS (MALDI): 1 3'82 (m’ 6 H)’ i63 E} E H)’ m/z= 329.8 9»bu ’“ ff: o l 84%; 3.47 (m, 4 H), 1.99 (m, .15. ,1 ). ”5‘“ “0’ N” ““01 2H), 1.65 (m, 2H), 1.46 (s, 6 H). 0 1H NMR (400 MHz, («'me Egg/"L” (003)280): 84.12 (m, MS (MALDI): i64 0653:“) 4 H), 3.79 (m, 4 H), m/z= 362.9 .. WEE 0 “Ci 3.46 (m, 2 H), 3.22 (m, ([M+H]+). 0:81 If N 6’ E5" 4 H), 1.46 (s, 6 H).
Method 18: 4-(difluoromethyl)gyridin-Z-amine (i65) F F F F \ \ I W, l / / N Cl N NH2 Palladium acetate (275 mg, 1.22 mmol, 0.05 eq.) and 2-dicyclohexylphosphino—2’,4’,6’- triisopropylbiphenyl (Sigma-Aldrich, product number 638064, 1.17 g, 2.45 mmol, 0.10 eq.) are dissolved in 1,4-dioxane (10 mL) under nitrogen atmosphere, and the resulting mixture is allowed to stir at room temperature for 45 minutes. This on is then added to a mixture of tert—butylcarbamate (Sigma, product number 167398, 4.30 g, 36.7 mmol, 1.5 eq.), Cs2C03 (15.9 g, 48.8 mmol, 2.0 eq.) and 2-chlorodifluoromethyl-pyridine (Manchester cs, product number , 4.00 g, 24.5 mmol, 1.0 eq.) in 1,4- dioxane (80 mL) under nitrogen atmosphere. The resulting reaction e is then heated at 90 °C for 3 hours, during which it turned brownish. After this time, the e is allowed to cool to room temperature. It is then diluted with ethyl acetate, washed with an aqueous saturated solution of ammonium chloride (2 x 30 mL) and deionized water. The c layer is dried over anhydrous sodium sulfate, filtered and the t is evaporated under reduced pressure. The brownish residue is mixed with 4 M HCI in dioxane (50 mL, ) and methanol (20 mL), and then heated at 80 °C for 45 s. Deionized water is added and the aqueous layer is washed with ethyl acetate (3 x). The aqueous layer is then basified to pH = 9, with solid sodium hydroxide. The aqueous layer is extracted with ethyl acetate (3 x). The combined organic layer is dried over anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure. The desired product i65 is obtained as a colorless solid, which is used in the next step without further purification (98% yield). 1H NMR (400 MHz, CDCI3): 8 8.16 (d, 2JH), = 5.2 Hz, 1 H), 6.74 (d, 2JH), = 4.8 Hz, 1 H), 6.59 (s, 1 H), 6.51 (t, 2JHf = 56 Hz, 1 H), 4.61 (br s, 2 H); 19F NMR (376 MHz, 00013): 5 — 116.0 (s, 2 F).
Method 19: 5-bromo difluorometh l ridinamine i66 F F F F \ \ l " l / / N NH2 N NH2 i65 I66 2015/076192 To a solution of compound i65 (3.00 g, 20.8 mmol, 1.0 eq.) in tetrahydrofuran (60 mL) is added N-bromosuccinimide (3.89 g, 21.9 mmol, 1.05 eq.) at 0 °C in an ice bath. The resulting mixture is stirred overnight, while it is allowed to warm up to room temperature.
Ethyl acetate is added and the organic layer is washed with aqueous sodium ate (8%). The organic layer is then separated and acidified with an aqueous 3 M HCl-solution.
The s layer is washed with ethyl acetate (3 x 50 mL) and then basified to pH = 10, with solid sodium hydroxide. The aqueous layer is extracted with ethyl acetate (3 x 50 mL). The combined organic layer is dried over ous sodium sulfate, filtered and concentrated to dryness under reduced pressure. The desired product i66 is obtained as a sh solid, which is used in the next step without further purification (79% yield). 1H NMR (400 MHz, CDCI3): 6 8.20 (s, 1 H), 6.75 (s, 1 H), 6.71 (t, 2J7); = 54 Hz, 1 H); 4.62 (br s, 2 H); 19F NMR (376 MHz, 00013): 6 — 118.9 (s, 2 F).
Method 20: N’- 5-bromo difluorometh l ridin l -N N-dimeth midamide i67 F F F F Br Br \ \ E I N/ N/ NArx'i// NH2 i66 i67 To a solution of compound i66 (3.68 g, 16.5 mmol, 1.0 eq.) in tetrahydrofuran (50 mL) is added N,N-dimethylformamide dimethyl acetal (Manchester Organics, t number 005030, 3.30 mL, 24.8 mmol, 1.5 eq.) and the resulting mixture is stirred at 60 °C for 3 hours. The mixture is d to cool to room temperature and the solvent is evaporated under reduced pressure. The crude product is purified by column tography on silica gel (cyclohexane / ethyl acetate 1:1) to afford the desired product i67 as a yellowish solid (82% yield). 1H NMR (400 MHz, CDCI3): 8 8.43 (s, 1 H), 8.34 (br s, 1 H), 7.17 (s, 1 H), 6.73 (t, ZJHf = 54 Hz, 1 H), 3.12 (s, 3 H), 3.10 (s, 3 H); 19F NMR (376 MHz, 00013): 8 — 118.6 (s, 2 F); MS (MALDI): m/z = 278.5 ([M+H]+).
Method 21: N’- 4- difluorometh l 4 4 5 5-tetrameth H 3 2-dioxaborolan l ridin yl)—N,N-dimethylformimidamide (i68) F F QC? F F \ O’B \ I ‘ N/ NAT/ N/ NAT/ i67 i68 To a 2 M on of pylmagnesium chloride (Sigma, product number 230111, 3.10 mL, 6.20 mmol, 1.15 eq.) in tetrahydrofuran (6 mL) is slowly added a solution of compound i67 (1.50 g, 5.39 mmol, 1.0 eq.) in tetrahydrofuran (5 mL) at 0 °C. The resulting brownish mixture is stirred at 0 °C for 45 minutes and then at room temperature for s. After this time, TLC ring hexane / ethyl acetate 1:1) showed complete consumption of starting material. 2-lsopropoxy—4,4,5,5-tetramethyl-1,3,2- dioxaborolane (Manchester Organics, product number W23343, 1.43 mL, 7.00 mmol, 1.3 eq.) is added and the mixture is heated at 60 °C for 3 hours. The mixture is then placed in an Erlenmeyer flask, cooled to 0 °C with an ice bath and quenched with a 15% aqueous solution of ammonium chloride. The layers are separated and the aqueous layer is extracted with ethyl acetate (3 x 40 mL). The combined organic layers are dried over anhydrous sodium sulfate, filtered and the t is evaporated under reduced pressure.
Heptane is added and the organic layer is washed with a saturated aqueous on of sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and then concentrated to dryness under reduced pressure. The desired product i68 is obtained as a brownish oil, which is used in the next step t further purification (94% yield). 1H NMR (400 MHz, CDCI3): 8 8.66 (s, 1 H), 8.51 (s, 1 H), 7.34-7.04 (m, 2 H), 3.12 (s, 3 H), 3.12 (s, 3 H), 1.34 (s, 12 H); 19F NMR (376 MHz, CDCI3): 8 — 115.6 (s, 2 F); MS ): m/z = 326.0 ([M+H]+).
Method 22: 4- difluorometh l rimidinamine i69 F F o o FVLOJYF m. N F F NH2 To a solution of ethyl vinyl ether (4.00 mL, 41.8 mmol, 1.0 eq.) in a mixture of pyridine (4.10 mL, 50.7 mmol, 1.2 eq.) and dichloromethane (40 mL), is added dropwise a solution of 2,2-difluoroacetic anhydride (Manchester Organics, (product number L24754, .90 mL, 50.1 mmol, 1.2 eq.) in dichloromethane (5 mL) at - 70 °C in a dry ice/ isopropanol bath. The ing solution is allowed to warm up to room ature overnight. The mixture is then washed with zed water, dried over anhydrous sodium sulfate, filtered and the t is evaporated under reduced pressure to afford an orange A on of guanidine-HCI (Sigma, product number 50940, 4.80 g, 50.2 mmol, 1.2 eq.) in ethanol (20 mL) is stirred at room temperature for 1 hour. To this solution are added sodium hydroxide pellets (2.00 g, 50.0 mmol, 1.2 eq.) in one portion. The resulting suspension is stirred at room temperature overnight.
The resulting mixture is diluted with dichloromethane (20 mL) and added dropwise over 1 hour. The resulting suspension is stirred at room ature for 2 hours.
Dichloromethane is evaporated under reduced pressure. Deionized water (25 mL) is added to the residue. The resulting mixture is stirred vigorously for 2 hours and is then allowed to stand at room temperature overnight. The formed solid is filtered off, washed with deionized water (2 x) and heptane (1 x) and then dried in vacuo. The desired product i69 is obtained as a colorless solid (65% yield). 1H NMR (400 MHz, : 8 8.43 (d, 2.0,), = 4.8 Hz, 1 H), 7.02 (br s, 2 H), 6.76 (d, 2.0,), = 5.2 Hz, 1 H), 6.67 (t, ZJHf = 55 Hz, 1 H); 19F NMR (376 MHz, 00013): 8 — 120.5 (s, 2 F).
Method 23:-b--romo4 difluorometh l rimidinamine i70 F F NANHZ i69 i70 To a solution of compound i69 (3.00 g, 20.7 mmol, 1.0 eq.) in tetrahydrofuran (90 mL) is added N-bromosuccinimide (3.86 g, 21.7 mmol, 1.0 eq.) portionwise at 0 °C. The reaction mixture is allowed to warm up to room temperature overnight. After this time, the solvent is evaporated under reduced pressure. The residue is taken up in ethyl e (200 mL), washed with an aqueous saturated solution of sodium carbonate (4 x), dried over anhydrous sodium sulfate, filtered and then concentrated to dryness under reduced pressure. The d product i70 is obtained as a yellowish solid, which is used in the next step without further purification (98% yield). 1H NMR (400 MHZ, (CD3)ZSO): 8 8.50 (s, 1 H), 7.30 (br s, 2 H), 6.87 (t, ZJHf = 53 Hz, 1 H); 19F NMR (376 MHz, (CD3)ZSO):8 — 121.4 (s, 2 F).
Method 24: N-tert—but l carbox late-N- 5-bromo difluorometh l rimidin l - a—(_)crbamatei71 BjfiiNNH2 —. F F NANBocz i70 i71 Compound i70 (4.35 g, 19.4 mmol, 1.0 eq.) and 4-(dimethylamino)pyridine (480 mg, 3.92 mmol, 0.20 eq.) are dissolved in tetrahydrofuran (50 mL). N,N-Diisopropylethyl- amine (7.50 mL, 42.1 mmol, 2.2 eq.) and di-terf—butyl dicarbonate (9.33 g, 42.7 mmol, 2.2 eq.) are then added at 0 °C and the resulting solution is d to warm up to room temperature overnight. The solvent is evaporated under reduced pressure. The crude product is purified by column chromatography on silica gel (cyclohexane / ethyl acetate 9:1 —> 4:1 ) to afford the d product i71 as a colorless solid (85% . 1H NMR (400 MHz, CDCI3): 8 8.92 (s, 1 H), 6.73 (t, 2J1); = 53 Hz, 1 H), 1.47 (s, 18 H); 19F NMR (376 MHz, 00013): 5 — 120.4 (s, 2 F).
Method 25: methyl (4R,5R)—5-methyloxo-oxazolidinecarboxylate (i72) o f o, / [mo JO H293” :M ‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘W, H131 :1” Ho «<27 0’ Under en atmosphere, an oven-dried flask equipped with a reflux condenser is charged with H-D-allo—threonine methyl ester-HCI (Bachem, product number 4044567, 2.00 g, 11.8 mmol, 1.0 eq.) and triphosgene (1.16 g, 3.91 mmol, 0.33 eq.).
Tetrahydrofuran (20 mL) is added and the resulting e is heated to reflux for 1 hour.
The mixture is then cooled down to room temperature, an aqueous NH4CI-solution (15%) is added and the aqueous layer is extracted with dichloromethane (3 x). The combined organic layer is dried over anhydrous sodium sulfate, ed and the solvent is evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane / ethyl e 1:1) gives the desired intermediate i72 as a colorless oil (66% yield). 1H NMR (400 MHz, (CD3)ZSO): 8 7.98 (br s, 1 H), 4.91-4.82 (m, 1 H), 4.42 (d, 3.1.”, = 8.4 Hz,1 H), 3.71 (s, 3 H), 1.17 (d, 3.1.”, = 6.5 Hz, 3 H).
WO 75130 Method 26: 4S 5R tert—but Idimeth lsil lox meth lmeth l-oxazolidinone (i73) o. f“ yo [Morse HNL’" “a“... . Hr?” “:f :34 ”‘0 o’ifiW‘O i72 I73 To a solution of methyl (4R,5R)—5-methyloxo-oxazolidinecarboxylate (i72, 1.18 g, 7.41 mmol, 1.0 eq.) in tetrathydrofuran (15 mL) is added LiBH4 (200 mg, 9.18 mmol, 1.2 eq.) portionwise at 0 °C under nitrogen atmosphere. The reaction e is allowed to stir at 0 °C for 10 minutes and then at room temperature for 1.5 hours. The on mixture is ed by addition of an aqueous saturated Nl-l4CI-solution, stirred for an onal hour at room temperature and then reduced to dryness under d pressure. The resulting residue is triturated with a mixture of ethyl acetate and dichloromethane (1:1), the solids are filtered off, washed with ethyl acetate / dichloromethane (1:1) and the filtrate is reduced to dryness under reduced pressure. The above residue is then dissolved in N,N-dimethylformamide (20 mL). lmidazole (581 mg, 8.53 mmol, 1.2 eq.) and tert—butyldimethylsilyl chloride (1.23 g, 8.16 mmol, 1.1 eq.) are added and the resulting reaction mixture is stirred at room temperature overnight. Brine is added and the aqueous layer is ted with ethyl acetate (3 x). The combined organic layer is dried over anhydrous sodium sulfate, filtered and the t is evaporated. Purification by column chromatography on silica gel (cyclohexane / ethyl acetate 3:1) gives the desired intermediate i73 as a colorless solid (64% yield). 1H NMR (400 MHz, (CD3)ZSO): 8 7.41 (br s, 1 H), 4.72-4.63 (m, 1 H), 3.66- 3.61 (m, 1 H), 3.58 (br d, 3.0,), = 4.4 Hz, 2 H), 1.32 (d, 3.0,), = 6.6 Hz, 3 H), 0.86 (s, 9 H), 0.05 (d, UH), = 2.6 Hz, 6 H).
General procedure 1: R2 “ F... F if l\ ”O x/ 3% 2F“ F X“: x2 N .38.. ,/ X; X l ,J, O m: '3' 1 —p é‘i‘N 3”1 R “x. /“-«.
RV X3/NCS T X “NW [N Ti 1 m. ,4 a ll N Nil—£2 i68 (I) Substituted monochloro-triazine or substituted monochloro—pyrimidine (1.0 eq.), compound i68 (1.1 eq.), potassium phosphate tribasic (2.0 eq.) and chloro(2-dicyclohexyl- phosphino-2’,4’,6’-triisopropyl-1,1’-biphenyl) [2-(2’-amino-1,1’-biphenyl)]-palladium(|l) (Sigma-Aldrich, product number 741825, 0.05 eq.) are charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (30 s) and deionized water (1.5 volume) are added and the ing mixture is then directly placed into an oil bath pre-heated at 95 °C. The reaction mixture is stirred at this temperature for 2 hours. A 5 M s HCI- solution (20 eq.) is added. The resulting mixture is heated to 60 °C ght. The pH of the resulting e is ed to 8-9 by addition of a 2 M aqueous solution of sodium hydroxide, the mixture is then extracted with ethyl acetate (3 x 20 volumes). The combined organic layers are dried over anhydrous sodium sulfate, filtered and the solvent is evaporated under reduced re. Purification by flash chromatography affords the desired products of structure (I).
General procedure 2: l R2 F3- F» ,F R2 k F - ’,F X1 «x X2F\ \ f“’0 l 3 13 B. l é xx? t L. / 13/ \N O I; 5N 3 + NN 61‘ R1 X3 RN 2L- {/L- —> g R‘ x3 ‘C: R N ,1- N‘ N(Boc)2 N N(Boc)2 3 N NH2 i71 (I) Compound i71 (1.0 eq.), 4,4,4',4',5,5,5',5'—octamethyl-2,2'-bi(1,3,2-dioxaborolane) (Manchester Organics, product number M23170, 1.5 eq.), potassium acetate (3.0 eq.) and [1,1’-bis(diphenylphosphino)—ferrocene]—dichloropalladium(ll) (Sigma-Aldrich, product number 697230, 0.099 eq.) are dissolved in 1,4-dioxane (12.5 s) under nitrogen atmosphere. The resulting mixture is heated at 100 °C for 15 minutes (solution turned black). TLC monitoring (cyclohexane / ethyl acetate 3:1) is used to show complete consumption of starting al.
To the resulting e, substituted chloro-triazine or substituted chloro- pyrimidine (1.1 eq.), an s solution of potassium carbonate (2 M, 3.0 eq.) and a previously mixed solution of triphenylphosphine (0.12 eq.) and palladium acetate (0.04 eq.) in tetrahydrofuran (100 volumes) are added. The resulting mixture is heated at 60 °C for 2 hours and subsequently allowed to cool to room ature.
A 5 M aqueous HCl-solution (20 eq.) is added. The resulting mixture is heated to 60 °C overnight. The pH of the resulting mixture is adjusted to 8-9 by addition of a 2 M aqueous solution of sodium hydroxide, the mixture is then extracted with ethyl acetate (3 x 20 volumes). The combined organic layers are dried over anhydrous sodium sulfate, filtered and the solvent is ated under reduced pressure. Purification by flash chromatography affords the desired products.
Method 27: tert—but | N-tert—butox carbon l-N- 5- 4-chloromor holino-1 3 5-triazin l difluorometh | rimidin mate i74 [,0 \ ,.o\_ I N :N] F [F\ ,F /“Qs 1 A, F F 35 “\ ,é, “N N x o /\ "l '3‘ 1: k I E N ~~N ,_ TI ’ / A“ /l L at C: "N” c: N N U “N“ ‘N(soc)2 lg V N "N(Boc)2 (800)2N N i71 i11 i74 Intermediate i71 (2.00 g, 4.71 mmol, 1.0 eq.), bis(pinacolato)diboron (1.80 g, 7.09 mmol, 1.5 eq.), KOAc (1.60 g, 16.3 mmol, 3.4 eq.) and [1 ,1’-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) (350 mg, 478 umol, 0.10 eq.) are mixed in 1,4-dioxane under en atmosphere and heated at 95 °C for 45 minutes. A pre-catalyst solution of palladium(||) e (43.0 mg, 192 umol, 0.04 eq.) and triphenylphosphine 148 mg, 564 umol, 0.12 eq.) in tetrahydrofuran (2 mL) is also prepared and d at room temperature for 1 hour. This solution is then added to the cooled above solution at room temperature, followed by the addition of 4-(4,6-dichloro-1 ,3,5-triazinyl)morpholine i11 (1.65 g, 7.05 mmol, 1.5 eq.) and s K2C03-solution (2.4 M, 5.90 mL, 14.2 mmol, 3.0 eq.). The resulting mixture is heated at 55 °C overnight. After this time, the mixture is poured onto an s NH4CI-solution (15%) and extracted with ethyl e (3 x). The combined organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under d pressure. Purification by column chromatography on silica gel (cyclohexane / ethyl acetate 1:0 9 4:1) gives product i74 as a colorless solid (36% yield). 1H NMR (400 MHz, CDCI3): 8 9.57 (s, 1 H), 7.55 (t, 2J7); = 54 Hz, 1 H), 3.99-3.91 (m, 4 H), 3.84-3.76 (m, 4 H), 1.49 (s, 18 H); 19F NMR (376 MHz, CDCI3): 8 — 121.0 (s, 2 F).
Method 28: 2R 3S amino tert—but ldi hen lsil lox butanol i75 1 46 ”fl/LNTWWNCH {ii‘i —> ““““““ \YXWOTEDPS it} H2 {QH2 D-allo—Threoninol (307 mg, 2.92 mmol, 1.0 eq.) is dissolved in N,N-dimethylformamide (3 mL) and imidazole (597 mg, 8.77 mmol, 3.0 eq.) is added. After 5 minutes, TBDPSCI (760 uL, 2.92 mmol, 1.0 eq.) is added slowly and then the reaction mixture is stirred at room temperature overnight. After this time, the solvent is evaporated under reduced pressure. The resulting e is taken up in ethyl acetate and washed with an aqueous saturated on of sodium bicarbonate (1 x) and brine (1 x). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
Purification by column chromatography on silica gel (100% ethyl acetate) gives the desired intermediate i75 as a colorless lid (50% yield). 1H NMR (400 MHz, CDCI3): 8 7.70-7.61 (m, 4 H), 7.47-7.36 (m, 6 H), 3.82-3.73 (m, 1 H), 3.69 (d, 3JH,H = 5.8 Hz, 2 H), 2.58 (q, 3.1.”, = 5.8 Hz,1 H), 1.12 (d, 3.1.”, = 6.5 Hz, 3 H), 1.07 (s, 9 H).
Method 29: 4S 5R tert—but ldi hen lsil lox meth l 5-meth loxazolidinone i76 w—OTBDPS .1... HM“7 xx Wm, xi. OTEDPS N...............................g. XEL /M f‘jfiig OJ" 0 i75 i76 Under nitrogen atmosphere, in an oven-dried flask equipped with a reflux condenser, intermediate i75 (433 mg, 1.26 mmol, 1.0 eq.) and triethylamine (440 uL, 3.15 mmol, 2.5 eq.) are dissolved in romethane (5 mL). At 0 °C in an th, triphosgene is then added (187 mg, 630 umol, 0.5 eq.). The resulting mixture is stirred overnight, while it is d to warm up to room temperature. The reaction is then quenched by addition of an aqueous NH4CI-solution (15%) and the aqueous mixture is extracted with dichloromethane (3 x). The combined organic layer is dried over anhydrous sodium sulfate, ed and the t is evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/ ethyl acetate 1:0 9 3:2) gives the desired intermediate i76 as a colorless solid (73% yield). 1H NMR (400 MHz, CDCI3): 8 7.66-7.61 (m, 4 H), 7.47-7.38 (m, 6 H), 4.99 (brs, 1 H), .74 (m, 1 H), 3.85- 3.79 (m, 1 H), 3.68-3.65 (m, 2 H), 1.34 (d, 3JH,H = 6.7 Hz, 3 H), 1.06 (s, 9 H).
Method 30: 4S 5R tert—but ldi hen lsil lox meth l 3dibromo rimidin l- -methyloxazolidin-2—one (i7?) WOTBDPS 3’ NWN H111] , :5 N N -oraops ”fimVA + m» Br Br 2L >a ”igwéjm’ 0 Br N [‘ 0’ 1 M 1*?”5‘0 i76 i77 Under nitrogen atmosphere, (4S,5R)—4-(((tert—butyldiphenylsilyl)oxy)methyl)—5- methyloxazolidin-2—one (i76, 681 mg, 1.84 mmol, 1.0 eq.) is dissolved in N,N- dimethylformamide (10 mL) and NaH (60% dispersion in mineral oil, 155 mg, 3.88 mmol, 2.1 eq.) is added portionwise at 0 °C, in an ice-bath. After 5 minutes, 2,4,6- mopyrimidine (583 mg, 1.84 mmol, 1.0 eq.) is added. The resulting mixture is stirred overnight, while it is allowed to warm up to room temperature. The on is then quenched by addition of an aqueous NH4CI-solution (15%) and the aqueous mixture is extracted with ethyl acetate (3 x). The combined organic layer is dried over anhydrous sodium sulfate, filtered and the solvent is evaporated under reduced pressure. Purification by column tography on silica gel (cyclohexane / ethyl e 1:0 9 9:1) gives the desired product i77 as a colorless foam (55% . 1H NMR (400 MHz, CDCI3): 8 8.25 (s, 1 H), 7.54-7.50 (m, 2 H), 7.45-7.33 (m, 6 H), 7.26-7.21 (m, 2 H), 4.85 (quint, 3.1.”, = 6.9 Hz, 1 H), .52 (m, 1 H), 4.14 (dd, 2.1.”, = 12 Hz, 3.1.”, = 2.8 Hz, 1 H), 3.98 (dd, 2.1.”, = 12 Hz, 3.1.”, = 1.4 Hz, 1 H), 1.77 (d, 3.1.”, = 6.5 Hz, 3 H), 1.04 (s, 9 H). [04. f l l j .\ .0. if N *N «creeps N 5N «OTBDPS 3 i ( + T j m “N. f‘ E: /2\ Br / hil/ .M {31! 8:“ V“ ‘65” x... ./ / (ff/“- 0’ (Sf/2%“ O O 0 i7? I78 Intermediate i7? (530 mg, 876 umol, 1.0 eq.), morpholine (80.0 uL, 915 umol, 1.0 eq.) and N,N-diisopropylethylamine (200 uL, 1.15 mmol, 1.3 eq.) are mixed in itrile (7 mL) and the resulting mixture is heated at 85 °C overnight. Then, the mixture is allowed to cool down to room temperature and the solvent is evaporated under d pressure. The desired product i78 is obtained as a colorless solid (12% yield) after purification by column chromatography on silica gel (cyclohexane / ethyl acetate 1:0 9 85:15). 1H NMR (400 MHz, CDCI3): 6 7.70 (s, 1 H), 7.59-7.55 (m, 2 H), .31 (m, 6 H), 7.22- 7.16 (m, 2 H), 4.82 (quint, 3JH,H = 6.2 Hz, 1 H), 4.50-4.44 (m, 1 H), 4.09 (dd, 2JHH = 11 Hz, 3.1.”, = 3.1 Hz, 1 H), 3.88 (dd, 2.1.”, = 11 Hz, 3.1.”, = 1.3 Hz, 1 H), 3.69-3.33 (m, 8 H), 1.74 (d, 3JH,H = 6.6 Hz, 3 H), 1.01 (s, 9 H).
Method 32: (E)—4-ethoxy—1,1-difluoro-butenone (i83) F F F . /0~ L ii F 813/081,!» W“ 4:84., Q ,.
” ML,» F 101 F )1” V “‘1 Q O O To a cooled (-70°C) solution of pyridine (61.5 mL, 760.5 mmol, 1.2 eq) in dichloromethane (500 mL) is added ethyl vinyl ether (60 mL, 626.5 mmol, 1 eq), followed by a on a difluoroacetic anhydride (88.5 mL, 760.5 mmol, 1.2 eq) in dichloromethane (75 mL). Then the mixture is slowly warmed to room temperature overnight. The mixture is transferred into a separating funnel and the organic layer is washed with water (6x800 mL) until the pH of the s layer becomes neutral. The organic layer is dried over sodium e and solvent is removed under reduced pressure to afford the desired product i83 as an orange oil (76.7 g, 81%). 1H NMR (400 MHz, DMSO-de): 6 7.92 (d, 3JHH = 12.5 Hz, 1H), 6.34 (t, 2.1.,F = 53.6 Hz, 1H), 5.87 (d, 3.1,), = 12.5 Hz, 1H), 4.14 (q, 3.1,), = 7,1 Hz, 2H), 1.28 (t, 3.1,), = 7,1 Hz, 3H); 19F {1 H} NMR (400 MHz, DMSO-de): 6 -127.39 (s, 2F).
Method 33: E difluorometh lethox h drox - entenenitrile i84 is 1: ~ 1 0H WM 4... 0 “A“ qufflhltbx'“ ‘M [M N‘Mt/k 11/ ”j” F F "NV i83 i84 To a cooled (-70°C) solution of n-butyl lithium 2.5M (102.9 mL, 256.7 mmol, 1 eq) in tetrahydrofuran (435mL) is added acetonitrile (13.4 mL, 256.7 mmol, 1 eq). A white suspension is formed and is stirred at -70°C for 1h30. A solution of ethoxy-1,1- difluoro-butenone (i83) (38.5 g, 256.7 mmol, 1 eq) in tetrahydrofuran (65 mL) is added to the white suspension (mixture beoomes an orange solution). The mixture is stirred at -70°C for 1h and slowly warmed to room temperature. Water (400 mL) is added.
Then ethyl acetate (600 mL) is added. Layers are separated and aqueous layer is extracted with ethyl acetate (3X600 mL). Combined c layers are dried over sodium sulfate and solvent is evaporated under d pressure. Filtration on a short pad of silica gel, using a mixture of cyclohexane/ethyl acetate (3:1) as eluent, g'ves the desired product i84 as a dark orange oil (43.4 g, H NMR (400 MHz, DMSO-ds): 6 6.66 (d, , = 12.8 Hz, 1H), 6.20 (s, 1H), 5.79 (t, 2.1.,F = 55.8 Hz, 1H), 4.75 (d, 3.1.8., = 12.8 Hz, 1H), 3.74 (q, 3.1.8., = 7.0 Hz, 2H), 2.88 (d, 3.1.8., = 16.8 Hz, 1H), 2.81 (d, 3.1.8., = 16.8 Hz, 1H), 1.21 (t, 3.1.8., :70 Hz, 1H); 19F {1H} NMR (400 MHz, DMSO-de): 6 -129.32 (d, ZJF; = 311.2 Hz, 1F), -130.05 (d, 2JP; = 311.2 Hz, 1F).
Method 34: 4-(difluoromethyl)pyridinamine (i65) R. [F F 1 M1. eff/Em ”3K /,/ ,, w» F ‘ r _... Q 1 3. N NH? AQ‘N i84 i65 To a solution of (E)—3-(difluoromethyl)ethoxyhydroxy-pentenenitrile (i84) (8.1 g, 42.4 mmol, 1 eq) in acetic acid (80 mL) is added O-methylhydroxylamine hydrochloride (Fluorochem, product number 078603) (10.6 g, 127.2 mmol, 3 eq). Mixture is stirred at 50°C for 7h. Then on mixture is cooled down to room ature and hydrobromic acid in acetic acid (33%) (14.2 mL, 84.8 mmol, 2 eq) is added. Reaction mixture is stirred at 90°C overnight. Reaction e is degassed and placed under nitrogen. Reaction mixture is maintained at room temperature with a water bath with ice while zinc powder (8.12 g, 127.2 mmol, 3 eq) is added portionwise. Reaction mixture is stirred 3 h at room temperature. Mixture is filtered over a short pad of celite and the cake is washed with ethyl acetate. Then the major part of the solvent is removed under reduced pressure. 60 mL of aqueous ammonium hydroxide (28%) is added. s layer is extrated with dichloromethane (3x150 mL). Combined organic layers are dried over sodium sulfate.
Compound i65 is recrystallized from dichloromethane and heptane as anti-solvent (solvent switch at the rotavap). Compound i65 is collected, as a light yellow solid, by filtration (5.12 g, 84%).
Preparation of nds of the Invention i2 i68 1 According to general procedure 1, compound 1 is obtained from starting materials i2 and i68 in 73% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.02 (s, 1 H), 7.65 (t, 2JHf = 55 Hz, 1 H), 6.83 (s, 1 H), 4.85 (br s, 2 H), 3.89-3.79 (m, 8 H), 3.77-3.72 (m, 8 H); 19F NMR (376 MHz, : 8 — 115.9 (s, 2 F); MS ): m/z = 393.9 ([M+H]+).
Example 2: 4- difluorometh l 4 6-dimor holino-1 3 5-triazin l rimidinamine 2 o .o.
F ,. 4‘0 .1 F “f LT] w<\ F /F Br j :\H< \ ,, ,\ é _ B )1 ‘3“ ——> 0, n ) + ——————————————————————> . fl .......NW.......LN N‘ ‘4 N(BOC)2 c)2 l N { .M j 0 v) 0“" N‘A‘NHz i71 i2 2 According to general procedure 2, compound 2 is obtained from starting materials i2 and i71 in 74% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.20 (s, 1 H), 7.62 (t, ZJHf = 54 Hz, 1 H), 5.97 (br s, 2 H), 3.91-3.68 (m, 16 H); 19F NMR (376 MHz, CDCI3): 8 — 121.5 (s, 2 F); MS (MALDI): m/z = 395.2 ([M+H]+). e 3: 5- 4- 3-oxa-8—azabic clo 3.2.1 octan-8— l 3-oxa-8—azabic clo 3.2.1 octan- 8— l-1 3 5-triazin l difluorometh l ridinamine 3 O 0.x EN j”m" 3L0 _’"”"\ ENE/F [N2] ,3}, N /;<”\O/é ‘/}§:~\\¢ «'11: F‘\ [,F (,3... A \Na + ll ‘1 . ; l; ,. k /l\ j M.“ x .~ g {/ N N Cl N N: f f / N N 0.3%) )4 / o E if,\l l? ._ v / N NH2 i1 i68 3 According to general procedure 1, compound 3 is obtained from starting materials i1 and i68 in 75% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.04 (s, 1 H), 7.71 (t, 2JHf = 55 Hz, 1 H), 6.83 (s, 1 H), 4.89 (br s, 2 H), 4.71-4.64 (m, 4 H), 3.79-3.76 (m, 4 H), 3.67-3.62 (m,4 H), .98 (m, 8 H); 19F NMR (376 MHz, CDCI3): 6 — 115.4-(— 117.3) (m, 2 F); MS ): m/z = 446.3 +). difluorometh l ridinamine 4 f0xtEEJ”MK l \ { C)lfl/W,‘ “Kymq FR‘E/ F LINN/V N/“X‘N O N'MLV‘N E...... F ,1 2i i .. - y ,1 l E N N</ “m,C1 "mNV \‘Té {if m If / xN7 j O V\//) *~. / O / mNC”? V NHZ 1 0 {El i 1 2 i68 4 According to general procedure 1, compound 4 is obtained from starting materials i12 and i68 in 57% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.03 (s, 1 H), 7.68 (m, 1 H), 6.83 (s, 1 H), 4.94 (br s, 2 H), 4.70-4.65 (m, 2 H), 3.93-3.57 (m, 12 H), 2.14-1.92 (m, 4 H); 19F NMR (376 MHz, CDCI3): 8 — 116.0-(— 116.2) (m, 2 F); MS (MALDI): m/z = 420.6 ([M+H]+)- i71 i12 5 According to general procedure 2, compound 5 is obtained from starting als i71 and i12 in 50% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.23 (s, 1 H), 7.65 (t, 2JH,F= 54 Hz, 1 H), 5.66 (br s, 2 H), 4.68 (m, 2 H), 3.90-3.61 (m, 12 H), 2.13-1.92 (4 H); 19F NMR (376 MHz, CDCI3): 6 — 120.4-(—121.5) (m, 2 F); MS (MALDI): m/z = 420.9 ([M+H]+)- i3 i68 6 According to l procedure 1, compound 6 is obtained from starting materials i3 and i68 in 79% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.87 (s, 1 H), 7.70 (t, 2JHf = 55 Hz, 1 H), 6.86 (s, 1 H), 5.48 (br s, 2 H), 4.73-4.72 (m, 2 H), 4.41-4.38 (m, 2 H), 3.98 (dd, JH,H = 11.6, 3.8 Hz, 2 H), 3.78 (d, JHH = 12 Hz, 2 H), 3.67 (dd, JHH = 12, 3.2 Hz, 2 H), 3.52 (td, JHH = 12, 3.0 Hz, 2 H), 3.27 (td, JHH = 13, 3.8 Hz, 2 H), 1.33 (d, 3JHH = 6.8 Hz, 6 H); 19F NMR (376 MHz, CDCI3): 8 — 115.4-(—116.2) (m, 2 F); MS (MALDI): m/z = 421.9 ([M+H]+).
Example 7: 5-(4,6-bis((S)—3-methylmorpholino)—1,3,5-triazinyl) (difluoromethyl)pyrimidinamine_(1) r-x s: >120 R} g LN)» L/N-u.
Br. ,1 :p\ /L l l L F F "' O, 1% \{l/ “5:: V? ; + N xN —* 'x, ,4 Q \1 t K {5*\ ; \N/JKCI/,j, A, $93: , , / N N(BOC)2 N 2 f ‘fir { r}: “N l/ \N J 0 v" 0 v" N NH? I71 i3 7 According to general procedure 2, compound 7 is obtained from starting materials W1 and i3 in 52% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.24 (s, 1 H), 7.66 (t, 2JHf = 54 Hz, 1 H), 5.77 (br s, 2 H), 4.73 (br s, 2 H), 4.45-4.32 (m, 2 H), 3.98 (dd, JHH = 12, 3.6 Hz, 2 H), 3.78 (d, JHH =12 Hz, 2 H), 3.67 (dd, JHH = 11, 2.8 Hz, 2 H), 3.52 (td, JHH = 12, 2.8 Hz, 2 H), 3.27 (td, JHH =13,3.2 Hz, 2 H), 1.33 (d, 3JH,H = 6.8 Hz, 6 H); 19F NMR (376 MHz, CDCI3): 8 — 120.5-(— 122.7) (m, 2 F); MS ): m/z = 423.3 ([M+H]+)- Example 8: S difluorometh l 4- 3-meth lmor holino mor holino-1 3 5-triazin yl)pyridinamine (8) “0., «521‘? {co ._ R» 1 1 1» l l NNR + mmmmmmmmmmmmmmmmmmmI» /‘ 0&3fo $791 x1: F» “F /.\N}I§,Ni0l \ .MN N )1 g, ., 11%“?ka xv,/l "f‘ g [i ll,“ L V N NH2 i13 i68 8 According to general procedure 1, compound 8 is obtained from starting materials H3 and i68 in 47% yield as a ess solid. 1H NMR (400 MHz, CDCI3): 8 9.03 (s, 1 H), 7.70 (t, 2JHf = 55 Hz, 1 H), 6.84 (s, 1 H), 4.78 (brs, 2 H), 4.75 (m, 1 H), 4.42-4.38 (m, 1 H), 4.00- 3.96 (m, 1 H), 3.84366 (m, 10 H), 3.55-3.50 (m, 1 H), 3.30-3.25 (m, 1 H), 1.33 (d, 3.1,”, = 6.8 Hz, 3 H); 19F NMR (376 MHz, CDCI3): 5 — 116.1-(-115.9) (m, 2 F); MS (MALDI): m/z = 408.9 ([M+H]+).
Example 9: S difluorometh l 4- 3-meth lmor holino mor holino-1 3 5-triazin yl)pyrimidinamine (9) Ck /O., l i F F \L F F l r l l u 0 <9 i N N Br\ j 1 «x /8\ / l J. ,L F F “N . 0 3.14."N l L‘l + N'QN ——> N"“‘N ,L- l .1! I 1: .2: /, l N N(Boc)2 N N(Boc)2 \N/ \N \ 1 CE 'N“ \N "Cl 'EN 1 O ,1 l A J ” NV ~\Ni—Iz I71 H3 9 According to general ure 2, compound 9 is ed from ng materials i71 and H3 in 60% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.24 (s, 1 H), 7.66 (t, 2JHf = 54 Hz, 1 H), 5.67 (br s, 2 H), 4.74 (m, 1 H), 4.41-4.38 (m, 1 H), 4.00-3.97 (m, 1 H), 3.90-3.72 (m, 9 H), 3.68-3.36 (m, 1 H), 3.56-3.49 (m, 1 H), 3.32-3.25 (m, 1 H), 1.33 (d, 3JH,H = 6.9 Hz, 3 H); 19F NMR (376 MHz, CDCI3): 8 — 121.3-(— 121.6) (m, 2 F); MS (MALDI): m/z = 409.4 ([M+H]+).
Example 10: 5- 4- 3-oxaazabic clo 3.2.1 octan l S meth lmor holino -1 3 5- n l difluorometh l ridinamine 10 (ckl o]l W“: 394%? Ri F B If O l: / N F F ‘3’: L” + Ll » : ‘l ’E‘ 1 :3 a N: 3:3 N: :1 o \ ‘7“ 03...: MN» NHE i18 i68 10 According to general procedure 1, compound 10 is ed from starting materials H8 and i68 in 42% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.04 (s, 1 H), 7.69 (t, 2JH,F = 55 Hz, 1 H), 6.84 (s, 1 H), 4.85 (br s, 2 H), 4.71-4.65 (m, 3 H), 4.42-4.39 (m, 1 H), 3.98-3.95 (m, 1 H), 3.79-3.76 (m, 3 H), 3.70-3.65 (m, 3 H), 3.56-3.53 (m, 1 H), 3.30- 3.27 (m, 1 H), 2.10-1.99 (m, 4 H), 1.33 (m, 3 H); 19F NMR (376 MHz, CDCI3): 6 —115.9— (—116.2) (m, 2 F); MS (MALDI): m/z = 434.2 ([M+H]+).
Example 11: 5- 4- 3-oxa-8—azabic clo 3.2.1 8- l S meth lmor holino -1 3 5- triazin l difluorometh l rimidinamine 11 According to general procedure 2, compound 11 is obtained from ng materials i71 and H8 in 46% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.25 (s, 1 H), 7.68 (t, 2JHf = 55 Hz, 1 H), 5.81 (br s, 2 H), 4.71-4.65 (m, 3 H), 4.42-4.38 (m, 1 H), 4.00- 3.96 (m, 1 H), .60 (m, 6 H), 3.55-3.50 (m, 1 H), 3.31-3.24 (m, 1 H), 2.11-2.00 (m, 4 H), 1.37-1.28 (m, 3 H); 19F NMR (376 MHz, CDCI3): 8 — 121.5-(— 121.7) (m, 2 F); MS ): m/z = 434.6 ([M+H]+).
Example 12: 4- difluorometh l 4-mor holino i erazin l -1 3 5-triazin yl)pyridinamine (12) 2015/076192 (.13.; o l I JO F F l l ,,,,, N N ;><\O"é‘“ l NAN N/igr F3 /F 1% L it (i. —* A; 1: FL L r) N N '1 1’ l “1 \\ OWWVNX ”NM-r""" F? N NH2 H4 i68 12 ing to general procedure 1, compound 12 is obtained from starting materials i68 and H4 in 86% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.85 (s, 1 H), 7.74 (t, 2JHF = 55 Hz, 1 H), 6.84 (s, 2 H), 6.75 (s, 1 H), 3.82-3.70 (m, 8 H), 3.69-3.60 (m, 4 H), 2.88-2.80 (m, 4 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.4 (s, 2 F); MS (MALDI): m/z = 393.8 ([M+H]+).
Example 13: 4- difluorometh l 4-mor holino i l -1 3 5-triazin yl)pyrimidinamine (13) F} F \:;;.\0 FT F % LY] [Vi BR i F F N D /\O/B N E + Nf‘N w’ NAN t J , l 5 1 Fl ,1; ,1 l; N N(Boc)2 l N" Nags»; 3 r}: N or i bl} N T i J} .OWWNK HNV U N FNHZ i71 H4 13 According to general procedure 2, compound 13 is obtained from starting materials i71 and H4 in 55% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.23 (s, 1 H), 7.64 (t, 2JHF = 55 Hz, 1 H), 5.60 (br s, 2 H), 3.83-3.75 (m, 12 H), 2.94-2.88 (m, 4 H); 19F NMR (376 MHz, CDCI3): 8 — 111.4 (s, 2 F); MS (MALDI): m/z = 395.1 ([M+H]+).
Example 14: S difluorometh l 4- 3-meth lmor holino i erazin l -1 3 5- triazin l ridinamine 14 to l ‘ l/ «>ch FF, 1‘:,.
/ N, “0’8” F ”55‘? g; NM“ F\ + l —> n is ,. ll ,1 l [// 3’.» ‘x.Cl N/ Nb“! ”\xww \N’/W\Vl 1 +0 TE/N.V “I‘lj/ HNx/ N \NH2 i21 i68 14 According to general procedure 1, compound 14 is obtained from starting materials i21 and i68 in 47% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.02 (s, 1 H), 7.67 (t, 2JH,F = 56 Hz, 1 H), 6.84 (s, 1 H), 4.90 (br s, 2 H), 4.74 (s, 1 H), 4.40 (d, JH,H = 16 Hz, 1 H), 3.98 (dd, JH,H= 4.0 Hz, 12 Hz, 1 H), 3.91 (m, 4 H), 3.78 (d, JH,H = 12 Hz, 1 H), 3.68 (dd, JHFH = 4.0, 12 Hz, 1 H), 3.56 (t, JH,H = 4.0 Hz, 1 H), 3.26 (dt, JH,H = 4.0, 12 Hz, 1 H), 2.99 (t, JH,H = 4.0 Hz, 4 H), 1.32 (d, JH,H = 8.0 Hz, 3 H);19F NMR (376 MHz, CDCI3): 8 — 115.9 (s, 2 F); MS ): m/z = 407.2 ([M+H]+).
Example 15: S difluorometh l 4- 3-meth lmor holino triazin l rimidinamine 15 _ o.
F F \I l t, J L _/, f' O F K, F \ N Br\ >8 F /L~, F\ SN ' é JR ' o N N l w, \‘N N ‘N + m A. J;F' A: J A A ,l' A L N/\N(Boc);; ‘N/“Meocb ( "f N Cl f N N' “‘1' ‘N 0\ ,N\ /} HN J L \ ,fi\ \N‘ ‘“ W. [f NH2 i71 i21 15 According to general procedure 2, compound 15 is ed from starting materials i71 and i21 in 30% yield as a colorless solid. 1H NMR (400 MHz, : 8 9.24 (s, 1 H), 7.66 (t, 2JH,F = 56 Hz, 1 H), 5.69 (br s, 2 H), 4.74 (s, 1 H), 4.40 (d, JH,H = 16 Hz, 1 H), 4.38 (dd, JH,H = 4.0, 12 Hz, 1 H), 3.83 (m, 4 H), 3.78 (d, JH,H =12 Hz, 1 H), 3.68 (dd, JH,H = 4.0, 12 Hz, 1 H), 3.54 (dt, JH,H = 4.0, 12 Hz, 1 H), 3.28 (dt, JH,H = 4.0, 12 Hz, 1 H), 2.92 (t, JH,H = 8.0 Hz, 4 H), 1.33 (t, JH,H = 8.0 Hz, 3 H); 19F NMR (376 MHz, CDCI3): 8 — 121.4 (s, 2 F); MS (MALDI): m/z = 408.7 ([M+H]+).
Example 16: 4- difluorometh l 2 6-dimor holino rimidin l 2-amine 16 FFFFF {\TA f [.ani “mg”? 13le\. T} / \‘A B F N O """"" NF? N ":15? F”\, ,x J J J. A W J: ,3 J.
N ”N/“c: “N’ ‘N f “N N ”‘W‘ o J K Q J J? J / I? ’ “8 “N’ “MHZ i22 i68 16 According to general procedure 1, compound 16 is obtained from starting materials i22 and i68 in 73% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.31 (s, 1 H), 7.30 (t, 2JH,F = 55 Hz, 1 H), 6.85 (s, 1 H), 6.04 (s, 1 H), 4.73 (br s, 2 H), 3.81-3.72 (m, 2015/076192 12 H), 3.65-3.59 (m, 4 H); 19F NMR (376 MHz, CDCI3): 5 — 115.1 (s, 2 F); MS (MALDI): m/z = 394.3 ([M+H]+).
/O\, F F J.. F /F LN J LNJ i “V,” 9 l l l Br '/\Q”B\/ N/ N/‘fil‘ F l: / \N V l ' + ' J l ,,,1 J f A ”N Q /J\ x N )2 N 2 N N Cl r N N )1 N o o. ,l I K N NH2 I71 i22 17 According to general procedure 2, compound 17 is ed from starting materials i71 and i22 in 7% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.60 (s, 1 H), 7.11 (t, 2JHf = 55 Hz, 1 H), 6.02 (s, 1 H), 5.46 (br s, 2 H), 3.80-3.74 (m, 12 H), 3.64- 3.60 (m, 4 H); 19F NMR (376 MHz, CDCI3): 5 — 119.5 (s, 2 F); MS (MALDI): m/z = 394.3 ([M+H]+)- i23 i68 18 According to general procedure 1, compound 18 is obtained from starting materials i23 and i68 in 89% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.94 (s, 1 H), 7.61 (t, 2JHf = 55 Hz, 1 H), 6.83 (s, 1 H), 5.50 (s, 1 H), 4.74 (br s, 2 H), 3.82-3.78 (m, 8 H), 3.61-3.57 (m, 8 H);19F NMR (376 MHz, CDCI3): 8 — 115.4 (s, 2 F); MS (MALDI): m/z = 393.3 ([M+H]+).
Example 19: 4'- difluorometh l -4 6-dimor holino— 2 5'-bi rimidin -2'-amine 19 WO 75130 [OR] o F‘TF ,3L0 FTP l l "N/ \N B Amos l N AN A A F l * A A it A ll A L N ‘N(Boc)2 “N \N(Boc)2 N N c: l/ N N 7' \N l O /I O\ /J “?L\ J N NH; i71 i23 19 According to general procedure 2, compound 19 is obtained from starting materials i71 and i23 in 7% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.16 (s, 1 H), 7.58 (t, 2JHf = 55 Hz, 1 H), 5.75 (br s, 2 H), 5.50 (s, 1 H), 3.82-3.79 (m, 8 H), 3.61-3.58 (m, 8 H); 19F NMR (376 MHz, CDCI3): 8 — 121.1 (s, 2 F); MS ): m/z = 395.3 ([M+H]+).
Example 20: 4- difluorometh l 4-mor holino—6-thiomor holino—1 3 zin l - pyridinamine (20) [MON] o A ,F l l N - A0 w i "B I i F F N““‘~“‘N 0‘ K “*1 WAN x.» l E} _—.,.. m a“: J\ A A; , in ”L r N N‘ “\Cl N NLi {K i? N/ ll 1 V, 531/ 3m///// "Ni; NHZ “5 i68 20 According to general procedure 1, compound 20 is obtained from starting materials H5 and i68 in 77% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.02 (s, 1 H), 7.65 (t, J = 55 Hz, 1 H), 6.84 (s, 1 H), 4.83 (br s, 2 H), 4.23-4.07 (m, 4 H), 3.90-3.79 (m, 4 H), 3.79-3.71 (m, 4 H), 2.71-2.62 (m, 4 H); 19F NMR (376 MHz, CDCI3): 8 — 116.0 (s, 2 F); MS (MALDI): m/z = 410.3 ([M+H]+).
Example 21: 4- rometh l 4-mor holino—6-thiomor holino—1 3 5-triazin l - pyrimidinamine (21) l O\ /,.O l l FTP N RN” /\ J Bu '1’ \ F F T: 3" AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA> + l?) ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, N N i ,A-‘\ A75 6. x ,/‘\, ’J/LN N N(Boc)2 [ I? N Ci (/ { N N ll N V s\ , \,/ N _ NH2 According to general procedure 2, compound 21 is obtained from starting materials i71 and HS in 70% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.21 (s, 1 H), 7.60 (t, 2Jim: 54 Hz, 1 H), 5.90 (br s, 2 H), 4.22-4.06 (m, 4 H), 3.91-3.78 (m, 4 H), 3.78- 3.71 (m, 4 H), 2.71-2.62 (m, 4 H); 19F NMR (376 MHz, : 6 — 120.5-(— 121.5) (m, 2 F); MS (MALDI): m/z = 411.2 ([M+H]+). azabic clo 3.2.1 8- l rimidin l difluorometh l ridinamine 22 i24 i68 22 According to general procedure 1, compound 22 is obtained from starting materials i24 and i68 in 61% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.34 (s, 1 H), 7.55 (t, 2JHf = 55 Hz, 1 H), 6.76 (s, 1 H), 6.60 (br s, 2 H), 6.36 (s, 1 H), 4.64-4.47 (m, 4 H), 3.67-3.49 (m, 4 H), 3.56-3.49 (m, 4 H), 1.98-1.79 (m, 8 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 114.9-(— 115.2) (m, 2 F); MS (MALDI): m/z = 445.3 ([M+H]+). oromethyl)pyridinamine (23) I(«OW F {WOW} \TJ \yPL‘ C? F .....f /W ,BW «:15 ),. ll 1 O 22,; WW FW [F + i » ‘l 4% ,w x. :7 x“b '«W x 41m /r» 2x l / g W WW;’2' N N c; N N N N w 1; (5». l O».\ 04% [l L / ‘w /' x 4' V W, N, NH? r? i29 i68 23 According to general procedure 1, compound 23 is obtained from starting als i29 and i68 in 54% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.30 (s, 1 H), 7.30 (t, 2JHf = 55 Hz, 1 H), 6.84 (s, 1 H), 6.04 (s, 1 H), 4.85 (br s, 2 H), 4.62 (br s, 2 H), 3.82- 3.74 (m, 6 H), 3.65-3.56 (m, 6 H), 2.09-2.00 (m, 2 H), .91 (m, 2 H); 19F NMR (376 MHz, CDCI3): 8 — 115.2-(—116.2) (m, 2 F); MS (MALDI): m/z = 419.0 ([M+H]+)- i71 i29 24 According to l procedure 2, compound 24 is obtained from starting materials i29 and i71 in 72% yield as a ess solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.71 (s, 1 H), 7.35 (s, 2 H), 7.32 (t, 2JHf = 54 Hz, 1 H), 6.45 (s, 1 H), 4.54 (br s, 2 H), 3.71-3.50 (m, 12 H), .78 (m, 4 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 119.2 (s, 2 F); MS (MALDI): m/z = 420.6 ([M+H]+).
Example 25: 5- 2 6-bis S meth lmor holino rimidin l difluorometh l ridin- 2-amine (25) [flow ,0 N) k1 l \XM’C? F {F Ax ,..B\ \> LT F\ A”: :1 fl O ,/ r ”l J * Ti 1 [ x? Nr/ x0; N {>12 (/ KN , \N o o t \U, .39 {1’ N “m2 i25 i68 25 According to general procedure 1, compound 25 is obtained from starting materials i25 and i68 in 57% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.31 (s, 1 H), 7.52 (t, 2JHf = 55 Hz, 1 H), 6.76 (s, 1 H), 6.59 (br s, 2 H), 6.30 (s, 1 H), 4.60-4.50 (m, 1 H), 4.44-4.33 (m, 1 H), 4.24-4.15 (m, 1 H), 4.12-4.04 (m, 1 H), 3.94-3.83 (m, 2 H), 3.74-3.64 (m, 2 H), 3.59-3.51 (m, 2 H), 3.45-3.35 (m, 2 H), 3.14-3.02 (m, 2 H), 1.18 (t, 3JH,H = 7.2 Hz, 6 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 113.7-(— 115.9) (m, 2 F); MS (MALDI): m/z = 421.1 +).
Example 26: 4'- difluorometh l -2 6-bis S meth lmor holino - 4 5'-bi rimidin -2’- amine (26) 2015/076192 o. 0 § f/ ..' x F\) F \v/LQ F 1 l 1 F\? g x‘N/r \N/ ”"7 Br‘\,/-/2 //\\' F 0”EN/2‘} 1 ,z/llmh x/ilx F\«\ 11‘? —* ill? H ”1“) M E‘Tjfll[ \N ‘N(Boc)2 N/ ‘N(Boc)2 i [ N C! [/1 ‘51” ”N/ “a i O r]: O “““““J K I}: N NH? .0, ml i71 i25 26 ing to general procedure 2, compound 26 is obtained from starting materials i25 and i71 in 56% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.60 (s, 1 H), 7.14 (t, 2JH,F = 54 Hz, 1 H), 5.98 (s, 1 H), 5.48 (br s, 2 H), 4.71-4.62 (m, 1 H), .23 (m, 2 H), 4.08-3.92 (m, 3 H), 3.83-3.65 (m, 4 H), 3.61-3.49 (m, 2 H), 3.25 (dt, 2JH,H =13 Hz, 3.1,”, = 3.6 Hz, 2 H), .27 (m, 6 H); 19F NMR (376 MHz, 00013): 8 — 119.5 (s, 1 F), 119.7 (m, 1 F); MS (MALDI): m/z = 423.0 ([M+H]+).
Example 27: S difluorometh l 6- 3-meth lmor holino mor holino rimidin yl)pyridinamine (27) [AEJ F \ IEKJ \ )1“? Fa?8 ,,,,,,, 1,0 ,3 4 r/,,»g:% :EJL”a“515 1 jfix \ Fx/F A {1% ,f"\ /1\«‘ “La E lTl N Cl N if? I? 1 N CK / j; Mw/ CLV, \ Ne”? i30 i68 27 According to general procedure 1, compound 27 is obtained from starting materials i30 and i68 in 74% yield as a ess solid. 1H NMR (400 MHz, CDCI3): 8 8.31 (s, 1 H), 7.30 (t, 2.0,; = 55 Hz, 1 H), 6.85 (s,1 H), 6.02 (s, 1 H), 4.75 (brs, 2 H), 4.35-4.25 (m, 1 H), 4.06-3.96 (m, 2 H), 3.83-3.69 (m, 10 H), 3.58 (dt, 2.1,”, = 12 Hz, 3.1,”, = 3.2 Hz, 1 H), 3.25 (dt, 2.0,), = 13 Hz, 3.1,”, = 3.8 Hz, 1 H), 1.31 (d, 3.1,”, = 6.8 Hz, 3 H); 19F NMR (376 MHz, CDCI3): 8 — 114.9-(— 115.0) (m, 2 F); MS (MALDI): m/z = 407.1 ([M+H]+).
Example 28: S -4'- difluorometh l 3-meth lmor holino mor holino— 4 5'- bi rimidin -2’-amine 28 x’O\-.,_ O VJ .9 F L l F F \ F\ BM 1 V" J3». f t 23 ,/ O ,/ (1.. ,,.g F F {g N N —» )1 + mmmmmmmmmmmmm+ 4m ' x a. 1)) ,- 1.. l} “ f k, 1 N N(Boc)z N N<Boc)2 { N/ Cl E' N 0 If OL t? 1Ei {El , \N, «g 1 N NHg i71 i30 28 ing to general procedure 2, compound 28 is obtained from starting materials i30 and i71 in 53% yield as a ess solid. 1H NMR (400 MHz, CDCI3): 8 8.60 (s, 1 H), 7.13 (t, 2./H,F= 54 Hz, 1 H), 6.01 (s,1 H), 5.47 (brs, 2 H), 4.71-4.63 (m,1 H), 4.31 (dd, 2.1,”, = 14 Hz, 3.1,”, = 2.4 Hz, 1 H), 3.97 (dd, 2.1,”, = 11 Hz, 3.1,”, = 3.4 Hz, 1 H), 3.79 (t, 3.1,”, = 4.6 Hz, 4 H), 3.72-3.66 (m, 2 H), 3.65-3.58 (m, 3 H), 3.58-3.50 (m, 2 H), 3.30-3.21 (m, 1 H), 1.30 (d, 3.1,”, = 6.8 Hz, 3 H); 19F NMR (376 MHz, 00013): 6 — 119.7 (brs, 2 F); MS (MALDI): m/z = 408.9 ([M+H]+).
Example 29: 5-(4-(8-Oxaazabicyclo[3.2.1]octanyl)(8-oxa azabicyclo[3.2.1]octanyl)-1,3,5-triazinyl)(difluoromethyl)pyridinamine 29 l Ejo. x/‘imO“N F\”‘ “F 2.x“ jg 5 E i. F F Odddddd 1’ ~43: N \‘N \ /" + F l —> :1 9:, L .1 N N1 1 N N“ 1 16,, J 1,1 1 ,, \O N 4,1 19,911 321 xvi? N’ NHZ i81 i68 29 According to general ure 1, compound 29 is obtained from starting materials i68 and i81 in 89% yield as a colorless solid. 1H NMR (400 MHz, : 89.03 (s, 1 H), 7.69 (t, 2JH,F = 55 Hz, 1 H), 6.83 (s, 1 H), 4.85 (br s, 2 H), 4.50-4.24 (m, 8 H), 3.28-3.12 (m, 4 H), 1.94 (br s, 4 H), 1.86-1.71 (m,4 H); 19F NMR (376 MHz, CDCI3): 8 — 115.1-(—117.2) (m, 2 F); MS (MALDI): m/z = 446.3 ([M+H]+).
Example 30: 5-[4,6-bis(2,2-dimethylmorpholinyl)-1,3,5-triazinyl]—4- (difluoromethyl)pyridinamine 30 1 63 /»O.\}// O \lx/ [ F F I ./ Nix/7‘0 j 31 xx -é. L 0 / x T /' £3» \ Fxx / F *1 ”'3‘ + l W N N l / \ch \C! t + \N am?“ / Nam \R 1 U» i ll .l 0V" I? 0‘» f N” ‘NHZ i80 i68 30 According to general procedure 1, compound 30 is obtained from ng materials i68 and i80 in 63% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.86 (s, 1 H), 7.71 (t, 2JHf = 55 Hz, 1 H), 6.84 (brs, 2 H), 6.76 (s, 1 H), 3.81-3.56 (m, 12 H), 1.14 (s, 12 H); MS ): m/z = 451.2 ([M+H]+).
Example 31: S difluorometh l 2- 3-meth lmor holino mor holino rimidin yl)pyridinamine (31) 0. ,ox { /] 3'3“ F { } N xii:0 / RN 1 >4 g; I l '\ x/"im? .x xx. Fx, F N a ’0 N : “ ll l ,. A L l / ,,,,,,,, ; “ / ” . i N Cl N l: f N N i/ x O .V/j / Q w/l \L N N NH2 1 0 l i28 i68 31 According to l procedure 1, compound 31 is obtained from ng materials i28 and i68 in 58% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.31 (s, 1 H), 7.52 (t, 2JHf = 55 Hz, 1 H), 6.74 (s, 1 H), 6.59 (br s, 2 H), 6.35 (s, 1 H), 4.59-4.51 (m, 1 H), 4.22-4.14 (m, 1 H), 3.91-3.84 (m, 1 H), 3.72-3.50 (m, 10 H), 3.44-3.35 (m, 1 H), 3.14-3.03 (m, 1 H), 1.16 (d, 3.1,”, = 6.7 Hz, 3 H); 19F NMR (376 MHz, (003)280): 5 — 113.7-(—115.3) (m, 2 F); MS (MALDI): m/z = 407.1 ([M+H]+).
Example 32: S -4’- difluorometh l 3-meth lmor holino mor holino— 4 5’- bi rimidin -2’-amine 32 l/o.\ (,0 F F L I 1 r 410 ka/F ix B i B J “xx / ~ /”¢ E '3’ \ ”:2 /. ,_ . , 1 i O —> ‘2’ + l1 ~~~~~~~~~~., 1 if .x x ///\ ,1, j. j:k ‘N’ N(BoC)2 N Mama); 1“" N” “N“ Cl 7’ N N ii N 0.. J ox J V V N NHZ According to general procedure 2, compound 32 is obtained from starting materials i28 and i71 in 63% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 8.60 (s, 1 H), 7.13 (t, 2.13,; = 54 Hz, 1 H), 5.99 (s, 1 H), 5.46 (br s, 2 H), 4.34-4.25 (m, 1 H), 4.06-3.97 (m, 2 H), .68 (m, 10 H), 3.58 (dt, 2.13”, = 12 Hz, 3.133, = 3.2 Hz, 1 H), 3.26 (dt, 2.13”, = 13 Hz, 3.133, = 3.7 Hz, 1 H), 1.31 (d, 3.133, = 6.8 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 8 — 119.5 (s, 2 F); MS (MALDI): m/z = 408.7 ([M+H]+).
Example 33: 4-(difluoromethyl)—5-[4-[(2S,6R)—2,6-dimethylmorpholinyl]—6-[(3R)—3- morpholinyl]-1,3,5-triazinyl]pyridinamine 33 ,0... o 3 f k \L F. ,1: 3 3 .3, 3 O “3k 33 + ‘l; —> 33 F \XAWN “N": “C: N 31 \/MN “31"“U/ <31 0 (3 N (5- /3 L 3" N NH; 31/ ”I” i82 i68 33 ing to general procedure 1, compound 33 is obtained from starting materials i68 and i82 in 71% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.74 (t, 2J3); = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.71-4.62 (m, 1 H), 4.45-4.34 (m, 2 H), 4.31-4.09 (m, 1 H), 3.90 (m, 1 H), 3.71 (m, 1 H), 3.55 (m, 3 H), 3.38 (m, 1 H), 3.13 (m, 1 H), 2.55 (m, 2 H), 1.20 (d, 3JH,H = 6.9 Hz, 3 H), 1.19 (d, 3JH,H = 6.9 Hz, 6 H); MS (MALDI): m/z = 436.1 ([M+H]+).
Example 34: 5-[4,6-bis[(2R,6S)—2,6-dimethylmorpholinyl]-1,3,5-triazinyl] (difluoromethyl)pyridinamine 34 Toff v.03 3 303/ ‘3 :31. 3 3. '1‘ $3,233?“ 0 + NE “3] N/QXN Fix/3F \5/ N 3N \[3 3 33 3 N” N” Cl l3 N N O 3/3 \N/ Ox. .3”; U” <. 23L. 1 3 I N NH2 i79 i68 34 ing to general procedure 1, nd 34 is obtained from starting materials i68 and i79 in 75% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.86 (s, 1 H), 7.71 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.64-4.46 (m, 4 H), 3.60-3.48 (m, 4 H), 2.63 (m, 4H), 1.14 (m, 12 H); MS (MALDI): m/z = 450.0 ([M+H]+).
Example 35: 4- 4- 6-amino difluorometh | rid | mor holino—1 3 5-triazin Imor holinone 35 {N1 . (N1 N/RN gig. 0’B \ NANF F (\N [NACI 1N/ N (\N IN% ovko KYl 0&0 l N/ NH2 i31 i68 35 According to l procedure 1, compound 35 is obtained from starting materials i31 and i68 in 10% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.08 (s, 1 H), 7.96 (t, 2JHf = 56 Hz, 1 H), 6.86 (s, 1 H), 4.98 (br s, 2 H), 4.35 (s, 2 H), 4.07-4.00 (m, 4 H), 3.95 (br s, 2 H), 3.90 (br s, 2 H), 3.78 (br s, 4 H);19F NMR (376 MHz, CDCI3): 8 — 117.4 (s, 2 F).
Example 36: 4- 4- 2-amino rometh | rimidin | mor holino—1 3 zin yllmorpholin-B-one (36) o o F F QL F F U [1 \ C? 1 hi F —* “‘ N NEsoc2 0311 / 111%/ / N NBOC2 fN N CI N N i\N 0&0 0A0 NANHZ i71 i31 36 ing to general procedure 2, compound 36 is obtained from starting materials i31 and i71 in 6% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 9.22 (s, 1 H), 8.10 (t, 2JHf = 56 Hz, 1 H), 7.97 (br s, 2 H), 4.28 (s, 2 H), 3.98 (s, 4 H), 3.90 (br s, 2 H), 3.81 (br s, 2 H), 3.70 (br s, 4 H); 19F NMR (376 MHz, (CD3)280): 8 — 121.1 (s, 2 F); MS (MALDI): m/z = 408.7 ([M+H]+).
Example 37: 5- 4 6-bis 3 7-dioxaazabic c|o 3.3.1 nonan | -1 3 5-triazin | (difluoromethyl)pyridinamine (37) R ,0 R R J t X “j x, x \4’ , a . ’ ! \1” }‘ Ext/y /}\Q Fx F iv, ,é T: j ,i, O‘ R; m , R a F N ‘~ N + ,g 1 ___________________,, § ,ii ,/Jx KM NI} \‘N x” \ N14 “N ,»/Z?::,.. -__,,,.N/ "N” “c: gg FT“ B l 0/ TY ‘ E j N NH2 0/1,... 0’ i7 i68 37 According to general procedure 1, compound 37 is obtained from starting materials i7 and i68 in 39% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.85 (s, 1 H), 7.68 (t, 3JH,F = 55 Hz, 1 H), 6.87 (br s, 2 H), 6.74 (s, 1 H), 4.51 (br s, 2 H), 4.45 (br s, 2 H), 4.07- 3.93 (m, 8 H), 3.79-3.67 (m, 8 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.8 (s, 2 F); MS (MALDI): m/z = 478.1 ([M+H]+). i35 i68 38 According to general procedure 1, compound 38 is obtained from starting materials i35 and i68 in 67% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.73 (t, 3JH,F = 55 Hz, 1 H), 6.87 (br s, 2 H), 6.75 (s, 1 H), 4.70-4.54 (m, 2 H), .43 (m, 2 H), 4.05-3.97 (m, 4 H), .67 (m, 4 H), 3.63-3.55 (m, 4 H) 2.00-1.83 (m, 4 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.8 (s, 1 F), — 115.9 (s, 1 F); MS (MALDI): m/z = 462.1 +).
Example 39: 5- 4 6-bis 3 3-dimeth lmor holin l -1 3 5-triazin l (difluoromethyl)pyridinamine (39) vvvvv 0‘21 [MN 1 NFL”Q FTP Law/K 1 ,1 L 1: 1: ’ “‘1“ 0 1 N”““~“N / :2! {TL j: + 1 7t 1;, flflflflflflflflflflflflflflflflflflflflflflflflflflflflflflfl, [\ 3% /i\ 1 1" N 01 N { N O»’’’’’’’I? 1:1! 511 1 *1 [13/ O\“’/ “ N” ““NHg i4 i68 39 According to general procedure 1, compound 39 is obtained from starting materials i4 and i68 in 28% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.78 (s, 1 H), 7.70 (t, 2JHf = 55 Hz, 1 H), 6.82 (br s, 2 H), 6.77 (s, 1 H), 3.87-3.75 (m, 8 H), 3.45 (br s, 4 H), 1.49 (s, 12 H); 19F NMR (376 MHz, (CD3)ZSO): 6 — (— 115.1) (m, 2 F); MS (MALDI): m/z = 450.1 ([M+H]+). e 40: 5- 4 6-bis 3R 5S -3 5-dimeth lmor holin l -1 3 5-triazin l (difluoromethyl)pyridinamine (40) 1 1 1:1. 2 N O 1111:/ \11 1 11 + ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1 ’ ’ x g N N Ci N {113 r/ N N O L». l ,x’ O“xx/K b ,,,,,,,J\ x I? N NH2 i6 i68 40 According to general procedure 1, compound 40 is obtained from ng materials i6 and i68 in 42% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.90 (s, 1 H), 7.82 (t, 2JHf = 55 Hz, 1 H), 6.84 (br s, 2 H), 6.77 (s, 1 H), 4.59-4.43 (m, 4 H), 3.82-3.73 (m, 4 H), 3.60-3.51 (m, 4 H), 1.29 (d, 2J1”, = 6.9 Hz, 12 H); 19F NMR (376 MHz, (003)280): 8 — 114.9—(— 115.0) (m, 2 F); MS (MALDI): m/z = 450.2 +).
Example 41: 5- 4 6-bis 3R meth lmor holin l-1 3 5-triazin l (difluoromethyl)pyridinamine (41) infik ,J‘o {-1 F , {NR J\ ,1/11{1.\ é ) J F F 1 ii “l y R / “m J1 )i ,4 i1. r I?! N/ Ci N A; [1” [TI N/ A NE, ON T 02‘ "/ L N “NI-12 i5 i68 41 According to general procedure 1, compound 41 is obtained from starting materials i5 and i68 in 98% yield as a colorless solid. 1H NMR (400 MHz, CDCI3): 8 9.04 (s, 1 H), 7.70 (t, 2.0,; = 52.0 Hz, 1 H), 6.84 (s, 1 H), 4.88 (br s, 2 H), 4.77-4.72 (m, 2 H), 4.41 (d, 2.0,), = 12.0 Hz, 2 H), 3.98 (dd, 2.0,), = 12.0 Hz, 3.0,), = 4.0 Hz, 2 H), 3.78 (d, 2.0,), = 12.0 Hz, 2 H), 3.68 (dd, 2JH,H= 12.0 Hz, 3.0,), = 4.0 Hz, 2 H), 3.53 (dt, 2.1,”, = 12.0 Hz, 3.1,”, = 4.0 Hz, 2 H), 3.28 (dt, 2.0,), = 12.0 Hz, 3.0,), = 4.0 Hz, 2 H), 1.33 (d, 2.0,), = 8.0 Hz, 6 H); 19F NMR (376 MHz, 00013): 8 — 115.9 (s, 1 F), — 116.0 (s, 1 F); MS (MALDI): m/z = 421.7 ([M+H]+). e 42: 4- difluorometh l 4- 3 3-dimeth lmor holin l mor holino—1 3 5- triazinl 2-amine 42 N l 9 6.3,): ((((( \ \T/ /' "' B “ / 25.x / '1“) 3‘ O + t 1 )1 A 3‘“ ii F. 321/ x, N 8» N? Cl I} §'/A\[]§ \ N I; \\.1 O‘Nx ”‘1 O I? \/‘ \ N11? \ i16 i68 42 According to general procedure 1, compound 42 is obtained from starting materials i16 and i68 in 35% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.83 (s, 1 H), 7.73 (t, 2JHf = 55 Hz, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 3.85-3.76 (m, 4 H), 3.76-3.63 (m, 8 H), 3.45 (br s, 2 H), 1.49 (s, 6 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.0 / — 116.3 (s, 2 F); MS ): m/z = 423.2 ([M+H]+). i33 i68 43 According to l procedure 1, compound 43 is obtained from starting materials i33 and i68 in 43% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 9.01 (s, 2 H), 7.81 (t, 2JHf = 55 Hz, 2 H), 7.00 (br s, 4 H), 6.82 (s, 2 H), 4.78-4.66 (m, 1 H), .35 (m, 1 H), 4.01-3.91 (m, 1 H), 3.81-3.72 (m, 1 H), 3.65-3.58 (m, 1 H), 3.52-3.42 (m, 1 H), 3.38- 3.23 (m, 1 H) 1.30 (d, 3.1),), = 6.7 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 6 — 114.3- (— 117.2) (m, 4 F); MS (MALDI): m/z = 465.1 ([M+H]+). i37 i68 44 According to general procedure 1, compound 44 is obtained from starting materials i3? and i68 in 75% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.89 (s, 1 H), 7.79 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.65 (brs, 1 H), 4.50 (br s, 2 H), 4.37-4.25 (m, 1 H), 3.93 (dd, 3JH,H = 11 Hz, 3JH,H = 3.2 Hz, 1 H), 3.79-3.67 (m, 3 H), 3.59- 3.51 (m, 3 H), 3.45-3.36 (m, 1 H), 3.22-3.11 (m, 1 H), 1.30 (d, 3JH,H = 6.7 Hz, 6 H), 1.24 (d, 3.1),), = 6.7 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 6 — 115.0 (br s, 2 F); MS (MALDI): m/z = 436.1 ([M+H]+). o\ ,,o {”ml/k LN \3 Q;~~~~o 1:ng i. K is i L \ O / 1:, F \ N \\N x / I//Nr§N/SJ t, + M N/J ”D C! \N ’16:)!“ng \, /L J 1L CE, 1 l: ,L 1? v N ‘NHZ i38 i68 45 According to general procedure 1, compound 45 is obtained from starting materials i38 and i68 in 71% yield as a ess solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.84 (s, 1 H), 7.74 (t, 2.1),,F = 55 Hz, 1 H), 6.63 (br s, 2 H), 6.76 (s, 1 H), 4.56 (br s, 1 H), 4.31-4.19 (m, 1 H), 3.93 (dd, 2.1),), =12 Hz, , = 3.9 Hz, 1 H), 3.64-3.61 (m, 4 H), 3.76-3.69 (m, 1 H), 3.56 (dd, 2.1),), = 11 Hz, 3.1),), = 3.2 Hz, 1 H), 3.46-3.36 (m, 3 H), 3.23-3.13 (m, 1 H), 1.50 (br s, 6 H), 1.23 (d, 3.1),), = 6.7 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 6 — 114.6- (— 115.5) (m, 2 F); MS (MALDI): m/z = 436.0 ([M+H]+). 2015/076192 Example 46: 4- difluorometh | 4- 3R methox meth | mor holin | 3R i39 i68 46 According to general procedure 1, compound 46 is obtained from ng materials i39 and i68 in 67% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.77 (t, 2JHf = 55 Hz, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 4.67 (brs, 2 H), 4.44-4.24 (m, 2 H), .83 (m, 3 H), 3.75-3.63 (m, 2 H), 3.60-3.36 (m, 5 H), 3.31 (s, 3 H), 3.21-3.04 (m, 2 H), 1.23 (d, 3.1,”, = 6.7 Hz, 3 H); 19F NMR (376 MHz, 80): 5 — 115.0 (br s, 2 F); MS (MALDI): m/z = 452.3 ([M+H]+). i36 i68 47 According to general procedure 1, compound 47 is obtained from starting materials i36 and i68 in 85% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.86 (s, 1 H), 7.72 (t, 2JHf = 55 Hz, 1 H), 6.84 (br s, 2 H), 6.75 (s, 1 H), 4.64 (br s, 1 H), 4.53-4.42 (m, 2 H), 4.37-4.25 (m, 1 H), 4.05-3.96 (m, 4 H), 3.92-3.84 (m, 1 H), 3.77-3.66 (m, 5 H), 3.60- 3.52 (m, 1 H), 3.44-3.35 (m, 1 H), 3.22-3.10 (m, 1 H), 1.23 (d, 3JH,H = 6.7 Hz, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 114.9—(— 117.1) (m, 2 F); MS (MALDI): m/z = 450.0 ([M+H]+)- Example 48: 4S 5R 4- 2-amino difluorometh | n lmor holino—1 3 5- triazin l h drox meth |meth l-oxazolidinone 48 o ,0 L l l l N AOTBS N F F l. ,L l N “”“N HN/I: FLY}: N N [OH A A + L b ~~~~~~~~~~~~~~~~~ A l 3%.wa "c: -0 /, N. o [I]; A] N N’ \r“ (Boc)2N” O N HzN' N o“ i74 i73 48 tert—Butyl N-tert—butoxycarbonyl-N-(5-(4-chloromorpholino-1,3,5-triazinyl)—4- (difluoromethyl)pyrimidinyl)carbamate (i74, 350 mg, 643 umol, 1.0 eq.), (4S,5R)—4- (((tert—butyldimethylsilyl)oxy)methyl)—5-methyloxazolidinone (i73, 174 mg, 709 umol, 1.1 eq.), 4,5-bis(diphenylphosphino)—9,9-dimethylxanthene (22.3 mg, 38.5 umol, 0.06 eq.), cesium carbonate (419 mg, 1.29 mmol, 2.0 eq.) and palladium(ll) acetate (5.80 mg, .8 umol, 0.04 eq.) are mixed in 1,4-dioxane (5 mL) under en atmosphere and heated at 95 °C for 2 hours. After this time, the reaction mixture is allowed to cool down to room temperature, zed H20 is added, and the aqueous layer is separated and ted with ethyl e (3 x). The combined organic layer is dried over ous sodium sulfate, filtered and the solvent is evaporated under reduced pressure.
The above residue is dissolved in tetrahydrofuran (5 mL) and aqueous HCI (3M, 2.00 mL, 6.00 mmol, 14 eq.) is added. The resulting mixture is heated at 60 °C overnight. Then, aqueous saturated sodium bicarbonate and ethyl acetate are added. The aqueous layer is separated and extracted with ethyl acetate (3 x). The combined organic layer is dried over anhydrous sodium sulfate, filtered and concentrated und d pressure. Purification by column chromatography on silica gel (100 % ethyl acetate) gives product 48 as a colorless solid (55% yield). 1H NMR (400 MHz, (CD3)ZSO): 8 9.23 (s, 1 H), 8.23 (t, 2JH,F = 54 Hz, 1 H), 7.81-7.53 (m, 2 H), 4.99 (t, 2JH,F = 5.2 Hz, 1 H), 4.82 (q, 2JH,F = 6.5 Hz, 1 H), 4.56-4.51 (m, 1 H), 4.03- 3.97 (m, 1 H), 3.95-3.60 (m, 9 H), 1.50 (d, ZJHf = 6.5 Hz, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 121.3 (s, 1 F), — 121.4 (s, 1 F); MS (MALDI): m/z = 439.1 ([M+H]+).
Example 49: 4S 5R 6- 2-amino rometh l rimidin l mor holino- ,0. .10 L, ,1 LAN A F. A: «Al FAA/.F I N T ..\ f Q [ l A F F t, /,l x l N' ”N AOTBDPS “Y N. N WOH BA ,B\ A l N 0 A... 1 w l ll + / I L t I A l A A l Br” \V ‘N‘””\_ N \V N” \, N ”N(Boc)2 N’ N(Boc)2 l A, .1- AL A, / l o‘ '0 H2N N 0 W1 W8 49 tert—Butyl N-[5-bromo(difluoromethyl)pyrimidinyl]-N-ten‘-butoxycarbonyl- carbamate (i71, 44.0 mg, 104 umol, 1.0 eq.), bis(pinacolato)diboron (27.0 g, 106 umol, 1.0 eq.), KOAc (31.0 mg, 316 umol, 3.0 eq.) and [1,1’-bis(diphenylphosphino)ferrocene]— dichloropalladium(|l) (7.70 mg, 10.5 umol, 0.10 eq.) are mixed in 1,4-dioxane (2 mL) under nitrogen atmosphere and heated at 95 °C for 55 minutes.
After this time, the above reaction mixture is allowed to cool down to room temperature.
Then, compound i78 (64.0 mg, 105 umol, 1.0 eq.), potassium phosphate tribasic (44.0 mg, 207 umol, 2.0 eq.), chloro(2-dicyclohexylphosphino-2’,4’,6’-triisopropyl- 1,1’-biphenyl) [2-(2’-amino-1,1’-bipheny|)]-pa||adium(|l) (Sigma-Aldrich, product number 741825, 8.20 mg, 10.4 umol, 0.10 eq.), 1,4-dioxane (2 mL) and deionized H20 (0.5 mL) are added and the resulting dark mixture is placed in a pre-heated oil bath at 95 °C for 16 hours. After this time, aqueous saturated sodium bicarbonate and dichloromethane are added. The aqueous layer is separated and extracted with dichloromethane (3 x). The combined organic layer is dried over anhydrous sodium e, filtered and concentrated under d pressure. This intermediate is purified by column chromatography on silica gel (cyclohexane / ethyl acetate 1:0 9 1:1) to afford a colorless semisolid.
The semisolid ed above is then dissolved in tetrahydrofuran (2 mL) and a solution of HCI in dioxane (1 M, 100 uL, 100 umol, 1.0 eq) is added. The resulting mixture is stirred at room temperature overnight. After this time, the solvents are evaporated and the residue is dried in vacuo.
The above salt is then dissolved in tetrahydrofuran (2 mL) and a solution of tetrabutylammonium fluoride hydrate in tetrahydrofuran (1 M, 100 uL, 100 umol, 1.0 eq.) is added. The reaction mixture is allowed to stir at room temperature for 2 days. After this time, aqueous saturated sodium bicarbonate is added and the product is extracted with ethyl acetate (3 x). The combined organic layer is washed with an aqueous ted NH4CI-solution (3 x), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford a ish solid. This solid is triturated with diethyl ether (5 x) and dried in vacuo. The d t 49 is ed as a ess solid (5.5 % yield). 1H NMR (400 MHz, CD30D): 58.64 (s, 1 H), 7.69 (s, 1 H), 7.15 (t, 2JH,F = 54 Hz, 1 H), 4.82-4.76 (m, 1 H), 4.66-4.61 (m, 1 H), 4.17 (dd, 2JH,H =12 Hz, 3JH,H= 4.1 Hz, 1 H), 3.78 (dd, 2.1.”, = 12 Hz, 3.1.”, = 1.5 Hz, 1 H), 3.72-3.61 (m, 8 H), 1.61 (d, 3.1.”, = 6.6 Hz, 3 H); 19F NMR (376 MHz, CD30D): 5— 121.4 (s, 1 F), — 121.5 (s, 1 F); MS ): m/z = 438.4 ([M+H]+).
Example 50: 4- difluorometh | 4- 3R meth lmor holin | 3-oxa azabic clo 3.1.1 he tan |-1 3 5-triazin | ridinamine 50 1 wk ”ng0 J a. f N/J\ N5; N yoga J11} F F N JN’N ‘ / ,ng U + T! AL vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvp i Ii 1 1 l“N/ “N Cl “NV ‘N (”PM “N” N (5 ""23 ii / Q J F J x" “I? ’ \f’ “‘ N“ i40 i68 50 According to general procedure 1, compound 50 is obtained from starting materials MO and i68 in 52% yield as a colorless solid. 1H NMR (400 MHz, SO): 8 8.90 (s, 1 H), 7.82 (t, 2JHf = 55 Hz, 1 H), 6.87 (br s, 2 H), 6.76 (s, 1 H), 4.55-4.51 (m, 1 H), .14 (m, 3 H), 4.12-4.25 (m, 2 H), 3.92-3.80 (m, 1 H), 3.76-3.68 (m, 3 H), 3.55-3.51 (m, 1 H), 3.38 (m, 1 H), 3.20-3.13 (m, 1 H), 2.68 (m, 1 H), 1.78 (m, 1 H), 1.20 (d, 3JH,H = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.0 (br s, 2 F); MS (MALDI): m/z = 420.6 ([M+H]+)- M1 i68 51 ing to general ure 1, compound 51 is obtained from starting materials M1 and i68 in 36% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.99 (s, 1 H), 7.89 (t, 2JHf = 55 Hz, 1 H), 6.84 (brs, 2 H), 6.77 (s, 1 H), 4.69 (m, 3 H), 4.37 (m, 1 H), 3.91-3.85 (m, 3 H), 3.75-3.53 (m, 4 H), 3.42-3.35 (m, 1 H), 3.22-3.15 (m, 1 H), 3.12-3.08 (m, 1 H), 1.85 (m, 1 H), 1.24 (d, 3.1,”, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 5 — 116.0 (br s, 2 F); MS (MALDI): m/z = 420.6 ([M+H]+).
Example 52: 4- rometh | 4- 3R meth lmor holin | 1R4R oxa azabic clo 2.2.1 he tan |-1 3 5-triazin | ridinamine 52 ,0 0 ENE\ E XXL? 1:ng k N 0' N .10 ~ (1,, i42 i68 52 According to general procedure 1, compound 52 is obtained from ng materials i42 and i68 in 44% yield as a colorless solid (1 :1 mixture of rotamers). 1H NMR (400 MHz, (CD3)ZSO): 8 8.89 (m, 1 H), 7.77 (m, 1 H), 6.84 (brs, 2 H), 6.76 (s, 1 H), 5.02-4.97 (m, 1 H), 4.68-4.66 (m, 2 H), 4.31 (m, 1 H), 3.89-3.85 (m, 1 H), 3.79-3.57 (m, 3 H), 3.57-3.44 (m, 4 H), 3.22 (m, 1 H), 1.90-1.83 (m, 2 H), 1.21 (d, 3.1,”, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.5 (br s, 2 F); MS ): m/z = 420.2 ([M+H]+).
Example 53: 4- difluorometh l 4- 3R meth lmor holin l 18 4S oxa azabic clo 2.2.1 he tan l-1 3 5-triazin l ridinamine 53 0,, o t E \i F“). F \ 2‘0 kMN E, 7‘ E i , x £3, F F O x, \ 65’\‘ W“““““—* A. [fix (I? E -/] r j? E \N 7 N ‘N CI N N N” \ ., [\‘j “V “N NHz i43 i68 53 According to general procedure 1, compound 53 is obtained from ng materials M3 and i68 in 53% yield as a colorless solid (1 :1 mixture of rs). 1H NMR (400 MHz, SO): 8 8.90 (m, 1 H), 7.77 (m, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 5.02-4.96 (m, 1 H), 4.68-4.62 (m, 2 H), 3.90 (m, 1 H), 3.80 (m, 1 H), 3.70 (m, 2 H), 3.57 (m, 2 H), 3.45 (m, 3 H), 3.20 (m, 1 H), 1.90-1.83 (m, 2 H), 1.21 (d, 3.1,”, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.0 (br s, 2 F); MS (MALDI): m/z = 420.2 ([M+H]+).
Example 54: 5- 4 6-bis 3R eth lmor holin l-1 3 5-triazin l (difluoromethyl)pyridinamine (54) o /.O.\ [ Yk \LQ RT} EMTK ,3 N1 + 1 m, 11 .1 »»»»»»»». . 111?... A. J MMMMMMM EN/LNHZ i8 i68 54 According to general procedure 1, compound 54 is obtained from ng materials i8 and i68 in 61% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.77 (t, 2JHf = 55 Hz,1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.47 (m, 4 H), 3.89-3.81 (m, 4 H), 3.51-3.34 (m, 4 H), 3.12 (m, 2 H), 1.71 (m, 4 H), 0.86 (m, 6 H). 19F NMR (376 MHz, (CD3)ZSO): 8 - 115.0 (br s, 2 F); MS (MALDI): m/z = 450.3 ([M+H]+).
Example 55: 5- 4 6-bis 8-oxaazas iro 3.5 5- l -1 3 5-triazin l oromethyl)pyridinamine(55) (.0.1 )0. 1, 1 1/ fi‘\w:\ 2}”? FRl/F hi 1,»: Fa“, [F “'1,” 4. > N4; 5N 1 * O/Bxxfxmifiy ------------------------~> . 1. :l .l 1,1 ,,,, \NM \N xN NN 'CN/ N ‘C’ {/3333 A . 11. 71 l V 1E1 N‘ NH; i9 i68 55 According to general procedure 1, compound 55 is obtained from starting materials i9 and i68 in 59% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.74 (s, 1 H), 7.65 (t, 2JHf = 55 Hz, 1 H), 6.81 (br s, 2 H), 6.75 (s, 1 H), 3.68 (m, 8 H), 3.49 (m, 4 H), 2.46-2.38 (m, 4 H), 2.25-2.16 (m, 4 H), 1.72-1.66 (m, 4 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.5 (br s, 2 F); MS (MALDI): m/z = 474.3 ([M+H]+). oromethyl)pyridinamine(56) (ck f,.o\ N” "“ Mfg/\N / ‘\ / F». ,xF + \O/B-M‘Hfi/xfi‘] 5‘14ka —> , 1. 11. , f ’11 N ”"N C: “‘N‘” “N f" "N N El “1 O\ //“} U8 /’ O.......J ..........
V N N NH2 i10 i68 56 According to general procedure 1, compound 56 is obtained from ng materials HO and i68 in 59% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.76 (t, 2JHf = 55 Hz, 1 H), 6.82 (br s, 2 H), 6.76 (s, 1 H), 4.50 (m, 2 H), 4.29 (m, 2 H), 4.02-3.84 (m, 4 H), 3.40 (m, 4 H), 3.08 (m, 2 H), 2.34 (m, 2 H), 1.02 (m, 6 H), 0.77 (m, 6 H); 19F NMR (376 MHz, (CD3)280): 5 — 115.0 (brs, 2 F); MS (MALDI): m/z = 478.4 QM+HTl i44 i68 57 ing to general procedure 1, compound 57 is obtained from starting materials M4 and i68 in 45% yield as a colorless solid (1 :1 e of rotamers). 1H NMR (400 MHz, (CD3)280): 8 8.87 (m, 1 H), 7.77 (m, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 4.71-4.35 (m, 4 H), 3.92 (m, 1 H), 3.72 (m, 1 H), 3.56 (m, 1 H), 3.42 (m, 1 H), 3.23-3.18 (m, 4 H), 1.24 (m, 3 H); 19F NMR (376 MHz, (CD3)280): 5 - 69, — 115.0 (brs, 2 F); MS (MALDI): m/z = 435.1 ([M+H]+). /05 cm L k x): F. .F l~ x .
N \>/ {‘3 T l? "\ Yd»? \O 13 U/W; iiiiiii, F //////\ / F a “£142“: RT F \ '\, '\ "m 5 K _.,/ 13/? is N Cl N hi1? N F )1 a P F E \ ,r/ F // 1?] N NHZ i45 i68 58 According to general procedure 1, compound 58 is obtained from starting materials M5 and i68 in 41% yield as a colorless solid (1 :1 mixture of rotamers). 1H NMR (400 MHz, (CD3)280): 8 8.87 (m, 1 H), 8.07 (m, 1 H), 7.77 (m, 1 H), 6.86 (br s, 2 H), 6.76 (s, 1 H), 4.65-4.77 (m, 1 H), 4.36-4.01 (m, 3 H), 3.83 (m, 1 H), 3.62 (m, 1 H), 3.52 (m, 1 H), 3.35 (m, 1 H), 3.10 (m, 1 H), 1.18 (d, 3JH,H = 6.9 Hz, 3 H); MS (MALDI): m/z = 421.1 ([M+H]+).
MG i68 59 According to general procedure 1, nd 59 is obtained from starting materials MG and i68 in 32% yield as a colorless solid (1 :1 mixture of rotamers). 1H NMR (400 MHz, (CD3)ZSO): 6 8.89-8.84 (m, 1 H), 8.12-7.37 (m, 2 H), 6.81-6.75 (m, 3 H), 4.64 (m, 1 H), 4.30 (m, 1 H), 3.90 (m, 1 H), 3.72 (m, 1 H), 3.56 (m, 1 H), 3.39 (m, 2 H), 3.14 (m, 2 H), 1.20 (d, 3.1,”, = 6.9 Hz, 3 H), 1.04 (m, 1 H), 0.42 (m, 2 H), 0.22 (m, 2 H); 19F NMR (376 MHz, (CD3)ZSO): 6 — 115.0 (br s, 2 F); MS (MALDI): m/z = 393.0 ([M+H]+). i4? i68 60 According to general procedure 1, compound 60 is obtained from starting materials M7 and i68 in 41% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.96 (s, 1 H), 7.75 (t, 2JH,F = 55 Hz, 1 H), 7.07 (br s, 2 H), 6.80 (s, 1 H), .97 (m, 2 H), 4.78-4.54 (m, 1 H), 4.33 (m, 1 H), 3.91 (m, 1 H), 3.71 (m, 1 H), 3.57 (m, 1 H), 3.41 (m, 1 H), 3.29 (m, 1 H), 1.27 (d, 3.1,”, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (003)280): 5 - 69, - 115.0 (brs, 2 F); MS (MALDI): m/z = 422.3 ([M+H]+).
Example 61: 5- 4- 2 2-difluoroethox 3R meth lmor 4- l-1 3 zin l- 4- difluorometh l ridinamine 61 (O\ O N”]\ l \ [ \. /L“Q FEF WN no-6. W < 1: A 41m !L U ,5 m F . £6 I i o 66w “or . 5 1 N “3% i 0” N F \N/ F m N WNNHZ M8 i68 61 ing to general procedure 1, compound 61 is obtained from starting materials M8 and i68 in 60% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.95 (s, 1 H), 7.89 (t, 2JHf = 55 Hz, 1 H), 7.04 (br s, 2 H), 6.80 (s, 1 H), 6.37 (m, 1 H), 4.68-4.53 (m, 3 H), 4.25 (m, 1 H), 3.90 (m, 1 H), 3.70 (m, 1 H), 3.55 (m, 1 H), 3.41 (m, 1 H), 3.25 (m, 1 H), 1.26 (d, 3JH,H = 6.9 Hz, 3 H).;19F NMR (376 MHz, (003)280): 6 — 115.0 (br s, 2 F), - 126; MS (MALDI): m/z = 404.1 ([M+H]+). e 62: 5-|4-|(3aR,6aS)—1,3,3a,4,6,6a-hexahydrofuro|3,4-clpyrrolyl||(3R)—3- meth lmor holin l-1 3 5-triazin l difluorometh l ridinamine 62) [ /<J\ “mL i=6 F { /5\ 3 l i WAN \OK , m N’P‘N F F <1 6 0* N 'l N M O “Ml-f IT] 0 ”/34 N NHZ i49 i68 62 According to general procedure 1, compound 62 is obtained from starting materials i49 and i68 in 20% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.90 (s, 1 H), 7.86 (t, 2JH,F = 55 Hz, 1 H), 6.82 (br s, 2 H), 6.76 (s, 1 H), 4.67 (m, 1 H), 4.35 (m, 1 H), 3.93-3.43 (m, 14 H), 3.16 (m, 1 H), 2.99 (m, 2 H), 1.21 (d, 3JH,H = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.0 (br s, 2 F); MS (MALDI): m/z = 435.2 ([M+H]+).
Example 63: 5- 4- 4aS 7aR -2 3 4a 5 7 7a-hexah dro- 1 4 dioxino 2 3-c - l 3R meth lmor holin l-1 3 5-triazin l difluorometh l ridinamine 63 i50 i68 63 According to general procedure 1, compound 63 is obtained from starting als i50 and i68 in 25% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.92 (s, 1 H), 7.88 (t, 2JHf = 55 Hz, 1 H), 6.84 (brs, 2 H), 6.76 (s, 1 H), 4.70 (m, 1 H), 4.36-4.26 (m, 3 H), 3.88 (m, 1 H), 3.79-3.53 (m, 12 H), 3.41 (m, 1 H), 3.09 (m, 1 H), 1.21 (d, 3JH,H = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.0 (br s, 2 F); MS (MALDI): m/z = 451.2 ([M+H]+).
Example 64: 4- rometh l 4- 4 4-difluoro i erid l 3R meth lmor holin- 4- l-1 3 5-triazin l ridinamine 64 o\ .,_,o\ LN k \::;L? F]? i k /: , 0 MIBM/4% / Fx F NfiiNfiiC, + «m» H[l FmF; i ‘ Ki?, F FL‘ J l XN J’Nfiz i51 i68 64 According to general procedure 1, compound 64 is obtained from ng materials i51 and i68 in 61% yield as a ess solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.88 (s, 1 H), 7.74 (t, 2JHf = 55 Hz, 1 H), 6.85 (brs, 2 H), 6.77 (s,1 H), 4.70 (m, 1 H), 4.32 (m, 1 H), 3.99 (m, 5 H), 3.72 (m, 1 H), 3.56 (m, 1 H), 3.41 (m, 1 H), 3.18 (m, 1 H), 2.01 (m, 4 H), 1.21 (d, 3.1,”, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 5 - 95.5, - 115.0 (brs, 2 F); MS (MALDI): m/z = 442.0 ([M+H]+). { 13‘ N (3‘ N {a J/,.~\,,31/ SIN, \U/ \Jj at.” V N 0'4 \ N NHz i52 i68 65 According to general procedure 1, compound 65 is obtained from starting materials i52 and i68 in 49% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.86 (s, 1 H), 7.75 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.65 (m, 1 H), 4.35 (m, 5 H), 3.87 (m, 1 H), 3.70 (m, 5 H), 3.57 (m, 1 H), 3.43 (m, 1 H), 3.16 (m, 1 H), 1.79 (m, 4 H), 1.20 (d, 31,1, = 6.9 Hz, 3 H); 19F NMR (376 MHz, (CD3)280): 5 — 115.5 (br s, 2 F); MS (MALDI): m/z = 449.3 ([M+H]+). 1,011.1 ‘ I .1 .1 :1, F F 1 , A 1 :71?“ {g 1 If .1?» .1/ F F 11‘ 0/ 1.“? /% {ix 1 11 1 1., 1 —* l 1?. J 1 l?! N C! N 1111 1 N N O Ox/K 11 \1 “V“ \ 311/ N/ \NHQ i55 i68 66 According to l procedure 1, compound 66 is obtained from ng materials i55 and i68 in 61% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.77 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.46 (m, 2 H), 3.81-3.77 (m, 6 H), 3.55 (m, 2 H), 3.44 (m, 2 H), 1.49 (s, 6 H), 1.28 (d, 3JH,H = 6.9 Hz, 6 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.0 (br s, 2 F); MS (MALDI): m/z = 450.4 ([M+H]+). [01 1 1 1. ,0.1 ~1N/ 1 \ £11-? F111,? N o 0 F 1': . N431“: N511!“ ,l... 0 »... 1.11 + 1 .1 1* ,1, 11 ,1. L1 1 1?. N Cl N $11 r N I T ‘H O 1 \ :11/ O1.“ 1N4 NNHZ i56 i68 67 According to general procedure 1, compound 67 is obtained from starting materials i56 and i68 in 37% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.84 (s, 1 H), 7.89 (t, 2JHf = 55 Hz, 1 H), 6.85 (brs, 2 H), 6.76 (s,1 H), 4.60 (m, 1 H), 4.31 (m, 1 H), 3.92 (m, 2 H), 3.83 (m, 4 H), 3.65 (m, 1 H), 3.51-3.41 (m, 5 H), 3.28 (s, 3 H), 3.12 (m, 1 H), 1.49 (s, 3 H), 1.48 (s, 3 H); 19F NMR (376 MHz, (CD3)280): 8 — 115.5 (brs, 2 F); MS (MALDI): m/z = 466.4 ([M+H]+).
Example 68: 3R 4- 6-amino difluorometh l rid l 3 3-dimeth lmor holin yl)-1,3,5-triazinyl|morpholinyl|methanol (68) /O~_. /0 HO {El ~~~~~~~~;/L(; FLF HO 1:1? 1;: F x, 0’ “1;? » 151;) a f: 1:3? (SN/J RNA NH? i57 i68 68 According to general procedure 1, compound 68 is obtained from starting materials i57 and i68 in 58% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.83 (s, 1 H), 7.77 (m, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 4.91 (m, 1 H), 4.35 (m, 2 H), 4.05 (m, 1 H), 3.97-3.70 (m, 6 H), 3.54-3.38 (m, 5 H), 3.12 (m, 1 H), 1.49 (s, 3 H), 1.48 (s, 3 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.5 (br s, 2 F); MS (MALDI): m/z = 453.2 ([M+H]+).
Example 69: 4- difluorometh l 4- 3 3-dimeth lmor holin l 3 7-dioxa azabic clo 3.3.1 9- l-1 3 zin l ridinamine 69 [0 0 l § l I? \ )JMO Paw/F “N “m “71 l l l / it N N x O B ”/55“; N \ N F‘K x. F KN.» + i 1 —~«—» )1 ,1 Cl N \ L I N «N “T,N N, ______ x} ii , x / )1 , If» A 0 fl) .. / x . o z x/ N j/j N NH; O l o i54 i68 69 According to general procedure 1, compound 69 is obtained from starting materials i54 and i68 in 57% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.83 (s, 1 H), 7.69 (t, 2JHf = 55 Hz, 1 H), 6.85 (br s, 2 H), 6.76 (s, 1 H), 4.47-4.37 (m, 2 H), 4.01 (m, 4 H), 3.80-3.71 (m, 8 H), 3.45 (m, 2 H), 1.48 (s, 6 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.7 (br s, 2 F); MS (MALDI): m/z = 464.3 +). e 70: 5- 4- 4-c clo ro l i erazin l 3 3-dimeth lmor holin l -1 3 5- triazin l difluorometh l ridinamine 70 0 xx {HAIL/N \ i g F‘x ,F 1/ “Q N WAN V0 ‘3 L N}. a,,,,,, F ,LQ 31 t [(41% ---------------- w ,1. at, r N N c: N N r” AN N U :1 7,14.» RN ,,,,, NW v7 RN N92 i58 i68 70 According to general procedure 1, compound 70 is obtained from starting materials i58 and i68 in 12% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.82 (s, 1 H), 7.72 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 3.82 (m, 4 H), 3.71 (m, 4 H), 3.44 (m, 2 H), 2.58 (m, 4 H), 1.64 (m, 1 H), 1.44 (s, 6 H), 0.45 (m, 2 H), 0.36 (m, 2 H); 19F NMR (376 MHz, (003)280): 5 — 115.4 (br s, 2 F); MS (MALDI): m/z = 460.4 ([M+H]+). o\ o [ M;;i\(‘) 1 x /L\\\\\ F F /£§ “\sz N N NAN / L 0.8..kvx.,§\ l.
N/AN F F \ ix 1’1‘\ L /?L i ,,,,,,, 31 l f N N c: N“ ‘N f “N1 / 11 « ~ .N. U. N. J J 4 x o W ‘4 h?! o , V N NH2 i59 i68 71 According to general procedure 1, compound 71 is obtained from starting als i59 and i68 in 42% yield as a colorless solid. 1H NMR (400 MHz, SO): 8 8.82 (s, 1 H), 7.73 (t, 2JHf = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 3.88-3.69 (m, 10 H), 3.47- 3.44 (m, 4 H), 3.24 (m, 3 H), 2.52-2.45 (m, 4 H), 1.44 (s, 6 H); 19F NMR (376 MHz, (CD3)ZSO): 6 — 115.4 (br s, 2 F); MS (MALDI): m/z = 478.4 ([M+H]+).
Example 72: 4- difluorometh l 4- 3 3-dimeth lmor holin-4 1 3 5-triazin l 2-amine 72 WC K0 \N ‘\>LQ FM} L: \N i “x , B 4"“,L .2 F. ,1: CC N N O 4» N” N L. H * l J”N ©ij —-~ )6, EL l o/ \N/ Cl N” “N o" "N 1.: ll 1 135/ N” ”“NHZ i60 i68 72 According to general procedure 1, compound 72 is ed from starting materials i60 and i68 in 41% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.86 (s, 1 H), 7.73 (t, 2JHf = 55 Hz, 1 H), 7.02 (br s, 2 H), 6.78 (s, 1 H), 5.62 (m, 1 H), 4.90 (m, 2 H), 4.63 (m, 2 H), 3.85 (m, 4 H), 3.49 (m, 2 H), 3.13 (s, 6 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.7 (br s, 2 F); MS (MALDI): m/z = 409.3 +).
Example 73: 4- difluorometh l 4- 3 3-dimeth lmor holin l 3S -tetrah drofuran- 3- lox -1 3 5-triazin l ridinamine 73 (o ) A1 L L L...;>Lwo. éfix ,«(.«L"\\ ,B LL” 0 0 ,1 {‘3 O 6;“ , FL X/F «VJ. "i it + TL , ,1. L L L o N cu N N 01 ,N ng LL 1; l Ix]: \N/ ‘NHg i61 i68 73 According to general procedure 1, nd 73 is obtained from starting materials i61 and i68 in 44% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.76 (t, 2JHf = 55 Hz, 1 H), 6.99 (br s, 2 H), 6.78 (s, 1 H), 5.48 (m, 1 H), 3.84-3.73 (m, 8 H), 3.49 (m, 2 H), 2.21 (m, 1 H), 2.05 (m, 1 H), 1.52 (s, 3 H). 1.51 (s, 3 H);19F NMR (376 MHz, (CD3)280): 8 — 115.7 (br s, 2 F); MS (MALDI): m/z = 423.3 ([M+H]+). e 74: 4- difluorometh l 4- 3 3-dimeth lmor holin l 3R -tetrah drofuran- 3- lox -1 3 5-triazin l ridinamine 74 (omI / ,L IOl/ LLN/ \ xxx/31“»? FLY/F LN / “x /O~\_ OLBL /«N N”? L N Nix} o\k N“ N FLY, F '35 l I] + \ M /E <\ 1 EL ““0“ Q"N“"'ol ‘N’A‘N A 0 “N ’8 :“\ Li . L L l. bi: ‘N “NHL i62 i68 74 According to l procedure 1, compound 74 is obtained from starting materials i62 and i68 in 37% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.76 (t, 2JHf = 55 Hz, 1 H), 6.99 (br s, 2 H), 6.78 (s, 1 H), 5.48 (m, 1 H), 3.84-3.73 (m, 8 H), 3.49 (m, 2 H), 2.21 (m, 1 H), 2.05 (m, 1 H), 1.52 (s, 3 H). 1.51 (s, 3 H);19F NMR (376 MHz, (CD3)280): 8 — 115.6 (br s, 2 F); MS (MALDI): m/z = 423.3 ([M+H]+).
Example 75: 4- rometh l 4- 3 3-dimeth lmor holin l tetrah dro ran lox -1 3 5-triazin l ridinamine 75 0L 0.“ L 14/ N” NILO FLT/F ILLN/lf my F F o NA :54‘OLéw Li \ 0 NLLLN l l L L ’* El“ Ml W L L L L i w’ 0 N Cl N’ “d x O N xii] xi “"‘N/ “N "‘NHZ i63 i68 75 According to general procedure 1, compound 75 is obtained from starting materials i63 and i68 in 61% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.87 (s, 1 H), 7.76 (t, 2JHf = 55 Hz, 1 H), 6.99 (br s, 2 H), 6.78 (s, 1 H), 5.15 (m, 1 H), 3.82 (m, 6 H), 3.48 (m, 4 H), 2.07-2.00 (m, 2 H), 1.74 (m, 2 H), 1.51 (s, 6 H); 19F NMR (376 MHz, (CD3)ZSO): 8 — 115.7 (br s, 2 F); MS (MALDI): m/z = 437.4 ([M+H]+).
Example 76: 4- rometh l 4- 3 3-dimeth lmor holin l 1 1-dioxo-1 4- thiazinan l-1 3 5-triazin l ridinamine 76 Q 0,: 1 O7 /' ’K/( . N), F,» :i . .
N? ”N 1 03» *1: N 1% + 11 i \f /, N/‘iQN‘jMCl —> N “Nix, , l N l N “I f L E 02§k U / Ow§x¢ N “NH 3 “'1“ 2 i64 “58 76 According to general procedure 1, compound 76 is obtained from starting materials i64 and i68 in 56% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.83 (s, 1 H), 7.68 (t, 2JH,F = 55 Hz, 1 H), 6.88 (br s, 2 H), 6.77 (s,1 H), 4.19 (m, 4 H), 3.83 (m, 4 H), 3.47 (m, 2 H), 3.22 (m, 4 H), 1.52 (s, 6 H); 19F NMR (376 MHz, (003)280): 5 — 115.3 (br s, 2 F); MS (MALDI): m/z = 470.2 ([M+H]+). i53 i68 77 ing to general procedure 1, nd 77 is obtained from starting materials i53 and i68 in 31% yield as a colorless solid. 1H NMR (400 MHz, (CD3)ZSO): 8 8.88 (s, 1 H), 7.78 (t, 2JHf = 55 Hz, 1 H), 6.84 (br s, 2 H), 6.76 (s, 1 H), 4.96 (m, 1 H), 4.73 (m, 1 H), .24 (m, 3 H), 4.05 (m, 1 H), 3.90 (m, 2 H), 3.72 (m, 2 H), 3.59 (m, 1 H), 3.51- 3.36 (m, 4 H), 3.23-3.02 (m, 2 H), 1.23 (d, 3.1,“, = 6.9 Hz, 3 H); MS (MALDI): m/z = 438.3 ([M+H]+)- WO 75130 ln-cell Western Blot A2058 cells are plated at 20,000 cells/well in a 96-well plate (Perkin Elmer, Cat. No. 6005558) and 24 hours later treated with different compounds for 1 hour. For each nd 7 different concentrations are applied on cells (5 uM, 1.25 uM, 0.625 uM, 0.3125 uM, 0.155 uM, 0.08 uM and 0.04 uM). Cells are fixed with 4% paraformaldehyde for 30 minutes at room temperature, washed 2 times with 1% BSA in PBS, permeabilized with 0.1% Triton X-100 in PBS/1% BSA for 30 minutes at room temperature and blocked with 5% goat serum in PBS/1% BSA/0.1% Triton X-100 for 30 minutes at room temperature. Cells are stained with primary antibody either with rabbit anti-pPKB S473 (1 :500; Cell Signaling Technology, Cat. No. 4058) ed with mouse anti-d-tubulin (1 :2000; used for normalization; Sigma, Cat. No. T9026) or with rabbit anti-pS6 S235/S236 (1:500; Cell Signalling Technology, Cat. No.4856) combined with mouse anti- lin (1 :2000; used for normalization) over night at 4 °C. After 3 times 5 minutes wash with PBS/1% BSA/0.1% triton cells are treated with the secondary antibodies goat-anti- mouse 80 (LICOR, Cat. No. 926-68070) and goat-anti-rabbit |RDye800 (LICOR, 926-32211) (each diluted 1:500 in PBS/1% BSA/0.1% triton) for 1 hour while shaking in the dark. Cells are washed 3 times 5 minutes with PBS/1% BSA/0.1% triton and plate scanned with the Odyssey Infrared Scanning system using both 700 and 800 nm channels. As control for 0% inhibition vehicle (0.2% DMSO) is added to cells. To correct for background staining in the data analysis wells are d only with secondary antibodies.
For data analysis the mean background signal from channel 700 nm and 800 nm are subtracted from each signal in l 700 nm and 800 nm, respectively. The signals in each channel are normalized to the 0% inhibition and then signal ratio 800 nm over 700 nm is performed to obtain the values for either pPKB S473 or p86 S235/S236 normalized to d-Tubulin.
|C50 values of each compound are ined by plotting the ized pPBK S473 and p86 S235/S236 signals, respectively, versus the compound concentrations (in logarithmic scale) and then by fitting a sigmoidal dose-response curve with variable slope to the data using GraphPadTM Prism.
Table 1: Comparative biological ties This invention This invention W02010/052569 W02010/052569 Compound 1 Compound 2 ,,o_ 0 [01 50, T T (N) N N F F F F N \N N"’L:N FREE lAN N/KN FWF A 4% 21 //\i\ (\N N/ [ Nr'L 0 \N N [,A_ I 9%)] N [’ N"/"["‘NH2 0d 1 NAM—'2 [TN (g [T N/ NHZ T["r\1""[\‘NH2 pPKB S473 IC50 108 149 34 64 8235/236 196 340 80 650 |C50 [nM] Table 2: Comparative ical activities This invention This ion W02010/052569 W02010/052569 Compound 6 Compound 7 o 505 O 50“., U T T E 1,, T T ,1 315i TiT 5 T T“T T N N \ /“N/ “NO if“) N N \N N Na» «N 0d [ [ N/ ([3\ /j LN [\NH; 0y NH2 N/ NH2 (Ev/I ELN‘I/\NH2 pPKB S473 IC50 155 255 59 118 8235/236 215 433 97 224 [C50 [nM] Table 3: Comparative biological activities This invention This invention W02010/052569 W02010/052569 Compound 8 Compound 9 0 ,OK 0 ,0\ [NT TNT [ij TNT N/kN F F N/LKN FKF F nil/KN F F [Ii/L33 FMS/F of)N N \ ,x, N A, fN N N l/ N N N I [ N/)\NH2 ’ N/ M‘N‘J 0d O NH2 (ZN/1 EN“ J\NHg pPKB S473 IC50 74 196 35 91 8235/236 68 90 72 164 |C50 [n M] Table 4: Comparative biological activities This ion This invention W02010052569 WO20 005 5691 2 Compound 12 Compound 13 H H H H N N EN N [N1 [N1 1N1 F F N \N “(/1th NgN F NALN [Kg/F 1 /"\N"R~N“*i\/"<>F\‘Ff’F (\N N/ \ flu/[M \N 1N/ <12 11 oy 1 \N/_.1:\N;.\ 4,,ng 0y AN 1 1 V [LN-4.1.12 pPKB S473 IC50 208 302 43 116 8235/236 515 743 150 416 |C50 [nM] Table 5: Comparative biological ties This invention This invention WO2007/084786 Compound 16 Compound 17 ,oN fox 1 “ Min {—17,}: 11:1” 0“ 11 5171' 1:11” pPKB S473 IC50 207 263 90 194 8235/236 184 277 149 384 |C50 [nM] Table 6: Comparative biological activities This invention This invention W02008/098058 WO 80582 Compound 18 Compound 19 [WOW 3,C>\: pPKB S473 IC50 243 555 78 175 8235/236 256 665 147 370 |C50 [nM] Table 7: Comparative biological activities This invention This invention WO2010052569 WO20 005 5691 2 Compound 20 Compound 21 (/0\ fix (/0\ {,o\ \l J l 1 N' ”'N' [NJ1 [My )9, F\ F g F [T F J1; Pkg/VF (is, REF l K‘ i, l [N [ [ S "j [N‘LNHZ 8V"; S\/ g , /' NHZ kN/l \NH2 S\ [\N/LNHz pPKB S473 IC50 146 311 57 343 8235/236 250 559 216 996 |C50 [nM] Table 8: Comparative biological activities This invention This invention WO2007/084786 Compound 25 Compound 26 1": £01 (“’1 1°: N ‘u, N m, N u,” N ",0 F F F F F F F F F E N‘ \ E NI \ _ N‘ \ : Ni \ (\N N/ \ (\N N/ \ (\N N/ \N 1 [ [ N/JWH2 [AN N/ \N OV‘ l N/ 0 N/ 0d O NH2 NH2 N/ NHz pPKB S473 [Gm 303 452 87 193 8235/236 294 553 191 617 |C50 [nM] Table 9: Comparative ical activities This invention This invention /084786 nd 27 Compound 28 £01 (01 1°) £01 N N N N gNing F ‘N‘gNF F (\N% gNl/gNr-FF NIXWFFF Oi; / / N \ fN \N (\N [ :N 0d 1 I ] N/J\NHZ 0Q NH2 N/ 0d NAN“? pPKB S473 [Gm 614 883 77 290 8235/236 766 1100 146 1027 |C50 [nM] Table 10: Comparative biological activities This invention This ion WO2007/084786 Compound 23 Compound 24 ’0» O O O N N N N F F L a (F F F F F F F N 2 V N \ N \ N \ /U‘N‘flflfi 0K;N 'N/ \ 1 CgNAN/ \N N 'N/ \N 0‘7 “N“xNHz N/ NHZ N/Jfiw2 Cg N/ NH2 pPKB S473 |C50 285 564 84 340 8235/236 230 562 167 740 |C50 [nM] Table 11: Comparative biological activities This invention This invention WO2007/084786 Compound 31 Compound 32 0: £01 £01 (01 N N N N F F F F F F F F F F E )NL\ ? NI \ § N. \ ? N| \ (\N N/ \ (\N N/ \ (\N N/ \N KN N/ \ O N/ 0 NH2 SN/ NH2 0Q {N/ Cd NH2 [N/ NH2 pPKB S473 |C50 146 248 100 191 8235/236 124 228 387 535 |C50 [nM] Table 12: Comparative biological activities This invention Compound 48 O ”0-, L A J T F i if if: 10“ 1 4&4“ N f0” 1T? NE; \,>“ 1?: I N \\;M O \[X‘ HzN/A NV 0/ H2N” N/ “0/ S473 100 689 |C50 [nM] P1100c 161 1864 IC50 [nM] 2015/076192 Table 13: Results of in-cell Western Blot ln-cell Western blot pPKB 8473 p86 8235/8236 Compound IC50 [nM] IC50 [nM] 1 108 196 2 34 80 3 231 105 4 178 135 85 135 6 155 215 7 59 97 8 74 68 9 35 72 138 93 11 61 96 12 219 407 13 37 120 14 349.5 883 49 286 16 207 184 17 90 149 18 243 256 19 78 147 146 250 21 57 216 22 57 216 23 285 230 24 84 167 303 294 26 87 191 27 614 766 28 77 146 31 146 124 32 100 387 2015/076192 In-cell Western blot pPKB 8473 p86 8235/8236 Compound IC50 [nM] IC5O [nM] 207 229 36 99 153 37 533 268 38 219 79 39 106 47 40 252 160 41 436 261 42 54 45 43 383 154 44 197 87 45 234 93 46 956 426 47 469 176 48 100 nd

Claims (16)

Claims
1. A compound of formula (I), 5 wherein X1, X2 and X3 are, independently of each other, N or CH; with the o that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other 10 (i) a morpholinyl of a (II) R3 R4 (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1- 15 C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form er a bivalent residue – R5R6– selected from -CH2-O-CH2-, -CH2-NH-CH2-, or C1-C3alkylene optionally substituted with 1 to 4 F, or any of the structures wherein the arrows denote the bonds in formula (II); or 20 (ii) a saturated 5- to 6-membered heterocyclic ring Z containing 1 to 2 heteroatoms independently selected from N, O and S, optionally substituted by 1 to 3 R9; wherein R9 is independently at each occurrence halogen, -OH, C1-C3alkyl, CH2OH, OH, CH2F, CHF2, CF3, CH2CF3, C1-C2alkoxy, lkoxyC1- C3alkyl, C3-C6cycloalkyl, =O, -NH2, NHCH3 or N(CH3)2; or two R9 substituents form 25 together a bivalent residue –R10R11– selected from -CH2-O-CH2-, -O-CH2CH2-O-, or C1-C3alkylene optionally substituted with 1 to 4 F; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; 17511707_1 ters) P42872NZ00 and tautomers, solvates and pharmaceutically acceptable salts thereof.
2. The nd of formula (I) according to claim 1, wherein X1, X2 and X3 are N; and tautomers, solvates and pharmaceutically acceptable salts thereof.
3. The compound of formula (I) according to claim 1 or claim 2, n said R1 and said R2 are independently of each other selected from 17511707_1 (GHMatters) P42872NZ00
4. The compound of formula (I) according to claim 3, wherein R1 and R2 are ndently of each other selected from 17511707_1 (GHMatters) P42872NZ00
5. The compound of formula (I) according to claim 1, wherein said compound is selected from 4-(difluoromethyl)(4,6-dimorpholino-1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; 5 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxaazabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)(difluoromethyl)pyridinamine; 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazinyl) (difluoromethyl)pyridinamine; 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazinyl) 10 (difluoromethyl)pyrimidinamine; 5-(4,6-bis((S)methylmorpholino)-1,3,5-triazinyl)(difluoromethyl)pyridinamine; 5-(4,6-bis((S)methylmorpholino)-1,3,5-triazinyl)(difluoromethyl)pyrimidinamine; (S)(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazinyl)pyridin amine; 15 (S)(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazinyl)pyrimidin- 2-amine; 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)methylmorpholino)-1,3,5-triazinyl) oromethyl)pyridinamine; 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)((S)methylmorpholino)-1,3,5-triazinyl) 20 (difluoromethyl)pyrimidinamine; 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyridinamine; 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyrimidinamine; (S)(difluoromethyl)(4-(3-methylmorpholino)(piperazinyl)-1,3,5-triazin yl)pyridinamine; 25 (difluoromethyl)(4-(3-methylmorpholino)(piperazinyl)-1,3,5-triazin yl)pyrimidinamine; 4-(difluoromethyl)(2,6-dimorpholinopyrimidinyl)pyridinamine; 4'-(difluoromethyl)-2,6-dimorpholino-[4,5'-bipyrimidin]-2'-amine; 4-(difluoromethyl)(4,6-dimorpholinopyrimidinyl)pyridinamine; 30 4'-(difluoromethyl)-4,6-dimorpholino-[2,5'-bipyrimidin]-2'-amine; luoromethyl)(4-morpholinothiomorpholino-1,3,5-triazinyl)pyridinamine; luoromethyl)(4-morpholinothiomorpholino-1,3,5-triazinyl)pyrimidinamine; 5-(6-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxaazabicyclo[3.2.1]octan yl)pyrimidinyl)(difluoromethyl)pyridinamine; 35 5-(2-(3-oxaazabicyclo[3.2.1]octanyl)morpholinopyrimidinyl) (difluoromethyl)pyridinamine; 17511707_1 (GHMatters) P42872NZ00 2-(3-oxaazabicyclo[3.2.1]octanyl)-4′-(difluoromethyl)morpholino-[4,5′-bipyrimidin]- 5-(2,6-bis((S)methylmorpholino)pyrimidinyl)(difluoromethyl)pyridinamine; 4'-(difluoromethyl)-2,6-bis((S)methylmorpholino)-[4,5'-bipyrimidin]-2'-amine; 5 (difluoromethyl)(6-(3-methylmorpholino)morpholinopyrimidinyl)pyridin amine; (S)-4'-(difluoromethyl)(3-methylmorpholino)morpholino-[4,5'-bipyrimidin]-2'-amine; 5-(4-(8-Oxaazabicyclo[3.2.1]octanyl)(8-oxaazabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)(difluoromethyl)pyridinamine; 10 5-[4,6-bis(2,2-dimethylmorpholinyl)-1,3,5-triazinyl](difluoromethyl)pyridinamine; (S)(difluoromethyl)(2-(3-methylmorpholino)morpholinopyrimidinyl)pyridin amine; (S)-4'-(difluoromethyl)(3-methylmorpholino)morpholino-[4,5'-bipyrimidin]-2'-amine; 4-(difluoromethyl)[4-[(2S,6R)-2,6-dimethylmorpholinyl][(3R)methylmorpholin 15 yl]-1,3,5-triazinyl]pyridinamine; 5-[4,6-bis[(2R,6S)-2,6-dimethylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin- 2-amine; 4-[4-[6-amino(difluoromethyl)pyridyl]morpholino-1,3,5-triazinyl]morpholin one; 20 2-amino(difluoromethyl)pyrimidinyl]morpholino-1,3,5-triazinyl]morpholin one; 5-[4,6-bis(3,7-dioxaazabicyclo[3.3.1]nonanyl)-1,3,5-triazinyl] (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxaazabicyclo[3.3.1]nonanyl)(3-oxa 25 azabicyclo[3.2.1]octanyl)-1,3,5-triazinyl]pyridinamine; 5-[4,6-bis(3,3-dimethylmorpholinyl)-1,3,5-triazinyl](difluoromethyl)pyridinamine; 5-[4,6-bis[(3R,5S)-3,5-dimethylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin- 2-amine; 5-[4,6-bis[(3R)methylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin 30 amine; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)morpholino-1,3,5-triazinyl]pyridin- 2-amine; 4-(difluoromethyl)[4-[(3R,5S)-3,5-dimethylmorpholinyl][(3R)methylmorpholin yl]-1,3,5-triazinyl]pyridinamine; 35 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)[(3R)methylmorpholinyl]-1,3,5- triazinyl]pyridinamine; 17511707_1 (GHMatters) P42872NZ00 4-(difluoromethyl)[4-[(3R)(methoxymethyl)morpholinyl][(3R) methylmorpholinyl]-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxaazabicyclo[3.3.1]nonanyl)[(3R) methylmorpholinyl]-1,3,5-triazinyl]pyridinamine; 5 (4S,5R)[4-[2-amino(difluoromethyl)pyrimidinyl]morpholino-1,3,5-triazinyl] (hydroxymethyl)methyl-oxazolidinone; )[6-[2-amino(difluoromethyl)pyrimidinyl]morpholino-pyrimidinyl] (hydroxymethyl)methyl-oxazolidinone; 4-(difluoromethyl)[4-[(3R)methylmorpholinyl](3-oxaazabicyclo[3.1.1]heptan- 10 6-yl)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)methylmorpholinyl](6-oxaazabicyclo[3.1.1]heptan- 3-yl)-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)methylmorpholinyl][(1R,4R)oxa azabicyclo[2.2.1]heptanyl]-1,3,5-triazinyl]pyridinamine; 15 luoromethyl)[4-[(3R)methylmorpholinyl][(1S,4S)oxa azabicyclo[2.2.1]heptanyl]-1,3,5-triazinyl]pyridinamine; -bis[(3R)ethylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridinamine; 5-[4,6-bis(8-oxaazaspiro[3.5]nonanyl)-1,3,5-triazinyl](difluoromethyl)pyridin amine; 20 5-[4,6-bis[(3R)isopropylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin amine; 5-[4-[(3aR,6aS)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrolyl][(3R)methylmorpholin- 4-yl]-1,3,5-triazinyl](difluoromethyl)pyridinamine; 5-[4-[(4aS,7aR)-2,3,4a,5,7,7a-hexahydro-[1,4]dioxino[2,3-c]pyrrolyl][(3R) 25 methylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(4,4-difluoropiperidyl)[(3R)methylmorpholinyl]-1,3,5- triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R)methylmorpholinyl](2-oxaazaspiro[3.5]nonanyl)- 1,3,5-triazinyl]pyridinamine; 30 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)[(3R,5S)-3,5-dimethylmorpholin yl]-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)[(3R)(methoxymethyl)morpholin- 4-yl]-1,3,5-triazinyl]pyridinamine; [(3R)[4-[6-amino(difluoromethyl)pyridyl](3,3-dimethylmorpholinyl)-1,3,5- 35 triazinyl]morpholinyl]methanol; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)(3,7-dioxa 17511707_1 (GHMatters) P42872NZ00 azabicyclo[3.3.1]nonanyl)-1,3,5-triazinyl]pyridinamine; 5-[4-(4-cyclopropylpiperazinyl)(3,3-dimethylmorpholinyl)-1,3,5-triazinyl] (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)[4-(2-methoxyethyl)piperazinyl]- 5 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)(1,1-dioxo-1,4-thiazinanyl)-1,3,5- triazinyl]pyridinamine; [(3R)[4-[6-amino(difluoromethyl)pyridyl][(3R)methylmorpholinyl]-1,3,5- triazinyl]morpholinyl]methanol; 10 4-(difluoromethyl)[4-[(3R,5R)-3,5-dimethylmorpholinyl][(3R)methylmorpholin yl]-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5S)-3,5-dimethylmorpholinyl][(3R)methylmorpholin yl]-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-morpholino(3-oxaazabicyclo[3.3.1]nonanyl)-1,3,5-triazin 15 yl]pyridinamine; 5-[4,6-bis(3-oxaazabicyclo[3.3.1]nonanyl)-1,3,5-triazinyl](difluoromethyl)pyridin- 2-amine; 5-[4-[6-amino(difluoromethyl)pyridyl](3,7-dioxaazabicyclo[3.3.1]nonanyl)- 1,3,5-triazinyl](difluoromethyl)pyridinamine; 20 4-(difluoromethyl)[4-[(3R)methylmorpholinyl](4-morpholinopiperidyl)-1,3,5- triazinyl]pyridinamine; 5-[4-(4-cyclopropylpiperazinyl)[(3R)methylmorpholinyl]-1,3,5-triazinyl] (difluoromethyl)pyridinamine; 5-[4-(4-cyclopropylpiperazinyl)[(3S,5R)-3,5-dimethylmorpholinyl]-1,3,5-triazin 25 yl](difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-[4-(2-methoxyethyl)piperazinyl][(3R)methylmorpholinyl]- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)-3,5-dimethylmorpholinyl][4-(2- yethyl)piperazinyl]-1,3,5-triazinyl]pyridinamine; 30 luoromethyl)[4-(1,1-dioxo-1,4-thiazinanyl)[(3R)methylmorpholinyl]- 1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3S,5R)-3,5-dimethylmorpholinyl](1,1-dioxo-1,4-thiazinan 3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-[(3R,5S)-3,5-dimethylmorpholinyl](3,7-dioxa 35 azabicyclo[3.3.1]nonanyl)-1,3,5-triazinyl]pyridinamine; 3-[4-[6-amino(difluoromethyl)pyridyl][(3R,5S)-3,5-dimethylmorpholinyl]-1,3,5- 17511707_1 (GHMatters) P42872NZ00 triazinyl]oxazolidinone; 5-(4-((1R,2R,4S,5S)oxaazatricyclo[3.3.1.02,4]nonanyl)((2R,4S)oxa cyclo[3.3.1.02,4]nonanyl)-1,3,5-triazinyl)(difluoromethyl)pyridinamine; 5-[4,6-bis(6,6-difluorooxaazabicyclo[3.2.1]octanyl)-1,3,5-triazinyl] 5 (difluoromethyl)pyridinamine; 5-[4,6-bis(6,7-difluorooxaazabicyclo[3.2.1]octanyl)-1,3,5-triazinyl] (difluoromethyl)pyridinamine; 6-aminopyridyl)[(3R)methylmorpholinyl]-1,3,5-triazinyl] (difluoromethyl)pyridinamine.
6. The compound of formula (I) ing to claim 5, wherein said compound is selected from the group consisting of - 4-(difluoromethyl)(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxaazabicyclo[3.2.1]octanyl)-1,3,5- 15 triazinyl)(difluoromethyl)pyridinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)morpholino-1,3,5-triazinyl) (difluoromethyl)pyridinamine; - 5-(4,6-bis((S)methylmorpholino)-1,3,5-triazinyl)(difluoromethyl)pyrimidin amine; 20 - (S)(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazinyl)pyridin- 2-amine; - 4-(difluoromethyl)(4-morpholino(piperazinyl)-1,3,5-triazinyl)pyrimidinamine; - 4-(difluoromethyl)(4,6-dimorpholino-1,3,5-triazinyl)pyridinamine; and - (difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazin 25 yl)pyrimidinamine; and ers, solvates and pharmaceutically acceptable salts thereof.
7. The compound of formula (I) according to claim 6, wherein said compound is selected from, 30 - 4-(difluoromethyl)(4,6-dimorpholino-1,3,5-triazinyl)pyrimidinamine; - 5-(4-(3-oxaazabicyclo[3.2.1]octanyl)(3-oxaazabicyclo[3.2.1]octanyl)-1,3,5- triazinyl)(difluoromethyl)pyridinamine; - (S)(difluoromethyl)(4-(3-methylmorpholino)morpholino-1,3,5-triazinyl)pyridin- 2-amine; 35 and tautomers, solvates and pharmaceutically acceptable salts thereof. 17511707_1 (GHMatters) P42872NZ00
8. The nd of formula (I) according to claim 5, wherein said compound is selected from 4-[4-[6-amino(difluoromethyl)pyridyl]morpholino-1,3,5-triazinyl]morpholin one; 5 4-[4-[2-amino(difluoromethyl)pyrimidinyl]morpholino-1,3,5-triazinyl]morpholin one; 5-[4,6-bis(3,7-dioxaazabicyclo[3.3.1]nonanyl)-1,3,5-triazinyl] (difluoromethyl)pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxaazabicyclo[3.3.1]nonanyl)(3-oxa 10 azabicyclo[3.2.1]octanyl)-1,3,5-triazinyl]pyridinamine; 5-[4,6-bis(3,3-dimethylmorpholinyl)-1,3,5-triazinyl](difluoromethyl)pyridinamine; 5-[4,6-bis[(3R,5S)-3,5-dimethylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin- 2-amine; -bis[(3R)methylmorpholinyl]-1,3,5-triazinyl](difluoromethyl)pyridin 15 amine; 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)morpholino-1,3,5-triazinyl]pyridin- 2-amine; 4-(difluoromethyl)[4-[(3R,5S)-3,5-dimethylmorpholinyl][(3R)methylmorpholin yl]-1,3,5-triazinyl]pyridinamine; 20 4-(difluoromethyl)[4-(3,3-dimethylmorpholinyl)[(3R)methylmorpholinyl]-1,3,5- triazinyl]pyridinamine; luoromethyl)[4-[(3R)(methoxymethyl)morpholinyl][(3R) methylmorpholinyl]-1,3,5-triazinyl]pyridinamine; 4-(difluoromethyl)[4-(3,7-dioxaazabicyclo[3.3.1]nonanyl)[(3R) 25 methylmorpholinyl]-1,3,5-triazinyl]pyridinamine; (4S,5R)[4-[2-amino(difluoromethyl)pyrimidinyl]morpholino-1,3,5-triazinyl] (hydroxymethyl)methyl-oxazolidinone.
9. The compound of formula (I) according to any one of the claims 1 to 4, wherein R1 30 and R2 are independently of each other a morpholinyl of formula (II).
10. The compound of formula (I) according to claim 9, wherein R1 is equal to R2.
11. The compound of formula (I) according to claim 9, wherein R1 is not equal to R2. 17511707_1 (GHMatters) P42872NZ00
12. The compound of formula (I) according to any one of the claims 1 to 4, wherein R1 and R2 are independently of each other a morpholinyl of formula (II) and said saturated 5- to 6-membered heterocyclic ring Z. 5
13. The nd of formula (I) according to claim 12, wherein said 5- to 6- membered heterocyclic ring Z is selected from
14. A pharmaceutical composition comprising a compound of a (I) according to 15 any one of the claims 1 to 13 and a pharmaceutically acceptable carrier.
15. Use of a compound of formula (I) according to any one of the claims 1 to 13 in the preparation of a medicament for the treatment or prevention of a disease or condition ted by PI3Ks and/or mTOR and/or PIKKs in a human.
16. The use of a compound according to claim 15, wherein said disease or disorder is a hyperproliferative disorder. 07_1 (GHMatters) P42872NZ00
NZ731504A 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines NZ731504B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192617 2014-11-11
EP14192617.0 2014-11-11
PCT/EP2015/076192 WO2016075130A1 (en) 2014-11-11 2015-11-10 Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines

Publications (2)

Publication Number Publication Date
NZ731504A NZ731504A (en) 2021-04-30
NZ731504B2 true NZ731504B2 (en) 2021-08-03

Family

ID=

Similar Documents

Publication Publication Date Title
US11186591B2 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
CN112313219B (en) 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
CA2975033C (en) Cdk2/4/6 inhibitors
EP3237423B1 (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
AU2008273889B2 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2866086C (en) Serine/threonine kinase inhibitors
AU2007287428B2 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR101469334B1 (en) N-9-substituted purine compounds, compositions and methods of use
AU2013225737A1 (en) Serine/threonine kinase inhibitors
AU2019340767A1 (en) Triazolo-pyrimidine compounds and uses thereof
GB2465405A (en) Triazine, pyrimidine and pyridine analogues and their use in therapy
US8828990B2 (en) N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
CA3228579A1 (en) Heterocyclic compounds and methods of use
CA3183368A1 (en) Tyk-2 inhibitor
KR20230035236A (en) Adenosine A2A receptor antagonists
CA3022758C (en) Treatment of skin lesions
NZ731504B2 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
BR112017009457B1 (en) DIFLUOROMETHYLAMINOPYRIDINES AND DIFLUOROMETHYLAMINOPYRIDINES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
NZ788302A (en) Treatment of skin lesions
NZ613786A (en) Compounds and methods for kinase modulation, and indications therefor
NZ613786B2 (en) Compounds and methods for kinase modulation, and indications therefor
BR112014010459B1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITION